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Abstract 
Though the use of engineered nanoparticles has been exponentially increasing, little 
attention has been given to the nanoparticles biodistribution in the body. This thesis 
aims to establish a physiologically based pharmacokinetic (PBPK) model that 
accounts for nano-specific biobehaviors in order to understand the biodistribution of 
various types of nanoparticles.  
I start with experimental data for polyethylene glycol-coated polyacrylamide (PAA-
peg) nanoparticles intravenously injected to rats. By accounting for the phagocytosis 
process, the PBPK model successfully predicts the dynamics of PAA-peg 
nanoparticles between and within organs. According to the model, phagocytizing cells 
(PCs) quickly capture nanoparticles until saturation and constitute a major reservoir 
for nanoparticles. 
The PBPK framework is then adapted to address cerium oxide (CeO2) nanoparticles. 
A system of experimental apparatus is designed to integrate the generation, aging, and 
inhalation exposure of CeO2 nanoparticles to rats. The amounts found in organs are 
further analyzed with a mass balance approach to gain a holistic understanding of the 
biodistribution. The PBPK model is then slightly modified to accommodate unique 
phenomenon for inhaled nanoparticles including mucociliary clearance and entry into 
the systemic circulation by penetrating the alveolar wall. The recovered amount is 
predominantly in lungs and feces, with extrapulmonary organs contributing less than 
2% in recovery rate. No differences in biodistribution patterns are found between 
fresh and aged CeO2 nanoparticles. The model predicts the biodistribution well and 
 xviii 
 
finds PCs in the pulmonary region are accountable for most of the nanoparticles not 
eliminated by feces. 
To expand the model’s applicability, additional biodistribution data of nanoparticles 
collected from literatures are used for parameterization, including three polymers 
nanoparticles, three different sizes of silver nanoparticles, and one CeO2 nanoparticles. 
Only parameters physiologically linked with the characteristics of nanoparticles are 
changed. Overall the model maintains its robustness by having a R
2
 of 0.69 – 0.97 
between the log10 of measured and predicted results. The changes of certain 
parameters also offer insights on the relationship between nanoparticles’ 
characteristics and biodistribution. 
In summary, this work highlights the importance of phagocytosis as a major 
determinant of nanoparticles biodistribution and provides a tool for better evaluating 
the human health risks posed by nanoparticles. 
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CHAPTER 1 
Introduction 
1.1 Motivation 
1.1.1 Nanoparticles in the modern world 
Humans have been exposed to airborne particles at nanosize (diameter < 100 nm) 
from natural origins such as forest fires for thousands of years. However, 
anthropological origins of these particles, such as internal combustion engines and 
power plants, became the major sources of exposure after the Industrial Revolution 
(Oberdörster et al. 2005). More recently, engineered nanoparticles (materials with at 
least one dimension of 100 nm or less are designed and produced by humans 
intentionally) emerged as a rapidly developing field of study for both scientific 
research and industrial application (Oberdorster et al. 2005). Engineered nanoparticles 
have demonstrated possessing unique properties in comparison with their bulk 
counterparts due to their small size, surface structure, solubility, shape, and 
aggregation (Nel et al. 2006).  These properties have led to the wide use of 
nanoparticles as an emerging technology in various industries such as medicine, 
energy, textile, food, metallurgy, etc. (Smith et al. 2013; Chakrabarti et al. 2014; Chen 
et al. 2014; Irzhak et al. 2014; Wijnhoven et al. 2009).  
1.1.2 Potential health risk from nanoparticles 
However, there is a growing concern about the potential toxicity of nanoparticles. 
Studies reported the potential toxicities of nanoparticles including oxidative stress 
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(Sayes et al. 2006; Warheit et al. 2007; Yu et al. 2014) as well as possible genotoxic 
effects (Lee et al. 2013; Martinez Paino et al. 2012). Human exposure to nanoparticles 
can come from the manufacturing phase of products having ingredients of 
nanoparticles such as workers’ occupational exposure (Wu et al. 2014), the use phase 
of products such as clothing or drugs (Lee et al. 2014), and disposal phase of these 
products after which nanoparticles may enter human bodies via different 
environmental compartments (Walser et al. 2012; Sun et al. 2014). 
Considering the observations of toxicity of nanoparticles and the potential human 
exposure, concerns about the human health risks of nanoparticles have been raised 
(Warheit et al. 2008; Khanna and Kumar 2014) and it requires innovative researches 
to provide scientifically sound basis to better assess the health risks of nanoparticles. 
1.1.3 Relationship between characteristics and hazards of nanoparticles 
Conventionally, the hazards of chemicals to human are mainly determined by the 
exposed mass and chemical composition. However, studies have shown that the 
extent of exposure and toxicity of nanoparticles to the biologic system could be 
affected by a wide range of characteristics of nanoparticles, even those with the same 
chemistry (Maynard 2007). Similarly, the biodistribution of nanoparticles within the 
body exhibits different patterns from that of the bulk counterparts due to the physical 
forms specific to nanoparticles such as size and shapes (Maynard et al. 2011). 
Toxicity of nanoparticles has been found to be linked with certain characteristics of 
the nanoparticles (Maynard 2007; Maynard et al. 2011). The toxic dose response 
relationship of nanoparticles with similar chemistry may be dependent on surface 
areas instead of mass (Oberdorster et al. 1994). Nanoparticles with the same surface 
areas but altered surface chemistry also induced different inflammatory responses 
(Maynard and Kuempel 2005). Differences in structures of aggregates for the same 
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primary nanoparticle could result in different biological responses (Shvedova et al. 
2005).  
Unlike their bulk counterparts, certain nanoparticles have been shown to migrate into 
the systemic circulation after deposition into either the lungs (Oberdörster et al. 2002; 
Nemmar et al. 2002; Semmler et al. 2004; He et al. 2010; Geraets et al. 2012; Aalapati 
et al. 2014) or the gut (He et al. 2010; Bockmann et al. 2000). The degree of 
penetration from the respiratory system to extrapulmonary organs may have a 
negative correlation with the size of nanoparticle (Oberdörster et al. 2005; Kreyling et 
al. 2002; Kreyling et al. 2009). Additionally, nanoparticles have been reported to 
translocate directly from the olfactory epithelium to the brain (Oberdörster et al. 2004; 
Elder et al. 2006). Certain surface modifications on nanoparticles could also affect the 
biobehaviors of nanoparticles inside the body, such as phagocytosis (Moghimi et al. 
2001; Liu et al. 2008). 
1.1.4 Importance of understanding the biodistribution of nanoparticles systematically 
Previous findings demonstrate that some nanoparticles are able to cross biological 
barriers and thus reach sensitive target organs while their bulk counterparts may not. 
Yet the determinants of these nano-specific phenomena remain barely explored in a 
systematic manner. It is therefore necessary to determine the extent to which and the 
modes of action by which nanoparticles become bioavailable, potentially 
bioaccumulate, and translocate from point of exposure to organs. Given the influences 
of different characteristics of nanoparticles on their biobehavior within the body, it is 
also critical to study how these characteristics may affect those determinants of the 
biodistribution of nanoparticles. In addition, combining with the information of what 
characteristics may lead to higher toxicities of nanoparticles, there is the potential for 
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developing a screening protocol based on their characteristics to identify nanoparticles 
that we should have high concerns on their hazards to human health. 
1.2 Physiologically basked pharmacokinetic modeling (PBPK) as a tool 
1.2.1 Brief introduction to PBPK 
PBPK models are built to mathematically describe the absorption, distribution, 
metabolism, and elimination of chemicals in the body based on quantitative 
interrelations among critical determinants of these processes with the aim of 
predicting the biodistribution of chemicals in the body (Krishnan 2007).. PBPK 
models are widely used for drug development (Grillo et al. 2012), animal toxicity 
testing designs (Lipscomb et al. 2012), and human health risk assessments (Lu et al. 
2008). PBPK models have been developed to successfully model the behaviors of 
toxicants and drugs since the 1930s (Teorell 1937; Jain et al. 1981; Gerlowski and 
Jain 1983; Ramsey and Andersen 1984). 
1.2.2 Past efforts using PBPK on nanoparticles 
With the rapid development of nanotechnology and attentions attracted to the risk of 
nanoparticles, PBPK models focusing on various nanoparticles emerged: Lin et al. 
(2008) provided a first PBPK for quantum dots based on experimentally-derived 
blood to tissue distribution ratios but did not offer clear explanation of these ratios; 
Lee et al. (2009) were able to predict the long-term persistency of quantum dots in 
mice and rats but were not able to capture the early biodistribution dynamics of these 
nanoparticles; Lankveld et al. (2010) presented a PBPK model for silver nanoparticles 
but did not specify the mechanisms governing the biodistribution processes; Li et al. 
(2012) developed a detail PBPK model for poly(lactic-co-glycolic) acid nanoparticles 
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but cannot be directly adapted to other types of nanoparticles. Up to this point, each of 
these models has been developed for a specific type of nanoparticle, without looking 
in further details at the ability to model various types of nanoparticles within a 
consistent framework. There is therefore a clear need to explore how a common 
framework can be adapted and parameterized in a parsimonious way to account for 
nanoparticle specificities. 
1.3 Bridging the gap 
1.3.1 Taking phagocytosis into account in PBPK models 
As demonstrated in a number of in vivo experiments, the reticuloendothelial system 
comprises a major clearance route for micrometer and nanometer-scale materials of 
biologic or anthropogenic origin (Moghimi et al. 2001; Cho et al. 2009). For example, 
nanoparticles intended for medical use may be modified with structural 
functionalizations with the specific aim to prevent or reduce phagocytosis (Moghimi 
et al. 2001; Liu et al. 2008). 
Despite the recent developments of PBPK models with nanoparticles, these models 
have not specifically addressed the role of cellular phagocytosis (Lin et al. 2008; Lee 
et al. 2009; Lankveld et al. 2010; Li et al. 2012). Phagocytosis of nanoparticles has 
been modeled based on in vitro experiments (Wilhelm et al. 2002; Luciani et al. 2009), 
but this mechanism has hitherto not been incorporated in the attempts to describe the 
overall biodistribution in the body. Wenger et al. (2011) developed a rat model based 
on experimental mass-balance correlations suggesting the importance of macrophage 
uptake saturation of phagocytosis in the organs. Nevertheless, the model lacks a 
physiological approach and brings limited understanding on the processes affecting 
biodistribution. 
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1.3.2 Scientific questions to be answered by this work 
To advance our knowledge in the biodistribution of nanoparticles in the body, this 
work was designed to answer the following scientific questions: 
A) How to account for nano-specific phenomena, such as phagocytosis in the 
biodistribution of nanoparticles? 
B) How to relate inhaled doses to nanoparticles uptake and how to describe 
the dynamics of nanoparticles between and within organs? 
C) What are the most influential determinants affecting the biodistribution and 
how these parameters need to be adapted to describe the specific behavior of 
various nanoparticles? 
By answering these questions, we can deepen our understanding of the biodistribution 
of nanoparticles and therefore enhance our ability to comprehensively assess their 
human health risks. 
1.3.3 Addressing various types of nanoparticles in a common framework 
This study proposes the use of PBPK model to answer the scientific questions above. 
To develop and test a model that can be easily adapted to different nanoparticles, the 
following strategy is proposed. First, two specific nanoparticles involving first hand 
data collected at the University of Michigan will be examined in depth in order to 
build the PBPK model that provides a common framework for other nanoparticles. 
Then, this PBPK model will be tested for its robustness by extending to other 
nanoparticles using a wider range of experimental results from published literature.  
Detailed biodistribution data of polyethylene glycol-coated polyacrylamide (PAA-peg) 
nanoparticles were collected and reported previously (Wenger et al. 2011). The PAA-
peg nanoparticles were administrated to rats via intravenous injection of a single dose. 
The concentrations of PAA-peg nanoparticles in various organs were then measured 
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over 120 hours. Saturation of PAA-peg nanoparticles was observed in most of the 
organs, which indicates the possibility of phagocytosis of nanoparticles. This study 
will use this intravenous injection of PAA-peg nanoparticles dataset to build up the 
initial PBPK model framework that takes into account the important role of 
phagocytosis in order to predict and explain the biodistribution of intravenously 
injected PAA-peg nanoparticles. 
A project was set up and financed by US-EPA to study the generation, 
characterization, and biodistribution in rats via inhalation of freshly combusted/UV 
light aged cerium oxide (CeO2) nanoparticles. This CeO2 nanoparticles project first 
designs an experimental apparatus that connects the generation and aging of CeO2 
nanoparticles and the exposure chamber directly, with a series of instruments to 
characterize the nanoparticles. After the rats are exposed to the CeO2 nanoparticles for 
four hours, feces, lungs, and extrapulmonary organs were analyzed for nanoparticles 
concentrations at different time points. This study will analyze the data collected in 
this joint project to reconstitute the mass balance of recovered amounts of 
nanoparticles and analyze the biological fate of inhaled CeO2 nanoparticles. Then, the 
PBPK model framework built from the PAA-peg nanoparticles data will be expanded 
for inhalation exposure with minimum modifications to the model’s structure. This 
inhalation PBPK model will be parameterized with the CeO2 nanoparticles data to 
address specific biobehavior of nanoparticles inside the body following inhalation 
exposure. 
After establishing the PBPK framework that can model exposures to nanoparticles by 
either intravenous injection or inhalation, additional biodistribution data for various 
types of nanoparticles will be gathered from the literature. These additional data will 
be employed to further parameterize the PBPK model developed in this study. To 
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keep the parsimony of the model framework, only parameters that reflect the specific 
characteristics of the different types of nanoparticles will be changed. The relationship 
between these parameters and the specific characteristics of each type of nanoparticles 
will also be explored empirically. 
1.4 Objectives of this thesis 
1.4.1 Specific aims 
The general objective of this thesis is to develop and evaluate a PBPK model that 
accounts for biobehaviors specific to nanoparticles whether exposed by intravenous 
injection or inhalation. The predictability of this PBPK model will be first established 
and tested using observed biodistribution of PAA-peg and CeO2 nanoparticles, in 
order to then be extended to different types of nanoparticles with minimum changes to 
the model itself. 
More specifically, this work aims to address the following Specific Aims: 
Specific Aim 1 – PBPK model for PAA-peg nanoparticles 
Specific Aim 1 aims to develop a PBPK model for PAA-peg nanoparticles 
intravenously injected in rats, accounting for nanoparticles phagocytosis as a 
sequestration process influencing the biodistribution throughout the body. It is 
hypothesized that sequestration by phagocytizing cells of the reticuloendothelial 
system is the most important pathway for regulating nanoparticles in blood and organs 
at sub-saturation doses.  
This Specific Aim 1 will more specifically address the following goals: 
a) Appropriately account for nano-specific phenomena, such as phagocytosis. 
b) Successfully describe the dynamics of nanoparticles between and within 
organs. 
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c) Identify the most influential determinants affecting the biodistribution of 
PAA-peg nanoparticles. 
Specific Aim 2 – PBPK model for CeO2 nanoparticles 
Specific Aim 2 aims to extend the PBPK model from Specific Aim 1 to study the 
biodistribution of CeO2 nanoparticles in rats exposed by inhalation, starting with a 
mass balance analysis. We hypothesize that inhaled nanoparticles small enough could 
penetrate the alveolar wall and enter the systemic circulation. Translocation from the 
lungs to the gastrointestinal tract (GI tract) by mucociliary clearance and then 
excreted by feces could also be an important pathway of elimination of inhaled 
nanoparticles. This Specific Aim 2 will more specifically address the following goals: 
a) Examine whether the characteristics and biobehavior of CeO2 
nanoparticles will change significantly after the UV-light aging process. 
b) Analyze the biodistribution of CeO2 nanoparticles after inhalation 
exposure, including main organs and feces to enable a mass balance 
calculation. 
c) Develop, parameterize, and evaluate a PBPK model that combines 
pulmonary deposition with internal biodistribution able to predict the 
biobehavior of CeO2 nanoparticles following inhalation exposure. 
Specific Aim 3 – Adaptation of the PBPK model to other nanoparticles 
Specific Aim 3 aims to test whether the PBPK model developed in this thesis can 
accommodate various types of nanoparticles with minimum changes. The PBPK 
model developed in Specific Aim 2 and 3 will be adapted to other experimental data 
for different types of nanoparticles gathered from the literature. Data for both 
intravenous injection and pulmonary exposure pathways will be examined to test the 
robustness of the model. Parameterization of the model to different nanoparticles will 
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also be used to explore how different characteristics of nanoparticles may influence 
the most important parameters that govern the biodistribution of nanoparticles. This 
Specific Aim 3 will address the following goals: 
a) Extend the current PBPK model framework to other types of nanoparticles 
with minimum changes to the model itself while maintain the robustness 
of the model. 
b) Evaluate the ability of the model to accommodate for unique 
characteristics of certain nanoparticles. 
c) Explore how different characteristics of the nanoparticles would impact 
the most influential parameters determining the biodistribution. 
1.4.2 Outline of this thesis 
This thesis is structured according to the above Specific Aims. Following the present 
introductory Chapter 1, Chapters 2, 3, and 4 address each of the three Specific Aims, 
following the format of a journal paper supplemented by additional information in 
Appendices 2, 3, and 4 respectively. Chapter 5 summarizes how the scientific 
questions asked in this work have been answered and proposes research topics that are 
worth exploring in the future. This work has generated a number of papers (both 
published and in preparation) and conference presentations (see publication list in 
Appendix 1). The contents of Chapter 2 have been published as a full research paper 
in the journal Nanotoxicology. The contents of Chapter 3 will be submitted to the 
journal of Particles and Fibre Toxicology as a full research paper. In a much more 
condensed format, the contents of Chapter 4 have been published as a conference 
proceedings paper at the International Conference on Safe Production and Use of 
Nanomaterials 2012. In addition to the core objective of the thesis focused on the 
development of PBPK of nanoparticles, I published a paper dedicated to the health 
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impacts modeling of polycyclic aromatic hydrocarbons. This publication is enclosed 
in Appendix 5 to illustrate the wider range of tools and experience I have apprehended 
during my PhD studies. 
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CHAPTER 2
1
 
Physiologically based pharmacokinetic modeling of 
polyethylene glycol-coated polyacrylamide nanoparticles in 
rats 
2.1 Introduction 
Wide production and use of nanoparticles increase the likelihood of unintentional 
exposure at workplaces and through the general environment (Abbott and Maynard 
2010; Li et al. 2010; Cassee et al. 2011; Lee et al. 2011; Weinberg et al. 2011). In vivo 
and in vitro studies have shown that nanoparticles have the potential to induce several 
health effects including oxidative stress, leading to inflammatory reactions as a 
function of nanoparticles properties (Oberdörster et al. 2005; Sayes et al. 2006; 
Warheit et al. 2007; Zhang et al. 2011). The degree of inflammatory response to 
nanoparticles depends on the biodistribution of nanoparticles in the body (Warheit et 
al. 2007; Cho et al. 2009). A literature review suggests that various types of inhaled 
(Oberdörster et al. 2002; Nemmar et al. 2002; Semmler et al. 2004) or intravenously 
injected (Oberdörster et al. 2002; Wenger et al. 2011; Panagi et al. 2001) 
nanoparticles can migrate to, and deposit in different organs via systemic circulation. 
Knowledge in this field of research remains however limited (Li et al. 2010; 
Khlebtsov and Dykman 2011). The various physiological determinants of 
nanoparticles behavior within the body must be systematically explored to better 
understand pharmacokinetic mechanisms. 
                                                 
1
 The content of this chapter has been published as a full research paper in Nanotoxicology. Li, D.; 
Johanson, G.; Emond, C.; Carlander, U.; Philbert, M.; Jolliet, O. Physiologically based 
pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticle in rats. 
Nanotoxicology 2014, 8(S1), 128-137. 
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Physiologically based pharmacokinetic (PBPK) models have investigated the 
behavior of exogenous chemicals within the body (Teorell 1937). Recently, several 
studies have employed PBPK models to describe the biodistribution of nanoparticles 
(Lin et al. 2008; Lee et al. 2009; Lankveld et al. 2010; Li et al. 2012). These models 
have not specifically addressed the role of cellular phagocytosis, a process of 
phagocytizing cells such as macrophages and monocytes internalizing the 
nanoparticles, although it is a key process affecting nanoparticles biodistribution 
(Moghimi et al. 2001; Cho et al. 2009). For example, nanoparticles intended for 
medical use may be modified with structural functionalizations with the specific aim 
to prevent or reduce phagocytosis (Moghimi et al. 2001; Liu et al. 2008). 
Phagocytosis of nanoparticles has been modeled based on in vitro experiments 
(Wilhelm et al. 2002; Luciani et al. 2009), but this mechanism has hitherto not been 
incorporated in the attempts to describe the overall biodistribution in the body. 
Wenger et al. (Wenger et al. 2011) developed a rat model based on experimental 
mass-balance correlations suggesting the importance of macrophage uptake saturation 
of phagocytosis in the organs. Nevertheless, the model lacks a physiological approach 
and brings limited understanding on the processes affecting biodistribution. 
Specific issues need to be addressed in the nanoparticle PBPK models: a) how to 
account for nano-specific phenomena, such as phagocytosis; b) how to describe the 
dynamics of nanoparticles between and within organs; and c) what are the most 
influential determinants affecting the biodistribution? 
Here we have developed a PBPK model in rats incorporating the nanoparticles 
phagocytosis mechanism and to explore the biodistribution of intravenous exposure of 
polyethylene on glycol-coated polyacrylamide (PAA-peg) nanoparticles. PAA-peg is 
an example of a nanoparticle engineered for intracellular delivery of sensory and 
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pharmaceutically active agents (Kuruppuarachchi et al. 2011). Our study provides a 
significantly improved understanding of the key determinants of nanoparticles 
biodistribution in rats with a more physiologically relevant PBPK framework. This 
framework provides a sound basis for further extension to other exposure routes, 
types of nanoparticles, and for subsequent evaluation of biodistribution of 
nanoparticles in humans. 
2.2 Methods 
2.2.1 Experimental data 
The PBPK model was developed based on anatomical and physiological 
considerations and on an experimental biodistribution study published by Wenger et 
al. (Wenger et al. 2011), where five groups of rats (n = 3) received a single 
intravenous dose of 7 000 μg 14C-labeled PAA-peg nanoparticles. The PAA-peg 
nanoparticles had a hydrodynamic radius of 35 ± 7 nm and a surface charge of + 2.31 
± 0.77 mV. Urine, feces, blood samples, and cage residues, were collected at 
sequential times and tissue samples of the liver, spleen, kidneys, heart, lungs, brain, 
lymph nodes (mesenteric, inguinal, and popliteal), and bone marrow (both femurs) 
were collected following euthanasia by CO2. Radioactivity levels were determined by 
liquid scintillation counting with correction for background chemiluminescence. 
Hepatic phagocytosis was visually observed by microscopy approach (Fig. 2.1).  
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Fig. 2.1 Light micrograph of liver from a rat exposed through the caudal vein to 
polyacrylamide hydrogel nanoparticles (35nm mean hydrodynamic radius) 
containing covalently bound Coomassie Blue (1%). This figure demonstrates that 
most of the nanoparticles are phagocytized, necrotic foci (arrows) incorporating 
nanoparticle laden macrophages (blue) and individual Kupffer cells being 
engorged with aggregates of nanoparticles. [Stain, H&E – 5um]. 
2.2.2 PBPK model 
The PBPK model consists of 10 compartments: arterial blood, venous blood, lungs, 
spleen, liver, kidneys, heart, brain, bone marrow, and the rest of the body (skin, 
muscle, skeleton, etc.). All compartments are interconnected via systemic circulation 
(Fig. 2.2). Within each organ compartment, there are three sub-compartments 
representing capillary blood, tissue, and phagocytizing cells (PCs). The arterial blood 
and venous blood compartments also have phagocytizing cells sub-compartments.  
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Fig. 2.2 Structure of the nanoparticle PBPK model, with phagocytizing sub-
compartment in each tissue. 
The exchange of nanoparticles between blood and tissue in each organ is described as 
a flow- and diffusion-limited process. Diffusion between blood and tissue is 
controlled by a permeability coefficient, which limits the effective blood flow 
(Krishnan 2007). We assume the same permeability coefficient for lungs, spleen, liver, 
kidneys, heart, and bone marrow. This permeability coefficient for the brain 
compartment is set to zero, under the assumption of a highly efficient blood-brain 
barrier. 
Most plasma proteins cannot pass the capillary membranes, hence the composition of 
interstitial fluid differs from that of plasma. As a consequence, the composition of the 
biocorona formed around the nanoparticles will differ between these two locations 
(Nel et al. 2009; Lundqvist et al. 2008). This may make the blood environment 
energetically more favorable than the interstitial fluid, resulting in an uneven 
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distribution between blood and interstitial fluid at steady-state (Mason et al. 1992). 
The uneven distribution of large anionic plasma proteins may also contribute to the 
uneven distribution of nanoparticles via the Gibbs-Donnan effect. The distribution 
between interstitial fluid and plasma is accounted for by fitting a tissue: blood 
partition coefficient. Although the composition of interstitial varies between tissues, 
the tissue: blood partition coefficient is assumed to be the same for all tissues. 
A fraction of the nanoparticles entering the tissue is sequestrated by PCs. When the 
amount of captured nanoparticles increases, the PCs can eventually be saturated. The 
PCs saturation level is organ specific, reflecting the variation in the density of PCs as 
well as differences in uptake capacity for different types of PCs among different 
organs. The effective uptake rate by PCs is a function of a maximum uptake rate and 
decreases as the PCs become saturated. This maximum uptake rate is the same for all 
compartments except for the spleen, due to its mesh-like structure that could trap 
nanoparticles in the spleen marginal zones and delay their contact with the splenic 
phagocytizing cells (Demoy et al. 1999; Moghimi 2002). Nanoparticles can also re-
enter the tissue after desorption from PCs by processes such as exocytosis (Chithrani 
and Chan 2007; Keighron et al. 2012). 
Excretion of nanoparticles occurs from liver tissue and capillary blood of kidneys. 
Biodegradation is considered negligible for the time-scale of this study due to the low 
biodegradability of cross-linked polyacrylamide (Smith et al. 1996, 1997). More 
details describing the dynamics of the model and the mathematical representations 
can be found in the method section and in the supplementary material. 
2.2.3 Main mathematical description of the model 
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We present here three main model equations describing the mass balances of a tissue t 
and of the PCs in this tissue. A more comprehensive mathematical representation of 
the model is given in the supplementary material (Appendix A2.1). 
Tissue: Since the model assumes a diffusion-limited process, the capillary blood and 
tissue in the organ should be described separately. As a result, the dynamic of 
nanoparticles in the tissue sub-compartment results from the net transfer with 
capillary blood, instead of the direct exchange between arterial blood and venous 
blood as in perfusion-limited process. A fraction of nanoparticles is captured by PCs 
and may re-enter the tissue by desorption. In certain organs, excretion of nanoparticles 
occurs as a clearance route from the body. The equation describing these processes is: 

    
excretionby  clearance
,
 PCs withninteractio
,,
bloodcapillary  er withnet transf
, )()/(
dt
dM
kMkCWPCCPA
dt
dM exe
demtabttttbtt
t   2.1 
where, 
Mt [µg] – Amount of nanoparticles in the tissue of organ t. 
Wt [g] – Weight of organ t. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
Ct,b [µg per g] – Concentration of nanoparticles in the capillary blood of organ t. 
PAt [mL per hour] – Permeability coefficient-surface area cross-product. It is 
approximated as the product of permeability coefficient between capillary blood and 
tissue (unitless) and regional blood flow (mL per hour), χα×Qt, in this model, 
assuming the surface area is proportional to the regional blood flow. 
P [unitless] – Partition coefficient of nanoparticles between tissue and blood.  
Mt,m [µg] – Amount of nanoparticles captured by PCs in organ t. 
kt,ab [per hour] – Current uptake rate of nanoparticles by PCs in organ t. 
kde [per hour] – Desorption rate of nanoparticles from PCs to tissue. 
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Me,ex [µg] – Amount to excreta from source e. e only applies to tissue in liver and 
capillary blood in kidneys. 
To eliminate the sub-compartment of capillary blood and simplify the model, Eq. 2.1 
can be transformed to Eq. 2.2 that expresses the dynamic in different organs directly 
as a function of the arterial blood (Cart) and permeability coefficient (χα). Details of 
this transformation can be found in the supplementary material (Appendix A2.1). 
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Phagocytizing cells: The change in mass of nanoparticles in PCs is the uptake from 
the tissue minus desorption from PCs back to tissue. The uptake rate kt,ab will decrease 
as the amount captured approaches the total PCs saturation level characterized by the 
PCs uptake capacity per unit weight. The equation describing these behaviors is: 

  
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where, 
kab0 [per hour] – Maximum uptake rate by PCs. 
Mt,cap [µg per g] – PCs uptake capacity for nanoparticles per organ t weight. 
2.2.4 Implementation of the model 
The PBPK model was implemented in Berkeley Madonna
TM 
version 8.3.18 (Berkeley, 
CA) and acslX
TM
 version 3.0.2.1 (Huntsville, AL). Parameters with unknown values 
were optimized by fitting the unknown model parameters against the experimental 
data given by Wenger et al. (Wenger et al. 2011) using the Nelder-Mead method in 
acslX
TM
. To create the most parsimonious model possible, we used a common generic 
parameter for most organs. We only differentiated parameters between compartments 
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when it was indispensable to explain the dynamics of the PAA-peg concentration in 
that compartment in a physiologically meaningful way. The following parameters 
were fitted: clearance rates from kidneys and liver, the fraction of residual capillary 
blood left in organs when analyzed for nanoparticles contents, partition coefficient 
between tissue and blood (same for all compartments), permeability coefficients 
between blood to tissue (same for all compartments but brain and rest of the body), 
PCs uptake capacity per organ weight (one for each compartment), the maximum 
uptake rate (same for all compartment but spleen) and desorption rate by PCs (same 
for all compartment). All other parameter values were taken from the scientific 
literature (Krishnan 2007; Travlos 2006; Brown et al. 1997; Bernareggi and Rowland 
1991; Brookes 1967). Values of all parameters and their standard deviations are listed 
in Table 2.1. 
2.2.5 Analysis of model accuracy and identifying influential parameters 
For the model evaluation we determine the deviation from the line of unity between 
the log10 of measured and predicted values (McKone 1993), and calculate the 
corresponding R
2
.  
We determine the most influential input parameters by performing a systematic 
sensitivity analysis using two approaches. First, we multiply or divide each parameter 
by a factor of 2 or 100 and compare the nanoparticles amount in a given compartment 
over time. Second, we analyze the relative sensitivity of the area under the mass-time 
curve (AUC) to different model parameters by comparing the relative change in AUC 
divided by a 1% relative change in parameter p: 
pdp
AUCdAUC
/
/
ysensitivit Relative      2.4 
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The relative sensitivities were calculated both for 10 hours and for 120 hours, to 
capture fast and slow processes, respectively. 
2.3 Results 
2.3.1 Model’s predictions of the biodistribution 
The model’s predictions fit well with measured data (R2 =0.97), as seen in Fig. 2.3, 
and illustrated in Fig. A2.1 in the Appendix (Appendix A2.2). The model suggests 
that 83% of the total nanoparticles found in richly perfused organs are stored in the 
PCs 120 hours after injection. As shown in Table 2.1, the specific PCs uptake 
capacity per organ weight for different organs varies by more than two orders of 
magnitude, consistently with the expected densities of PCs that are the highest in 
spleen and liver.  
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Table 2.1 Descriptions and values of parameters for the model. 
Parameter (unit) Description Generic values a Spleen (s) Liver (l) 
Bone 
marrow (bm) 
Lungs 
(lu) 
Heart 
(h) 
Kidneys (k) 
Rest of the 
body (rest) 
Brain (br) 
Blood 
(blood) 
Wt (g) 
b Weight of organs N/A 
0.779 ± 
0.101 
10.0 ± 1.02 7.60 
1.20 ± 
0.109 
0.873 ± 
0.0877 
2.37 ± 
0.196 
213 
1.35 ± 
0.139 
16.5 ± 
0.522 
Wt,b (g) 
c 
Weight of capillary blood in 
organ 
N/A 0.0172 2.11 0.760 0.432 0.226 0.379 8.51 0.0945 N/A 
Qt (mL per h) 
d Blood flow to organ N/A 72.7 1245 133 4980 254 702 2473 99.6 4980 
Mt,cap (µg per g) 
e 
Phagocytizing cells uptake 
capacity per organ weight 
N/A 
631 ± 
8.50 
74.8 ± 
0.203 
41.2 ± 0.799 
25.5 ± 
0.0671 
5.03 ± 
0.0521 
1.08 ± 
0.00835 
17.6 ± 
0.155 
0.0827 ± 
12.2 
0.0396 ± 
0.000374 
χα (unitless) 
e 
Permeability coefficient 
between blood to tissue 
1.06×10-3 ± 
1.12×10-5 
generic generic generic generic generic generic 
8.25×10-5 ± 
4.41×10-7 
0 N/A 
P (unitless) e 
Partition coefficient between 
tissue and blood 
0.147 ± 0.00191 generic generic generic generic generic generic generic generic 1 
kab0 (per h) 
e 
Maximum uptake rate by 
phagocytizing cells 
16.1 ± 0.306 
0.112 ± 
0.000990 
generic generic generic generic generic generic generic generic 
kde (per h) 
e 
Desorption rate by 
phagocytizing cells 
4.90×10-19 ± 
7.26×10-17 
generic generic generic generic generic generic generic generic generic 
CLEe (per h) 
e Clearance rate to excreta N/A N/A 
1.18×10-2 ± 
2.92×10-4 
N/A N/A N/A 
6.56×10-3 ± 
5.35×10-5 
N/A N/A N/A 
frβ 
e 
Fraction of capillary blood of 
organs left when analyzed 
0.177 ± 0.0257 generic generic generic generic generic generic generic 
0.346 ± 
0.0208 
N/A 
a χα, P, kab0, kde have generic values for most compartments. "generic" indicates the corresponding generic value for each parameter 
b Values expressed in average ± standard deviation from experimental data, except for bone marrow (assumed to be 3% of the total body weight [Travlos 2006]), and the rest of the body (the result of 
subtracting all other organs' weights from total body weight). The average values are used in the model 
c Values obtained by multiplying the literature estimates of the percentage (w/w) of capillary blood in the organs (Brown et al., 1997) with the experiment values of organ weights. The percentage for 
bone marrow is estimated in this study 
d Values obtained from literature (Brookes 1967; Bernareggi and Rowland 1991; Krishnan 2007). For the rest of the body, it is assumed to be the difference between total cardiac output and the sum of 
blood flows through other organs 
e Values expressed in optimized value ± standard deviation obtained from parameterization by acslXTM (version 3.0.2.1) 
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Fig. 2.3 Amount of PAA-peg nanoparticles predicted by the PBPK model 
predicted versus measured data in different organs. Error bars show the 
standard deviation of measured data. “PCs” is the abbreviation for 
phagocytizing cells. (A) blood. (B) liver. (C) lungs (D) heart. (E) kidneys. (F) 
spleen. (G) brain. (H) bone marrow. (I) rest of the body 
The time course of nanoparticles amount in the blood compartment (arterial and 
venous blood combined) exhibits two phases (Fig. 2.3A). During the first four hours 
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after dosing, the amount in blood decreases quickly as the nanoparticles rapidly 
distribute to the organs, whereafter they are internalized by the PCs. After about four 
hours, a slower decay is observed as the PCs in the richly perfused organs are 
saturated and the nanoparticles diffuse into the rest of the body. 
For the liver, lungs, heart, and kidneys (Fig. 2.3B, 2.3C, 2.3D, and 2.3E), the 
nanoparticles in the capillary blood of each compartment are transferred into the 
tissue and captured by the PCs in a relatively fast process, which reaches saturation 
plateau within 30 minutes to four hours. After saturation, PCs loaded with 
nanoparticles represent the major storage depot. 
The spleen acts similarly to the organs discussed above except the PCs within have a 
lower uptake rate which delays the time for saturation (see Fig. 2.3F), due to the 
mesh-like structure of the spleen.  
The blood-brain barrier blocks most of the nanoparticles from entering the tissue in 
the brain compartment (see Fig. 2.3G). Less than 0.2% of the injected nanoparticles 
were found in the brain. In accordance with other studies describing nanoparticles 
biodistribution (Oberdörster et al. 2002; Yokel et al. 2012; Sadauskas et al. 2007), this 
restricted amount of nanoparticles in the brain may well be explained by the 
nanoparticles content of residual capillary blood not entirely removed from the brain 
samples.  
In contrast to all other tissues, the model is less suited to describe the experimentally 
observed time courses in bone marrow (Fig. 2.3H). In the original experiment, 
Wenger et al. (Wenger et al. 2011) reported only 0.02 g of bone marrow sampled, 
which is less than 3% of the total bone marrow weight (Travlos 2006), suggesting 
poor recovery. In addition, the standard deviations of the measured amount of 
nanoparticles were far higher for bone marrow than for the other tissues, suggesting a 
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high variability in the measurements. Additional data with a higher recovery rate and 
more precise measurements are needed to develop more accurate predictions for the 
bone marrow. 
Due to the lower permeability coefficient between capillary blood and tissue, the 
kinetics of the rest of the body exhibits a different dynamic than the other organs (Fig. 
2.3I). The nanoparticles are transferred from capillary blood rather slowly into the 
tissue and captured by PCs. Due to its large share (84%) of the whole body weight the 
rest of the body represents a major depository with 65% of the injected dose at the end 
of the experiment. Though the nanoparticles amount in the rest of the body has only 
been measured at the end of the experiment, the evolution of this amount is consistent 
with observed data in other organs and the mass balance of nanoparticles in the entire 
body. 
2.3.2 Influential parameters 
The most influential parameters affect the biodistribution of PAA-peg nanoparticles 
as follows. 
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Fig. 2.4 Sensitivity analysis of the amount of nanoparticle in liver to the four 
most influential parameters. (A) PCs uptake capacity per liver weight (Ml,cap) . (B) 
partition coefficient between tissue and blood (P). (C) permeability coefficient 
between capillary blood and tissue in liver (χrich). (D) maximum uptake rate by 
PCs (kab0). Error bars show the standard deviation on measured data. “PCs” is 
the abbreviation for phagocytizing cells. Reference values from Table 2.1 are in 
black and sensitivity study are shown in red and blue. 
  
 
2
7 
Table 2.2 Relative sensitivities (unitless) for the most influential parameters 
a
. 
Organ 
Mt,cap   P   χrich   χrest   kab0 
10 
hours 
120 
hours 
  
10 
hours 
120 
hours 
  
10 
hours 
120 
hours 
  
10 
hours 
120 
hours 
  
10 
hours 
120 
hours 
Blood 0.00 0.00   -0.07 -0.12   -0.08 -0.01   -0.06 -0.50   0.00 0.00 
Liver 0.41 0.69 
 
0.17 0.17 
 
0.20 0.02 
 
-0.03 -0.13 
 
0.01 0.00 
Lungs 0.27 0.44   0.45 0.32   -0.05 -0.01   -0.04 -0.28   0.00 0.00 
Heart 0.07 0.15 
 
0.60 0.54 
 
-0.04 -0.01 
 
-0.05 -0.42 
 
0.00 0.00 
Kidneys 0.02 0.04   0.71 0.69   -0.04 -0.01   -0.06 -0.48   0.00 0.00 
Spleen 0.00 0.10 
 
0.51 0.63 
 
0.16 0.10 
 
-0.05 -0.33 
 
0.18 0.62 
Brain 0.00 0.00   -0.07 -0.12   -0.08 -0.01   -0.06 -0.50   0.00 0.00 
Bone marrow 0.06 0.57 
 
-0.03 0.57 
 
0.71 0.07 
 
-0.04 -0.19 
 
0.01 0.00 
Rest of the body 0.00 0.02   -0.06 -0.06   0.11 -0.01   0.28 0.41   0.00 0.00 
a
 For descriptions of the parameters, please refer to Table 2.1 
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The PCs uptake capacity of nanoparticles per unit weight (Mt,cap) is the most 
influential parameter in the liver. It determines the maximum PAA-peg nanoparticles 
amount and the model is highly sensitive to this parameter throughout the entire time-
course (Fig. 2.4A), with high relative sensitivities of 0.41 and 0.69 over 10 and 120 
hours respectively (Table 2.2). Once captured by PCs, nanoparticles will not be easily 
transferred to other compartments since the desorption of nanoparticles from the PCs 
back into the tissues are rather slow. Therefore a near constant nanoparticle storage in 
PCs is reached once the PCs are saturated (Fig. 2.4A dashed lines). Similar effects are 
shown in lungs and bone marrow (Table 2.2), which have high values for Mt,cap (Table 
2.1). On the contrary, Mt,cap is not a sensitive parameter for blood, heart, kidneys and 
brain (Table 2.2) since the majority of nanoparticles in these organs are not captured 
by the PCs. The PCs in the spleen and the rest of the body do not reach saturation for 
most of the 120 hours, and are therefore not sensitive to Mt,cap (Table 2.2). 
The partition coefficient between tissue and blood (P) has a moderate influence on the 
short-term kinetics in the liver and virtually no influence on the long-term kinetics 
(Fig. 2.4B and Table 2.2). This is due to the fact that for liver, the amount of 
nanoparticles in the tissue represent about one third of the nanoparticles in the early 
phase, but is strongly reduced later as the concentration in the blood is itself reduced. 
The partition coefficient between tissue and blood has a dominant influence on lungs, 
heart, kidneys, spleen. These organs have a higher proportion of nanoparticles in the 
tissues and the spleen does not reach saturation in PCs (Table 2.2). 
The permeability coefficient between capillary blood and tissue (χα) determines the 
speed of nanoparticles passage from capillary blood into the tissue. This parameter 
only affects the short-term kinetics in liver (Fig. 2.4C), with moderate relative 
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sensitivity of 0.20 for 10 hours AUC (Table 2.2). Among organs, the influence of χα is 
only large in bone marrow (Table 2.2) because of lower blood flow rate relative to 
organ weights. This permeability coefficient (χrest) has also a large influence on both 
the short-term and long-term kinetics of the rest of the body (Table 2.2, more details 
can be found in Appendix A2.3).  
In the considered range, lowering the maximum uptake rate by PCs (kab0) has little 
influence on most organs, unless it is reduced by two orders of magnitude and thus 
becomes a limiting factor to the capture of nanoparticles by PCs, as observed in the 
spleen (Table 2.1 and Table 2.2).  
For the brain, the model considers the residual capillary blood left in the brain 
responsible for the detected nanoparticles and therefore the relative sensitivities are 
similar for blood and brain (Table 2.2). All parameters have low to moderate 
influences on blood except the permeability coefficient to the rest of the body χrest for 
the 120 hour AUC. This is because most nanoparticles in blood migrate to the rest of 
the body after the phagocytizing saturation capacity is reached in richly perfused 
organs. 
This analysis of the most influential parameters reveals that the partition coefficient 
between tissue and blood, the permeability coefficient between capillary blood and 
tissue, and the maximum uptake rate by PCs have a relatively small influence on the 
long-term biodistribution of PAA-peg nanoparticles for most organs. 
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2.4 Discussion 
We have observed large variations in uptake capacity of up to two orders of 
magnitude. These are consistent with the expected densities of phagocytizing cells 
(PCs): we also find the highest PCs uptake capacities for spleen, liver, bone marrow, 
and lungs in accordance with other studies (Lang and Dobrescu 1991; Hyafil et al. 
2007) that indicated these organs have the highest density of PCs. For the distribution 
of PAA-peg nanoparticles among organs, the uptake capacity is especially important 
to spleen, liver, bone marrow, and lungs. The importance of the uptake capacity might 
be lower or even negligible in organs with lower density of PCs. The high uptake 
capacity value for the rest of the body seems counter-intuitive as the rest of the body 
is not known for high level of phagocytizing cells. This could suggest that the uptake 
capacity parameter also represents other mechanisms in addition to phagocytosis. For 
example, protein binding is also proposed as an explanation for the intracellular 
uptake saturation for gold nanoparticles (Chithrani et al. 2006). This possibility of 
multiple mechanisms being responsible for the saturation phenomenon requires 
further investigation.  
The tissue-specific phagocytizing capacities are in relation to the observed PAA-peg 
nanoparticles time course in the corresponding tissues. It is therefore important to 
validate that the fitted capacities are consistent with other similar experimental studies, 
i.e. using the same route of administration, same, strain, age and identical 
nanoparticles. According to the present model, the PCs uptake capacity per liver 
weight is about 74.8 µg per g of tissue. Considering that there are about 27 million 
macrophages per gram of rat liver (Alpini et al. 1994) and assuming that all PCs in the 
liver are macrophages, the uptake capacity of the liver PCs corresponds to 2.8 pg or 
3.8 million PAA-peg nanoparticles per macrophage (the average molar mass of the 
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PAA-peg nanoparticle in this study was 440 000 g/mole). This is consistent with other 
in vitro studies finding 3.2 to 48 million nanoparticles per macrophage (Wilhelm et al. 
2003; Robert et al. 2011).  
Nanoparticles uptake by PCs has several implications on the toxicity of nanoparticles. 
First, by storing the nanoparticles, the PCs could prevent the organs from being 
directly damaged when exposed to potential toxic nanoparticles. Second, during the 
nanoparticles sequestrations, the PCs can be stressed, impairing the body’s immune 
system. Third, the nanoparticle-loaded PCs could slowly release nanoparticles back to 
the tissue over time and serve as a long-term internal source of nanoparticles inside 
the body, extending organs exposure duration even after external nanoparticles 
sources are eliminated. 
A better understanding of the mode of action concerning the uptake of nanoparticles 
by PCs is crucial not only regarding bioaccumulation and toxicity, but also with 
respect to pharmacologic effects and drugs therapeutic threshold. 
Nanopharmaceuticals drugs preparation might end up being captured by PCs before 
reaching their target thus and inhibiting or reducing their pharmacological effects. 
PCs saturation by non-toxic nanoparticles might nevertheless reduce the immune 
response to pathogens and increase the body’s vulnerability to diseases. 
Our model has the advantage compared to previous biodistribution models for 
nanoparticles (Lin et al. 2008; Lee et al. 2009; Lankveld et al. 2010; Li et al. 2012; 
Wenger et al. 2011) in that it describes the interactions between PCs and nanoparticles 
in a more detailed and, as we believe, a more physiologically based manner. For 
example the distribution coefficient given by Lin et al. (2008) is empirical rather than 
physiological and represents an amalgamation of several processes such as deposition, 
protein binding, transport through capillaries, phagocytosis, transcytosis, and 
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endocytosis. By providing a more detailed representation of the different mechanisms, 
our model enables us to identify the critical processes that determine the behavior and 
biodistribution of nanoparticles. In our opinion, this forms a sound basis for further 
refinement and adaptation to other types of nanoparticles and other species including 
human. 
This work points out an important limiting step driving the equilibrium constant  of 
polyacrylamide nanoparticles, namely the partition coefficient between tissue and 
blood, the diffusibility parameter (namely permeability coefficient) between capillary 
blood and tissues, the uptake capacities of PCs, and the uptake rate of PCs. These are 
the major unknown estimates that require optimization in order to model the 
biodistribution of other nanoparticles.  
Despite the PAA-peg nanoparticles concentration in the organs being generally higher 
than the concentration in blood, the introduction of PCs compartments within each 
tissue implies that the apparent partition coefficient between tissue (excluding PCs) 
and blood may be smaller than 1, thus the partition coefficient of 0.15 obtained by 
best fit (Table 2.1). The apparent partition coefficient between tissue and blood may 
be linked to the composition of the biocorona formed around the nanoparticles. 
Various properties of the nanoparticles, e.g. size, surface charge, and ligands, and 
crystallinity can influence the  composition of the biocorona and therefore affect the 
interaction between nanoparticles and the biological system (Nel et al. 2009). The low 
apparent partition coefficient implies that, disregarding the redistribution due to 
phagocytosis, the modeled nanoparticles have a preference for blood. 
A limiting amount of nanoparticles in the brain could be explained by a residual 
capillary blood containing nanoparticles not entirely removed from the brain samples. 
The assumption of zero permeation value used for the brain is in accordance with the 
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prediction obtained using the PBPK model. However, we cannot exclude that minor 
permeation occurs. Higher amounts in the brain have been reported for other 
intravenous exposure to nanoparticles (Oberdörster et al. 2004; Elder et al. 2006; 
Yokel et al. 2012; Hardas et al. 2010), suggesting higher permeation in brain for other 
nanoparticles such as cerium oxide. 
The absolute uptake rates and capacities of PCs are expected to vary across different 
types of nanoparticles as influenced by nanoparticles size, surface modification, 
surface charge and chemical reactivity (Moghimi et al. 2001; Wilhelm et al. 2002; 
Walkey et al. 2012). The relative abundance and types of PCs in different organs are 
intrinsic anatomical-physiological and animal dependent. It could also be related to 
defensive immune response triggered by a pathological response.  It will therefore be 
interesting to test the hypothesis that the relative PCs uptake capacities vary similarly 
across organs as a function of nanoparticles properties. Individual types of PCs have 
different uptake capacities for the same type of nanoparticles. For example, the uptake 
capacity of monocytes is about 50 times lower than those of macrophages as 
suggested in the literature (Luciani et al. 2009). In our model, the uptake capacity 
represents the overall uptake of all types of PCs.  In the future, it would be of interest 
to differentiate the uptake for each main type of PCs. The desorption rate of PAA-peg 
nanoparticles from the PCs back to tissue plays a negligible role since it is orders of 
magnitude lower than the uptake rate, which agrees with the findings of Luciani et al. 
(2009). 
Although this model considers phagocytosis to be solely responsible for the saturation 
phenomenon observed in the experiment, we cannot exclude other mechanisms, such 
as protein binding, that would result in similar outcome. The parameter Mt,cap may 
thus represent a mixture of different mechanisms rather than phagocytosis only. 
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Figure 1 nevertheless shows that phagocytosis plays a dominating role in the 
distribution of PAA-peg nanoparticles in the liver. 
Future efforts should therefore focus on these most influential parameters affecting 
the biodistribution of nanoparticles, and how these parameters depend on 
nanoparticles properties such as type, size and surface charge. Better knowledge is 
especially needed about the PCs, their uptake kinetic for nanoparticles and their 
quantitative abundance in different organs. Other potentially important mechanisms 
such as protein binding should also be investigated further. Obtaining experimental 
values is a priority for the partition coefficient between tissue and blood, the 
permeability coefficient between capillary blood and tissues. 
2.5 Conclusions 
According to the PBPK model developed in this work, the PCs are the major reservoir 
of PAA-peg nanoparticles in the organism. Because of the high net uptake by 
phagocytizing cells, nanoparticles will only accumulate in organ tissues after the 
saturations of PCs occurred. When extrapolating this model to human, certain 
physiological parameters such as blood flow, organ weight, etc. can be directly 
adapted for a human’s setting while the partition coefficient, permeability coefficient, 
and parameters governing the PCs behavior should be investigated further before 
making predictions with this model.  
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CHAPTER 3
2
 
Physiologically based pharmacokinetic modeling of cerium 
oxide nanoparticles by inhalation exposure in rats 
3.1 Introduction 
Nanoparticles emerged as a type of innovative material that holds multiple promising 
features when compared to their bulk counterparts (Nel et al. 2006). Commercial 
applications of nanomaterials may expose human to nanoparticles and raise concerns 
about potential human health impacts, given toxic effects of nanoparticles were 
observed (Wang et al. 2014; Choi et al. 2009; Kendall and Holgate 2012). This paper 
focuses on exposure and biodistribution of Cerium oxide (CeO2) nanoparticles, which 
are mainly used as a diesel fuel additive to improve combustion efficiency (Wakefield 
et al. 2008) and can be released to the environment by diesel engines. Several in vitro 
and in vivo studies have shown that these CeO2 nanoparticles can generate reactive 
oxygen species that induce oxidative stress and inflammatory responses, which can 
cause adverse human health effects (Aalapati et al. 2014; Thill et al. 2006). To better 
understand the toxic effects of CeO2 nanoparticles, it is necessary to first characterize 
the biodistribution of CeO2 nanoparticles in the entire body. 
Several studies have shown that intravenously injected CeO2 nanoparticles could be 
found in all major organs in rats following systemic circulation even 90 days after 
injection (Yokel et al. 2012; Hardas et al. 2010; Yokel et al. 2009). An intratracheal 
instillation study found that besides of lungs, the largest quantity of instilled CeO2 
                                                 
2
 The content of this chapter will be submitted as a full research paper to Particle and Fibre Toxicology. 
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nanoparticles was in the feces in the first two days after exposure (He et al. 2010). 
Recently conducted inhalation studies on CeO2 nanoparticles showed that the lungs 
are the major deposit organ while CeO2 nanoparticles could penetrate from the lungs 
into the systemic circulation as they were found in other extrapulmonary organs 
(Geraets et al. 2012; Aalapati et al. 2014).  However, these inhalation studies did not 
include feces and fail to provide a more comprehensive mass balance of the inhaled 
dose of CeO2 nanoparticles. In addition, diesel fuel combustion and refining processes 
emit SO2 that may be physically associated with CeO2 nanoparticles. There is 
therefore a need to characterize environmental transformation and physicochemical 
properties of aged CeO2 nanoparticles using their interactions with UV radiation and 
ambient air co-pollutants, and compare them to freshly-combusted CeO2 nanoparticles. 
To better understand exposure, provide insights on the main mechanisms responsible 
for biodistribution and possibly extrapolate biobehavior from rodent models to 
humans, it is useful to complement biodistribution experimental data with 
pharmacokinetic modeling. Physiologically based pharmacokinetic (PBPK) models 
have been used to study and predict the biodistribution of chemicals inside the body 
for decades (Krishnan 2007). Several PBPK models have been specifically developed 
for nanoparticles (Lin et al. 2008; Lee et al. 2009; Lankveld et al. 2010; Li et al. 2012) 
but failed to specifically address the role of phagocytosis, which was observed as a 
key process of nanoparticle biodistribution (Moghimi et al. 2001; Cho et al. 2009; 
Luciani et al. 2009). Li et al (2014) built a whole body PBPK model that incorporated 
phagocytosis but the model was limited to intravenous injection of nanoparticles. One 
PBPK model for inhalation exposure of nanoparticles has been developed for silver 
nanoparticles by Bachler et al (2013), but this model only considers biliary excretion 
from the liver to feces and cannot explain the high amount of nanoparticles found in 
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feces in a previous pulmonary in vivo study (He et al. 2010). Currently, there is no 
detailed PBPK model describing the biodistribution of inhaled CeO2 nanoparticles. 
There is therefore a need for developing a PBPK model parameterized for CeO2 
including deposition in the respiratory system and translocation/excretion. 
The objectives of this study are: 
1. Generate and characterize both fresh and UV-light aged CeO2 nanoparticles. 
2. Measure the biodistribution of CeO2 nanoparticles in an in vivo rat inhalation 
study, including main organs and feces and analyze the mass balance. 
3. Develop, parameterize, and evaluate a PBPK model that combines pulmonary 
deposition with internal biodistribution, able to predict the biodistribution 
kinetic of CeO2 nanoparticles.  
3.2 Methods 
3.2.1 Experimental apparatus 
Fig. 3.1 shows the schematic of the entire experimental apparatus located at Michigan 
State University consisting of a nanoparticle generation facility, a photochemical 
chamber, a series of instruments that characterize the aerosol flow, and a nose-only 
inhalation exposure chamber for rats.   
Generation of CeO2 nanoparticles: CeO2 nanoparticles with a density of 6.96 g/cm
3
 
were generated using the University of Michigan combustion synthesis (UMCS) 
facility was transported to Michigan State University for animal exposure.  The 
UMCS facility uses a multi-element H2/O2 diffusion flame burner to provide a high-
temperature oxidizing environment for cerium acetate (cerium(III) acetate hydrate; 
Sigma-Aldrich, 99.99% trace metals basis) precursor decomposition, oxidation, and 
particle formation. The burner was operated continuously to generate appropriate 
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quantities of nanoparticles for analysis. Further information on the synthesis facility 
can be found in Bakrania et al. (2007a; 2007b), Miller et al. (2005), and Hall et al. 
(2004). 
Photochemical chamber: The atmospheric reaction chamber is a 500-L fluorinated 
ethylene propylene Teflon bag designed in collaboration with Ingeniven Inc. (North 
Hampton, NH, United States).  Thirty (UVA-340) fluorescent lamps (40 W each) 
were used to simulate sunlight in the short wavelength region from 365 nm down to 
the solar cutoff of 295 nm. These lamps were placed beside the chamber to simulate 
~250 W/m
2
 of direct UV flux in the chamber, which is equivalent to five times solar 
UV flux. Reflections from the interior surface of the enclosure are expected to 
significantly increase this figure and actual UV flux levels were measured with a UV 
meter.   
Nanoparticle characterization: A scanning mobility particle sizer (SMPS) with an 
electrostatic classifier (TSI-3080, TSI Inc., Shoreview, MN, USA) was used to 
monitor the aerosol number density and particle size distribution as a function of time 
during the animal exposure studies.  Specifically, the size distribution of the aerosol 
was monitored during the experiments in real time using a differential mobility 
analyzer (DMA) (TSI-3081, TSI Inc., Shoreview, MN, USA) connected to a 
condensation particle counter (CPC) (TSI-3010, TSI Inc., Shoreview, MN, USA). The 
SMPS uses a particle size impactor filter to remove particles >~0.5 µm in size.  
Additionally, a cascade impactor filter (Sioutas Impactor, SKC Inc., Eighty Four, PA, 
USA) was incorporated after the photochemical chamber, upstream of the exposure 
carousel, filter packs and SPMS, to remove larger particles and agglomerates. 
Gas sampling (GS) was used to measure the NOx, CO, O3, and CO2 levels in the 
nanoparticles carrier gas. These gases were by-products of the combustion process 
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used to generate the ceria nanoparticles, and also represent gases found at ambient 
conditions in urban environments. Additional measurement of post combustion O2 
levels were performed using an emission analyzer (MEXA-584L, HORIBA 
Instruments, Ann Arbor, MI, USA) to ensure that the oxygen was at atmospheric 
levels, i.e. near 20% on a mole fraction basis.  
The nanoparticles mass during each exposure study was measured using filter pack 
assemblies. Four 47-mm Teflon (PTFE) filters (Gelman Science) in Teflon/Teflon-
coated aluminum filter packs were attached to two ports of the exposure chamber to 
determine the total nanoparticle mass deposited during sampling times corresponding 
to the exposure studies.  The filter packs were used according to the Federal 
Reference Method (U.S. EPA 1999). Four pumps were used to control the flow rates 
to the exposure carousel, the filter packs, the SMPS and the GS system.  Additional 
details on the aerosol transport system, including dimensions and flow rates, can be 
found in Fatouraie et al. (2015). 
Transmission electron microscopy (TEM) was performed at the University of 
Michigan’s electron microbeam analysis laboratory using a high resolution electron 
microscope (JEOL 3011, JEOL USA Inc., Peabody, MA, USA) in order to 
characterize the nanoparticles morphology and size distribution. The nanoparticles 
were sampled on copper grids (carbon film, 300 mesh copper, Electron Microscopy 
Sciences, Hatfield, PA, USA) placed in the aerosol flow after the impactor filter. Bulk 
properties such as crystalline structure and the average crystallite size were analyzed 
using powder x-ray diffraction (XRD) equipment (Bruker D8 Discover with GADDS, 
BRUKER AXS Inc., Madison, WI, USA).  Details on the sample preparation for the 
nanoparticle materials analysis can be found in Fatouraie et al. (2015). 
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Fig. 3.1 Schematic representation and photo of the experimental apparatus. The 
dimensions are not to scale. 
3.2.2 Animal study design 
Animals and inhalation exposure: Male Sprague-Dawley rats 200 – 235 g, 9 weeks of 
age, were obtained from Charles River Laboratories (Portage, MI, United States) and 
 42 
 
housed for at least seven days in shoebox-style cages prior to experimental protocols 
with access to food and water ad libitum. Study protocols were approved by the 
Institutional Animal Care and Use Committee of Michigan State University, an 
AAALAC accredited institution.  
Rats were acclimated to nose-only restraining devices (CH Technologies, Westwood, 
NJ, USA) in the days preceding exposure. Nine rats were exposed to CeO2 
nanoparticles in a 12-port nose-only exposure system (CH Technologies) for a single 
four hour exposure. Three ports of the system were used to collect nanoparticle 
samples. The exposure environmental conditions were 25±3°C, 50±15% humidity, 
and the dilution levels in the burner were controlled to achieve oxygen concentration 
of 20% on a mole fraction basis with the thresholds of 25 ppb for O3 and 50 ppb for 
NOx. Two runs of nine rats per run were used for both freshly generated CeO2 
nanoparticles and aged CeO2 nanoparticles. After exposure, 3 rats each were 
sacrificed after 15 min, 24h, and seven days (n = 3 per time point per run). Blood, 
lungs, liver, kidneys, heart, brain, olfactory bulb, spleen, feces, and urine were 
collected for CeO2 nanoparticles concentration analysis. Feces and urine were 
collected only for the first 24 h post exposure.  
Determination of CeO2 nanoparticle concentrations in organs/feces/urine: All 
equipment and supplies used for trace element analysis were rigorously acid-cleaned 
in a 5-step, 11-day procedure.  Detailed procedures on the lung tissue digestion and 
the analysis were documented previously (Harkema et al. 2004; Morishita et al. 2004). 
In brief, all biological samples were weighed and then acid-digested in concentrated 
nitric acid. Sample extracts were then diluted and analyzed for Ce using inductively 
coupled plasma–mass spectrometry (ELEMENT2, Thermo Finnigan, San Jose, CA, 
USA). The detection limit of this method is 0.002 ng/mL. The background cerium 
 43 
 
levels in all sampled organs were determined in a preliminary study with two control 
rats which were not exposed to the CeO2 nanoparticle aerosol. All background levels 
were below detection limit. 
3.2.3 PBPK modeling 
Model framework: The foundation of this PBPK is based on our previously developed 
PBPK model for intravenously injected nanoparticles (Li et al. 2014), extending it for 
inhalation exposure. The present PBPK model consists of 10 compartments: arterial 
blood, venous blood, lungs, spleen, liver, kidneys, heart, brain, GI tract, and rest of 
the body. All compartments are interconnected via systemic circulation (Fig. 3.2). 
Within each organ compartment, there are three sub-compartments representing 
capillary blood, tissue, and phagocytizing cells (PCs). The arterial blood and venous 
blood compartments also have phagocytizing cells sub-compartments. Nanoparticles 
are inhaled by the rats when exposed. Following inhalation, the nanoparticles are 
deposited into three different regions of the respiratory system: head region, 
tracheobronchial region, and pulmonary region. The deposition fractions in these 
three regions were modeled as a function of the density and size distribution of 
nanoparticles recorded by the SMPS using the Multiple-Path Particle Dosimetry 
Model (MPPD v 2.11; http://www.ara.com/products/mppd.htm) (see Appendix A3.1 
for detailed calculation). 
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Fig. 3.2 Structure of the nanoparticle PBPK model for inhalation, with 
phagocytizing cells sub-compartment in each tissue. 
After deposited in the head region, nanoparticles could be exchanged with the brain 
via olfactory bulb. Nanoparticles deposited in the tracheobronchial region could be 
transferred to the pharynx by mucociliar, then swallowed down to the GI tract and 
eventually excreted via feces. The mass balance analysis of observed data (see Fig. 
3.4B in the results section) led us to made the assumption that the small enough 
nanoparticles (diameter < 70 nm) are those which predominantly have the potential to 
penetrate the alveolar wall and enter the systemic circulation. During exposure, a 
fraction of these small nanoparticles are directly transferred from the pulmonary 
region to the blood; once deposited in the pulmonary region, the small nanoparticles 
are also transferred to the blood at a different rate. Phagocytizing cells (PCs) loaded 
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with nanoparticles could also be transferred to the tracheobronchial region by 
mucociliary transportation.  
The exchange of nanoparticles between blood and tissue in each organ is described as 
a flow- and diffusion-limited process. The flow limited process is controlled by a 
permeability coefficient, which limits the effective blood flow (Krishnan 2007). 
Except for brain, we assume the same permeability coefficient for all organs. The 
permeability coefficient for the brain compartment is set to zero, under the 
assumption of a highly efficient blood-brain barrier as observed by (Hardas et al. 
2010). The diffusion-limited process is controlled by the tissue: blood partition 
coefficient and assumed to be the same for all organ tissues (Li et al. 2014). 
A fraction of the nanoparticles entering the tissue is sequestrated by PCs until the PCs 
are eventually saturated. The PCs saturation level is organ specific, reflecting the 
variation in the abundance of PCs as well as differences in uptake capacity for 
different types of PCs among different organs. The effective uptake rate by PCs is a 
function of a maximum uptake rate and decreases as the PCs become saturated. This 
maximum uptake rate is the same for all compartments except for the spleen, due to 
its mesh-like structure that could trap nanoparticles in the spleen marginal zones and 
delay their contact with the splenic PCs (Demoy et al. 1999; Moghimi 2002). 
Nanoparticles can also re-enter the tissue after desorption from PCs by processes such 
as exocytosis (Chithrani and Chan 2007; Keighron et al. 2012). For a given animal 
species, the uptake capacity and uptake rate for each PC may vary between different 
nanoparticles, while the relative abundance of PCs densities in different organs was 
taken the same for all nanoparticle type. 
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Excretion of nanoparticles occurs from head region, GI tract, liver tissue, and 
capillary blood of kidneys. Degradation of CeO2 nanoparticles is considered 
negligible for the time-scale of this study. 
Main mathematical description of the model: We present here three main model 
equations describing the mass balances of a tissue t and of the PCs in this tissue. A 
more comprehensive deduction of the mathematical representation of the model is 
given in Appendix A3.2. 
The dynamic of nanoparticles in the tissue sub-compartment can be majorly described 
in two parts: 1) the transfer between arterial blood and venous blood and; 2) 
interaction with the PCs. In certain organs, excretion of nanoparticles occurs as a 
clearance route from the body. The equation describing these processes is: 
 
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where, 
Mt [µg] – Amount of nanoparticles in the tissue of organ t. 
χα [unitless] – Permeability coefficient between capillary blood and tissue. 
Qt [mL per hour] – Regional blood flow in organ t. 
Cart [µg per g] – Concentration of nanoparticles in arterial blood. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
P [unitless] – Partition coefficient of nanoparticles between tissue and blood.  
Wt [g] – Weight of organ t. 
Mt,m [µg] – Amount of nanoparticles captured by PCs in organ t. 
kt,ab [per hour] – Current uptake rate of nanoparticles by PCs in organ t. 
kde [per hour] – Desorption rate of nanoparticles from PCs to tissue. 
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Me,ex [µg] – Amount to excreta from source e. e only applies to tissue in liver and 
capillary blood in kidneys. The elimination of nanoparticles directly from the GI tract 
is described separately (Appendix A3.2). 
The change in mass of nanoparticles in PCs is the uptake from the tissue minus 
desorption from PCs back to tissue. The uptake rate kt,ab will decrease as the amount 
captured approaches the total PCs saturation level characterized by the PCs uptake 
capacity per unit weight. The equation describing these behaviors is: 

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where, 
kab0 [per hour] – Maximum uptake rate by PCs. 
Mt,cap [µg per g] – PCs uptake capacity for nanoparticles per organ t weight.  
In addition, a series of equations describing the deposition and transfer of 
nanoparticles in different regions of the respiratory system can be found in the 
Appendix A3.2. 
Model implementation: The PBPK model was implemented in Berkeley Madonna
TM
 
version 8.3.18 (Berkeley, CA). Parameters with unknown values were optimized by 
fitting the unknown model parameters against the experimental data. To create the 
most parsimonious model possible, we used a common generic parameter for most 
organs. We only differentiated parameters between compartments when it was 
indispensable to explain the dynamics of the CeO2 concentration in that compartment 
in a physiologically meaningful way. The parameters fitted in this study are bolded in 
Table 3.1. The fraction of residual capillary blood left in organs when analyzed for 
nanoparticles contents and the PCs uptake capacities in organs were taken from our 
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previous model (Li et al. 2014). All other parameter values were taken from the 
scientific literature (Krishnan 2007; Travlos 2006; Brown et al. 1997; Bernareggi and 
Rowland 1991; Brookes 1967). Values of all parameters are listed in Table 3.1 below.  
Evaluation of the model and identification of key parameters: The same model 
evaluation approach was applied as in Li et al. (2014): we determined the deviation 
from the line of unity between the log10 of measured and predicted values (McKone 
1993), and calculated the corresponding R
2
 and squared geometric standard deviation 
from the unity line. 
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Table 3.1A Description and values of parameters for the model that have the same values across all runs. Values in bold are 
fitted for this experiment. 
Parameter (unit) Description 
Generic 
values a 
Spleen (s) Liver (l) Lungs (lu) Heart (h) 
Kidneys 
(k) 
GI 
tract 
(gi) 
Brain 
(br) 
Rest of the 
body (rest) 
Blood 
(blood) 
Wt/WB (unitless) 
b % of organ weight to body weight - 0.0031 0.040 0.0047 0.0034 0.0094 0.044 0.0053 0.84 0.050 
Wt,b/Wt (unitless) 
c 
% of capillary blood in organ to 
organ weight 
- 0.22 0.16 0.10 0.18 0.32 0.10 0.070 0.017 - 
frQt (unitless) 
d Fraction of cardiac output to organ - 0.015 0.046 1 0.051 0.14 0.21 0.02 0.51 1 
Mt,cap (µg per g) 
e 
Phagocytizing cells uptake capacity 
per organ weight 
- 634 74.8 
25.5, 32.5 
f 
5.03 1.08 0.0014 0.083 17.6 0.016 
χα (unitless) 
Permeability coefficient between 
blood to tissue 
0.30 generic generic generic generic generic generic 0 0.018 - 
P (unitless) e 
Partition coefficient between tissue 
and blood 
0.074 generic generic generic generic generic generic generic generic 1 
kab0 (per h) 
e 
Maximum uptake rate by 
phagocytizing cells 
0.98 0.54 generic generic generic generic generic generic generic generic 
kde (per h) 
e 
Desorption rate by phagocytizing 
cells 
4.90×10-19 generic generic generic generic generic generic generic generic generic 
CLEe (per h) 
e Clearance rate to excreta - - 0.006 
2.70, 
0.0017 g 
- 0.0019 0.072 - - - 
frβ (unitless) 
e 
Fraction of capillary blood of organs 
left when analyzed 
0.144 generic generic generic generic generic generic 0.37 generic - 
a χα, P, kab0, kde have generic values for most compartments. "generic" indicates the corresponding generic value for each parameter. 
c Values were obtained by from Wenger et al. (2011) except for the GI tract, which was obtained from Bernareggi and Rowland (1991). 
c Values were obtained from literature estimates of the percentage (w/w) of capillary blood in the organs (Brown et al., 1997) except for lungs and GI tract, which were estimated by the authors. 
d Values obtained from literature (Brookes 1967; Bernareggi and Rowland 1991; Krishnan 2007).  
e Values obtained from Li et al. (2014) and He et al. (2010), see Chapter 4 for details. 
f 22.5 is for the lungs tissue, 32.5 is for the pulmonary region of the lungs. 
g 2.70 is for direct clearance out of the body from the head region, 0.0017 is for clearance out of the body from the pulmonary region. 
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Table 3.1B. Descriptions and values of parameters for the interactions between different regions of 
the respiratory system and other organs for the four runs. Values in bold are fitted for this 
experiment. 
Parameter (unit) Description Fresh 1 Fresh 2 Aged 1 Aged 2 
frhead (unitless) 
a Fraction of inhaled nanoparticles deposited in the head region 0.098 0.11 0.096 0.097 
frtra (unitless) 
a 
Fraction of inhaled nanoparticles deposited in the tracheobronochial 
region 
0.037 0.034 0.034 0.036 
frpul (unitless) 
a Fraction of inhaled nanoparticles deposited in the pulmonary region 0.16 0.14 0.14 0.16 
frgi (unitless) 
b Fraction of inhaled nanoparticles deposited in the GI tract 0.62 0.90 0.91 1.41 
frs (unitless) 
a Fraction of nanoparticles smaller than 70 nm in diameter 0.080 0.032 0.045 0.082 
  
Generic parameters 
kgiab (per h) Absorption rate of GI tract 0.0035 
kpulb (per h) Transfer rate from pulmonary region to blood 6.00E-06 
kheadbr (per h) Transfer rate from head region to brain 0.0097 
kbrhead (per h) Transfer rate from brain to head region 0.10 
kpulmtra (per h) 
c 
Transfer rate of inactive phagocytizing cells from pulmonary region to 
tracheobronchial region 
0.0011 
kgi (per h) 
c Transfer rate from tracheobronchial region to GI tract 0.056 
frairblood (unitless) Direct transferred fraction from nanoparticles in air to blood 0.26 
delaygi (h) Time delay for nanoparticles to travel from respiratory system to GI tract 2 
delayf (h) 
d Time delay for nanoparticles in feces to be excreted out 8 
a Values calculated based on size distribution of SMPS data and MPPD model. 
b This fraction (or the sum of this fraction with those for the respiratory system) could be higher than 1 due to uncertainty in the data caused by various 
factors such as ingestion of nanoparticles. 
c Values obtained from He et al. (2010), see Chapter 4 for details. 
d Value obtained from Wenger et al. (2011) 
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3.3 Results 
3.3.1 Characterization of CeO2 nanoparticles 
The real time characterization of particle size distribution during an exposure study, 
as measured using the SMPS, is shown in Fig. 3.3A, for second study of aged 
nanoparticles. The individual distributions are shown for 60, 120, and 180 minutes 
after the start of the experiments as well as the average particle size distribution over 
the 240 minutes of particle generation. The size distribution indicates a slightly bi-
modal distribution with peaks around 25 nm and 90 nm, with ~90% of the particles 
less than 200 nm in size. The estimates for the particle diameters are based on the 
equivalent diameter of a spherical particle with the same mass. The same size 
distribution trends were observed for both the fresh and aged particles.  Additional 
details on the time history of the particle size distribution are provided in Fatouraie et 
al. (2015). After converting the number based concentrations to mass based 
concentrations, the size distribution for all four runs follow a log-normal distribution 
(Fig. A3.1, Appendix A3.1) with the following geometric means and 95% confidence 
intervals:  146 nm (95% CI, 50, 334), 195 nm (95% CI, 66, 334), 174 nm (95% CI, 61, 
338), and 151 nm (95% CI, 52, 322), for fresh 1, fresh 2, aged 1, and aged 2 runs 
respectively. 
The exposure concentrations based on filter pack measurements of CeO2 
nanoparticles for runs fresh 1, fresh 2, aged 1, and aged 2 were 172 µg/m
3
, 585 µg/m
3
, 
483 µg/m
3
, and 439 µg/m
3
, respectively. During the fresh 2 run, exposure levels 
varied between an initial period of 197 minutes at low exposure level to fix an 
experimental problem, and a subsequent period of 163 minutes with much higher 
exposure, with 585 µg/m
3 
being the time averaged concentration for the entire six 
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hours of exposure. The duration of the other three experiments was four hours. The 
exposure concentrations based on SMPS were 351 µg/m
3
, 1 250 µg/m
3
 during 163 
minutes, 416 µg/m
3
, and 433 µg/m
3
, for runs fresh 1, fresh 2, aged 1, and aged 2 
respectively. These SMPS based concentrations were highly consistent with the filter 
packs measured concentrations except for run fresh 1. Based on the size distribution 
recorded by the SMPS, the exposure concentrations of nanoparticles smaller than 70 
nm for runs fresh 1, fresh 2, aged 1, and aged 2 were 27.9 µg/m
3
, 38.9 µg/m
3
 during 
163 minutes 26.4 µg/m
3
, and 35.6 µg/m
3
, respectively, showing less variation 
between runs than the total concentrations. 
TEM images are presented in Fig. 3.3B for typical fresh nanoparticles. The images 
show the nanoparticles are highly agglomerated structures which consist of small 
primary particles. TEM image analysis indicates the average diameter of the primary 
particles is 2 – 3 nm. Consistent with the SMPS data, analysis of the TEM images 
revealed no significant differences between the fresh and aged particles in terms of 
primary particle size or the agglomerated morphology. 
Bulk powder samples collected on the impactor surfaces were used for XRD analysis 
and to determine the phase, composition and average crystallite size of the 
nanoparticles. Because the nanoparticles were sampled on the impactor surface (to 
acquire sufficient material for analysis), the results are biased to larger particle sizes 
than the particles transported to the exposure chamber.  However, the results are 
expected to be consistent for composition and phase data. Typical XRD spectra for 
fresh nanoparticles are presented in Fig. 3.3C.  All peaks in the spectra correlate well 
with the crystallographic reference database for CeO2 [Powder diffraction file, 
compiled by JCPDS. International Centre for Diffraction Data, Swarthmore, PA 
(1990)].  The reference spectra are provided in Fig. 3.3C for comparison. Average 
 53 
 
crystallite size was determined based on the spectral peak broadening according to the 
Scherrer equation using the methods described in Bakrania et al. (2007b).  Detailed 
analysis was performed for the [111] and [220] features. An average crystallite size of 
6.67 ±0.06 nm was determined, which is as expected, slightly higher than the TEM 
values of primary particle diameter. 
Together the SMPS, TEM and XRD data indicate both the fresh and aged 
nanoparticles are agglomerates of small primary particles of CeO2 approximately 2 – 
3 nm in size, and  the agglomerate dimensions (based on the SMPS data) span a size 
distribution up to ~200 nm in size. 
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Fig. 3.3 Characterizations for the CeO2 nanoparticles in this study. (A) Size 
distributions based on concentration in particle numbers recorded by the SMPS. 
(B) Bright field TEM images of CeO2 particles with two magnifications. (C) XRD 
spectra of the powder sample collected on the impactor surface. A reference 
XRD peak is presented for comparison. The labels correspond to the peak angles. 
3.3.2 Biodistribution of CeO2 nanoparticles 
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Table 3.1 summarizes the concentrations of CeO2 nanoparticles found in the organs. 
Lungs consistently had the highest concentrations across different runs, followed by 
feces. A preliminary study measured the evolution of CeO2 nanoparticles 
concentrations in feces during the days following exposure (Appendix A3.3): 
compared to the first day post exposure, concentrations of CeO2 nanoparticles in feces 
were reduced by 97% on the fourth day post exposure and remained stable at low 
concentrations afterwards, as also observed by He et al. (2010). For the 
extrapulmonary organs (blood, kidneys, heart, brain, liver, and spleen), concentrations 
in blood showed a slight decrease over time. Concentrations in spleen, liver, and 
kidneys rose steadily while concentrations in heart remained relatively stable. CeO2 
nanoparticles were detected in the olfactory bulb and in the brain for fresh 1 and fresh 
2 runs, while mostly below detection limit for the aged 1 run. The concentrations in 
the olfactory bulb were exceptionally high for the fresh 2 run (higher than in other 
extrapulmonary organs by one order of magnitude). For the aged 2 run, the brain had 
the highest concentrations among all runs, while the concentrations in the olfactory 
bulb were below detection limit except on one day post exposure. Urine also had 
concentrations of CeO2 nanoparticles comparable to blood concentration one day post 
exposure. The decreasing lung concentrations and the increasing concentrations in 
extrapulmonary organs may suggest that the CeO2 nanoparticles deposited in the 
lungs could have served as a secondary source of exposure to the extrapulmonary 
organs, either by direct transfer from the lungs or through an indirect route via GI 
tract. Detailed concentrations for each rat are given in Appendix A3.4. 
Combining these concentrations with the different organ weights, we then calculated 
the masses of CeO2 nanoparticles and performed a mass balance analysis in Fig. 3.4. 
The total inhaled amount based on filter packs measured concentrations was lowest 
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for fresh 1, the highest for fresh 2, and was intermediary for aged 1 and aged 2 runs, 
with 2.56 µg, 13.35 µg, 7.20 µg, and 6.52 µg, respectively (Fig. 3.4A). One day post 
exposure, feces dominated the recovered masses (71% – 92%) due to their high 
weight and high concentrations of CeO2 nanoparticles (Fig. 3.4A). Although higher in 
concentrations, the lungs had lower weights than the feces and therefore contributed 
less than the feces to the total recovered mass, while remaining very important (7% – 
18%). Urine and extrapulmonary organs both contributed 4% – 6% to the total 
recovered mass in run fresh 1 but less than 0.5% of the total recovered mass for the 
other runs, the absolute recovered mass being approximately the same across the four 
experiments. The total inhaled amount for nanoparticles smaller than 70 nm based on 
SMPS measured concentrations for runs fresh 1, fresh 2, aged 1, and aged 2 were 0.42 
µg, 0.40 µg, 0.39 µg, and 0.53 µg, respectively (Fig. 3.4B). Interestingly, these 
absolute amounts of lower size nanoparticle found in the extrapulmonary organs were 
also rather constant across all runs and varied by less than 65%, while the total 
inhaled amount varied by a factor of five. This may suggest that only the fraction of 
CeO2 nanoparticles that are small enough could penetrate the alveolar wall and find 
their way into the extrapulmonary organs. The GI tract, muscles, skins, furs, and 
skeletons of the rats were not analyzed for CeO2 contents. The unrecorded mass of 
nanoparticle in these organs could explain the lower than 100% recovery rates for the 
fresh 1 and fresh 2 runs. The overestimated recovery rates for aged 1 and aged 2 runs 
could be associated with the variability and uncertainty in feces measurements, or 
could also reflect additional exposure routes, e.g. deposition on furs and later 
ingestion. 
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Table 3.2 Measured concentrations of CeO2 nanoparticles at different post exposure time in different organs (ng/g) 
a, b
. 
Organ 
Fresh 1, filter packs based 
concentration 172 µg/m3, SMPS 
based <70 nm concentration 27.9 
µg/m3 
Fresh 2 c, filter packs based 
concentration 585 µg/m3, SMPS based 
<70 nm concentration 38.9 µg/m3 
Aged 1, filter packs based 
concentration 483 µg/m3, SMPS 
based <70 nm concentration 26.4 
µg/m3 
Aged 2, filter packs based 
concentration 439 µg/m3, SMPS 
based <70 nm concentration 35.6 
µg/m3 
15 min 1 day 7 day 15 min 1 day 7 day 15 min 1 day 7 day 15 min 1 day 7 day 
Blood 3.10±0.88 2.90±0.22 1.85±0.07 2.36±0.33 2.32±0.11 2.10±0.35 1.50±0.13 1.76±0.24 0.91±0.33 1.16±0.29 0.57±0.09 0.91±0.35 
Lungs 317±129 225±31 93.9±129 1593±144 935±1317 1014±1417 1307±391 495±469 775±325 953±758 1421±250 929±317 
Spleen 0.92±0.74 0.21±0.07 2.26±2.73 0.12±0.05 0.46±0.16 3.14±4.39 - - - 1.19±0.07 1.55±0.46 1.92±0.24 
Liver 0.49±0.12 1.47±0.22 6.65±4.62 0.95±0.22 1.55±1.49 4.46±5.63 0.31±0.21 1.27±0.99 6.36±2.81 0.32±0.15 1.63±0.55 3.57±0.64 
Kidneys 0.22±0.06 0.99±0.35 1.67±0.43 0.94±0.03 1.41±0.81 3.47±3.21 0.24±0.09 0.58±0.11 1.73±0.40 1.20±0.16 1.93±0.18 2.96±0.54 
Heart 0.13±0.03 0.37±0.38 0.33±0.06 0.61±0.14 0.56±0.13 0.66±0.28 0.25±0.19 0.49±0.45 0.25±0.07 1.36±0.13 1.32±0.15 1.47±0.05 
Brain 
0.16±0.01 5.55±8.91 0.77±0.11 1.11±0.17 0.95±0.03 1.42±0.19 0.34 d BDL BDL 1.64±0.47 1.83±0.76 1.41±0.29 
Olfactory 
bulb 
0.69±0.07 0.84±0.08 0.69±0.29 13.0±10.6 5.92±3.65 4.69±1.71 BDL BDL BDL BDL 0.92 d BDL 
Feces - 91.6±4.3 - - 769±431 - - 672±431 - - 656±117 - 
Urine - 5.79±3.37 - - - - - 1.66±1.26 - - 1.98±2.06 - 
a All values displayed are mean±standard deviation (n=3). 
b "BDL" stands for below detection limit; "-" stands for no samples. 
c The exposure duration for run fresh 2 was six hours, instead of four hours for all other runs. Please refer to text for more details. 
d Only one sample was above detection limit. 
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Fig. 3.4 Biodistribution of CeO2 nanoparticles in different organs. (A) Mass 
balance of recovered amount on one day post exposure compared to calculated 
total inhaled amount of nanoparticles, error bars showing one standard 
deviation on feces. (B) Mass evolution for extrapulmonary organs compared to 
total inhaled nanoparticles < 70 nm. 
3.3.3 PBPK model simulation 
Fig. 3.5 shows the evolution of modeled with amount of nanoparticles and compares 
it with the observed data in the feces (cumulated data), the lungs and the 
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extrapulmonary organs. Model results are able to reproduce the different observed 
trends. The CeO2 nanoparticle levels in the lungs increase rapidly during the exposure 
period, peak at the end of exposure, and then slowly decrease over time. After eight 
hours of delay, cumulated CeO2 nanoparticles amounts in the excreted feces increase 
rapidly until around the third day after exposure, before entering a phase of much 
slower increase. The CeO2 nanoparticles amounts in the extrapulmonary organs are 
much smaller than those in feces and lungs. These amounts increase quickly during 
the exposure period like what is seen in the lungs, but keep increasing after exposure 
until the end of the experiment (Fig. 3.4B and Appendix A3.5) in contrast to the 
decreasing levels in the lungs. 
When examining individual extrapulmonary organs (Fig. A3.2 in Appendix A3.4), the 
model suggests that the CeO2 nanoparticles are almost exclusively (over 99%) stored 
in the PCs in all organs except for the blood for the entire time span of this study. For 
the blood, during exposure period the transfer of CeO2 nanoparticles from alveolar 
region to blood overwhelms the uptake by PCs in the blood. After exposure ends, 
there are still considerable amounts of CeO2 nanoparticles not captured by PCs in the 
blood because the PCs are saturated due to the low uptake capacity of PCs in the 
blood. These “free” CeO2 nanoparticles in the blood then circulate to other 
extrapulmonary organs and are captured by the PCs in those organs over time.  
As illustrated in Fig. 3.5 and Fig. 3.6, the model’s predictions for the four runs in this 
study fit generally well with measured data (R
2
 ranged from 0.85 to 0.93). The GSD
2
 
ranged from 4.5 to 11.5, indicating that the accuracies of predictions of individual 
data points is of maximum one order of magnitude compared to the variation of four 
orders of magnitude differences between all organs and time points. 
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Fig. 3.5 Predicted amounts of CeO2 nanoparticles in different organs compared 
to experimentally derived amounts. Error bars represent one standard deviation 
of measured data. 
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Fig. 3.6 Log10 of predicted CeO2 nanoparticle mass in different organs as a 
function of log10 of measured mass. 
3.4 Discussion 
The experimental design of this study enabled us to compare freshly generated and 
UV-light aged CeO2 nanoparticles with minimal changes in all other conditions. As 
the other conditions were well controlled, the differences in the characteristics of the 
fresh and aged CeO2 nanoparticles can be explained solely by the UV-light aging 
process. Based on the results obtained from this study, the size distribution, 
morphology, and crystalline structure of the fresh and aged CeO2 nanoparticles were 
similar. Meanwhile, other studies showed that under irradiation, some nanoparticles 
may have altered surface chemistry that resulted in different toxicity or behaviors in 
the environment (Badireddy et al. 2014; Rancan et al. 2014). It would be of interest to 
study the surface chemistry of fresh and aged CeO2 nanoparticles in the future. 
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Performing the mass balance analysis is critical to ensure that the majority of 
introduced CeO2 nanoparticles were accounted for. More than half of the recovered 
nanoparticles were found in the feces. Data on the feces showed substantial variations 
and could explain the near or more than 100% recovery rate observed in the runs for 
aged CeO2 nanoparticles. The variation of the feces data may be due to a number of 
factors such as amount of nanoparticles deposited on rats’ fur, the possible behaviors 
of the rats that may lead to ingestion of fur-deposited nanoparticles during and post 
exposure, and contamination of the collected sample feces by the fur of the rats or 
metabolic cages. Similarly, the high concentrations in the urine samples could 
actually result from contamination by the feces as urine and feces were in contact in 
the metabolic cages before being analyzed. 
Despite the differences in total inhaled dose among the four runs (up to a factor of 
five difference), the amounts recovered in all the extrapulmonary organs were quite 
similar (within 65% of each other). In parallel, the amounts of CeO2 nanoparticles of 
smaller sizes (70 nm) based on the SMPS’s records also showed less than 35% 
variation. This could indicate that only the smaller nanoparticles could enter from the 
lungs to the blood circulation. Previous studies also confirmed this observation 
(Semmler et al. 2004; Takenaka et al. 2001). By filtering nanoparticles down to a 
gradient of maximum sizes, future research should be conducted to study the 
relationship between nanoparticle size and uptake in the extrapulmonary organs by 
inhalation. 
Previous intravenous studies of nanoparticles do not support the hypothesis of 
nanoparticles penetrating the blood-brain-barrier and entering the brain (Hardas et al. 
2010; Li et al. 2014). In this study, although the concentrations of CeO2 nanoparticles 
we found in the brain and olfactory bulb were not consistently above detection limit, 
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the detected concentrations in the brain were of the same order of magnitude as that in 
the blood. This could support the hypothesis proposed by others that nanoparticles can 
enter the brain through the olfactory bulb (Oberdörster et al. 2004; Elder et al. 2006). 
Besides the cumulated feces, most of the recovered CeO2 nanoparticles were found in 
the lungs for all four runs in this study, which is consistent with previous studies (He 
et al. 2010; Geraets et al. 2012; Aalapati et al. 2014). In contrast to He et al. (2010), 
this study showed higher amounts recovered in the feces than in the lungs. This 
difference can be explained by the difference in the exposure methods – He et al. used 
intratracheal instillation, which will limit nanoparticle deposition outside the 
respiratory system and exclude the possibility of direct intake to the GI tract via 
ingestion during exposure or from the nanoparticles deposited on the fur. Among the 
extrapulmonary organs, liver and blood had the highest amount of CeO2 nanoparticles. 
The amount of nanoparticles in liver, spleen, and kidney increased over time, the 
amount in blood decreased over time, and the amount in heart and brain stayed 
relatively stable. These patterns agree with previous pulmonary studies as well in 
general (He et al. 2010; Geraets et al. 2012) although the blood concentration reported 
by He et al. (2010) kept increasing and the spleen results from Geraets et al. (2012) 
did not show any clear time evolution pattern. Aalapati et al. (2014) exposed mice to 
CeO2 nanoparticles daily for four weeks and examined the contents in different organs 
two and four weeks after the last exposure. They found a steady decrease in 
nanoparticle concentrations in both the lungs and extrapulmonary organs. CeO2 
nanoparticles might have been cleared on a longer time frame. However, this decrease 
was not found by He et al. (2010) after four weeks of instillation in their study nor by 
us in our one week post exposure measurements. 
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The PBPK model in this study accounts for different physiologic mechanisms to 
predict and explain the dynamics of CeO2 nanoparticle levels in different organs. In 
our model, in contrast to Bachler et al (2013), elimination to feces is predominantly 
originated in the GI tract lumen, not biliary excretion from the liver. This pathway is 
also supported by the high concentrations of nanoparticles found in the GI tract 
samples analyzed so far, which was one order of magnitude higher than those in the 
liver. The sources of nanoparticles in the GI tract lumen are a mixture of direct entry 
during exposure, ingestion from the deposited nanoparticles on the fur, and the 
transport of saturated PCs from the pulmonary region by mucociliary movement to 
the larynx then swallowed down to the GI tract. The first two are responsible for the 
fast increase of nanoparticles in feces within 24 hours post exposure while the 
mucociliary clearance of nanoparticles loaded PCs is responsible for the continuous 
excretion throughout the study. This transport of nanoparticle saturated PCs from the 
lungs to the GI tract then to feces is also the major contributor of the slow decrease of 
CeO2 nanoparticles in the lungs and a widely accepted clearance route for inhaled 
nanoparticles (Takenaka et al. 2001; Hofmann and Asgharian 2003; Yang et al. 2008). 
The model predicts the majority of nanoparticles in the lungs are captured by the PCs 
in the pulmonary region. This agrees well with microscopic evidences from Takenaka 
et al. (2001). 
According to the PBPK model, the majority of nanoparticles entering the blood are 
coming from the smaller nanoparticles in the pulmonary region during exposure 
period. This explains the sudden increase in the blood compartment in the model and 
the highest concentrations observed in the blood 15 min post exposure. After 
exposure, part of the nanoparticles transported in to the GI tract could be absorbed 
before being excreted during the fecal retention time. These absorbed nanoparticles 
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from the GI tract, together with small amounts of nanoparticles that are desorbed from 
the PCs in the pulmonary region, enter the systemic circulation and drive the levels of 
nanoparticles in the extrapulmonary organs (except for blood) higher or keep them 
stable throughout this study. The phagocytosis of nanoparticles is a well-documented 
phenomenon (Moghimi et al. 2001; Cho et al. 2009; Li et al. 2014) and supports the 
model’s predicts that most of the CeO2 nanoparticles are captured by PCs in the 
different organs. It is noteworthy that the level of exposure in this study is much lower 
than other CeO2 nanoparticle pulmonary exposure studies (He et al. 2010; Geraets et 
al. 2012; Aalapati et al. 2014). The concentrations in extrapulmonary organs were 
also much lower than nanoparticle studies of intravenous injection (Wenger et al. 
2011; Yokel et al. 2012; Yokel et al. 2009). Therefore, the PCs in all organs including 
the pulmonary region in the lungs are not saturated in the current model. 
Most PBPK models for nanoparticles are only applicable to intravenous injection (Lin 
et al. 2008; Lee et al. 2009; Lankveld et al. 2010; Li et al. 2012; Li et al. 2014). Our 
model is one of the two existing PBPK models that can predict the biodistribution of 
inhaled nanoparticles (Bachler et al. 2013). Compared to Bachler et al. (2013), our 
model advances the field by taking into account the dynamic of nanoparticles in the 
feces directly excreted from the GI tract, which has been shown to be a major deposit 
of nanoparticles in this study and the results from He et al. (2010). Nevertheless, our 
model also has several limitations. First, the amount in the liver is systematically 
underestimated at the end of this study. Our model could not predict an increase over 
time large enough to reach the measured levels seven days post exposure (Appendix 
A3.5). We may miss certain physiologic pathways that cause this increase in the liver. 
For example, the nanoparticles may undergo endocytosis by the M cells in the GI tract 
for a period of time before being exocytosed and be in contact with the GI tract wall 
 66 
 
(Shakweh et al. 2004). This may create a delayed effect for the nanoparticles to be 
absorbed by the GI tract and make the nanoparticles in the GI tract a source that can 
slowly release free nanoparticles to the GI tract to absorb over time. Second, the 
model is able to predict individual data points within one order of magnitude. 
However, the measured data also displayed large variations identified by large 
standard deviations (Table 1). These large variations in both the measured data and 
model predictions could be inherently caused by the exposure conditions as the rats’ 
individual behaviors during and post exposure could result in different intake of CeO2 
nanoparticles. 
3.5 Conclusions 
CeO2 nanoparticles were generated and aged under UV-light before being inhaled by 
rats in one integrated system in this study. Characterizations of the fresh and aged 
nanoparticles showed little differences in size distribution, morphology, or crystalline 
structure. The biodistribution of fresh and aged CeO2 nanoparticles follow the same 
patterns, with the highest amounts recovered in feces and lungs. The slow decrease of 
nanoparticle concentrations in the lungs is explained by clearance to the GI tract and 
then to the feces. For the extrapulmonary organs, the nanoparticles level in the blood 
peaked at the end of exposure then went down. The PBPK model successfully 
predicts the dynamic of CeO2 nanoparticles in various organs measured in this study. 
The model suggests most of the nanoparticles were captured by PCs, which agrees 
with the literature. When applying this model to other nanoparticle inhalation studies, 
the exposure conditions including the size distribution of the nanoparticles should be 
clearly defined as these would greatly affect model predictions. 
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CHAPTER 4
3
 
Adaptation of the physiologically based pharmacokinetic 
model to other nanoparticles 
4.1 Introduction 
Nanoparticles have found wide application in multiple industries including drug 
delivery, fuel efficiency, cosmetics, etc. (Wakefield et al. 2008; Sao et al. 2015; 
Willhite et al. 2014). The population may be exposed to these nanoparticles either 
directly when using these nano-engineered products, or indirectly after the 
nanoparticles have been released into the environment. Various types of nanoparticles 
exhibit have been found to have different toxic effects in either in vivo or in vitro 
studies (Sayes et al. 2006; Aalapati et al. 2014; Zhang et al. 2011). Since negative 
human health risks result from the combination of exposure and toxicity potentials for 
nanoparticles as any other hazardous chemical, biodistribution of nanoparticles need 
to be well understood in order to perform meaningful human health risk assessments. 
However, tools to systemically and consistently evaluate the biodistribution of 
different types of nanoparticles are missing so far. 
Physiologically based pharmacokinetic (PBPK) models have been used to predict the 
biodistribution of both drugs and harmful substances inside the body (Krishnan 2007)  
and can also be adapted to the study of nanoparticles biodistribution. A number of 
PBPK models emerged for different types of nanoparticles in recent years (Lin et al. 
                                                 
3
 The content of this chapter has been summarized in a conference proceeding paper for the 
International Conference on Safe Production and Use of Nanomaterials 2012. Li, D.; Emond, C.; 
Johanson, G.; Jolliet, O. Using a PBPK model to study the influence of different characteristics of 
nanoparticles on their biodistribution. J. Phys.: Conf. Ser. 2013, 429 012019. 
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2008; Lee et al. 2009; Lankveld et al. 2010; Li et al. 2012). However they face one or 
both of the following limitations: 1) lack the explanation power for certain 
biobehaviors of nanoparticles such as phagocytosis or mucociliary clearance from the 
pulmonary regions in the lungs; 2) built around one certain type of nanoparticles and 
have not demonstrated the ability to be adapted to predict biodistribution of other 
types of nanoparticles. As a result, it would be hard to use any one of the previous 
PBPK models for nanoparticles to successfully understanding the biodistribution of 
different types of nanoparticles via exposure from different routes. In addition, 
compared to multimedia fate models that can screen the environmental fate and 
human exposure of thousands of chemicals at a time (Arnot et al. 2006; Rosenbaum et 
al. 2008; Wambaugh et al. 2013), PBPK modelers have traditionally focused on one 
single chemical at a time. In the same time, there is a need to develop a PBPK model 
that can study different types of nanoparticles and identify which parameters can 
remain constant and which need to be adapted to reflect specific characteristics of the 
individual type of nanoparticles.  
To address this need we aim to adapt the PBPK model developed for intravenous 
injection of polyethylene glycol-coated polyacrylamide (PAA-peg) nanoparticles and 
inhaled cerium oxide (CeO2) nanoparticles to provide a common framework to assess 
different types of nanoparticles without major changes in the model structure. We aim 
here in particular to explore whether this framework is a good candidate for a 
parsimonious PBPK model, able to assess the biodistribution of different types of 
nanoparticles. 
The objectives of this exploratory study are: 
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1. Extend the current PBPK model framework to other types of nanoparticles 
with minimum changes to the model itself while maintain the robustness of the 
model. 
2. Evaluate the ability of the model to accommodate for unique characteristics of 
certain nanoparticles. 
3. Explore how different characteristics of the nanoparticles are reflected in the 
most influential parameters determining the biodistribution 
4.2 Methods 
4.2.1 Experimental data 
We first define a set of criteria to be met for a certain nanoparticles biodistribution 
dataset to be selected for analysis in this study. 1) The nanoparticles should be clearly 
characterized with the mean diameter of size, status of surface modification, and 
administrated dose. This is to ensure the characteristics of different types of 
nanoparticles can be compared. 2) The data set should present the biodistribution of 
nanoparticles in the blood and in at least five of the following organs: blood, liver, 
spleen, lungs, kidneys, heart, carcass, or excreta. This is to ensure the majority of 
important organs are accounted for. 3) There should be at least three time points when 
organs were analyzed for nanoparticles levels. This is to ensure a time evolution of 
the biodistribution in different organs can be deducted. 4) The mass balance based on 
the administrated dose and amount recovered in the measured organs should give at 
least a recovery rate of at least 50%, unless very specific reasons were given to 
account for the missing amount of nanoparticles. This is to ensure a holistic dynamic 
of nanoparticles between organs can be represented. 
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Based on the above criteria, the following datasets were selected (Table 4.1). For 
intravenous pathway: Wenger et al. (2011) presented data for 31 nm polyacrylamide 
(PAA, in addition to the PAA-peg used in Chapter 2 for model parameterization) 
nanoparticles administered by intravenous injection to rats; Panagi et al. (2001) 
provided biodistribution of 114 nm poly(Lactide-co-glycolide)-
monomethoxypoly(ethyleneglycol) (PLGA-mPEG) nanoparticles administered by 
intravenous injection to mice; Liu et al. (2008) provided data for larger size 319 nm 
coated breviscapine-loaded poly(D, L-lactic acid) (BVP-PLA) nanoparticles 
administered by intravenous injection to rats; and Lankveld et al. (2010) was selected 
for three different sizes of silver (Ag) nanoparticles from 20 to 110 nm, administered 
by intravenous injections to rats. For pulmonary exposure pathway: He et al. (2010) 
was selected for CeO2 nanoparticles through intratracheal instillation to rats. These 
literatures reported studies are compared to the PAA-peg nanoparticles and CeO2 
nanoparticles studies detailed in the previous chapters. Since all four runs of the CeO2 
inhalation study showed similar biodistribution patterns, run fresh 1 is selected 
because it has more samples measured than the other runs. Table 4.1 summarizes the 
specifications of each dataset, including the fraction of nanoparticles recovered in the 
experiment typically ranging from 10% to 100%. 
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Table 4.1 Specifications of different nanoparticles biodistribution experiments. 
Nanoparticles 
Size 
(nm) 
Surface 
modification 
Literature source 
Animal 
species 
Exposure 
route 
Dose 
(µg) 
Study 
duration 
(days) 
Time 
points 
Recovery 
rate 
PAA-peg 31 Yes 
Wenger et al., 
2010 
Rats 
Single i.v. 
injection 
7000 5 5 ~ 100% 
PAA 31 No 
Wenger et al., 
2010 
Rats 
Single i.v. 
injection 
11300 5 5 ~ 100% 
PLGA-
mPEG 
114 Yes Panagi et al., 2001 Mice 
Single i.v. 
injection 
1050 0.125 4 ~ 100% 
BVP-PLA 319 Yes Liu et al., 2008 Rats 
Single i.v. 
injection 
2200 1 3 6% - 19% 
Ag(20) 20 No 
Lanveld et al., 
2010 
Rats 
Five 
repeated i.v. 
injections 
119 17 8 2% - 11% 
Ag(80) 80 No 
Lanveld et al., 
2010 
Rats 
Five 
repeated i.v. 
injections 
132 17 8 
12% - 
33% 
Ag(110) 110 No 
Lanveld et al., 
2010 
Rats 
Five 
repeated i.v. 
injections 
138 17 8 
10% - 
55% 
CeO2 
(instilled) 
13 No He et al., 2010 Rats 
Single 
intratracheal 
instillation 
200 28 4 ~ 100% 
CeO2 
(inhaled) 
146 No 
Chapter 3 of this 
thesis 
Rats 
Four hours 
nose-only 
inhalation 
2.56 7 3 49% 
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4.2.2 PBPK models 
The PBPK framework and model has been described in details in Chapter 2 and 
Chapter 3. A brief summary is given in this section. 
The PBPK model for intravenous injection consists of 10 compartments: arterial 
blood, venous blood, lungs, spleen, liver, kidneys, heart, brain, bone marrow, and the 
rest of the body (skin, muscle, skeleton, etc.). The PBPK model for pulmonary 
exposure consists of 10 compartments: arterial blood, venous blood, lungs, spleen, 
liver, kidneys, heart, brain, gastrointestinal tract (GI tract), and the rest of the body 
(skin, muscle, skeleton, etc.). Within each compartment, there are three sub-
compartments representing capillary blood, tissue and phagocytizing cells (PCs) and 
remaining tissue. The conceptual framework of the model is illustrated in Fig. 4.1 and 
Fig. 4.2. 
 
Fig. 4.1 PBPK framework for intravenous injection of nanoparticles. 
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Fig. 4.2 PBPK framework for pulmonary exposure of nanoparticles. 
The exchange of nanoparticle between blood and tissue in each organ is described as a 
flow- and diffusion-limited process, the latter being controlled by permeability 
parameters, which limits the effective blood flow (Krishnan 2007). The permeability 
coefficient for the brain compartment is set to zero, under the assumption of a highly 
efficient blood-brain barrier. The possibility of uneven distribution between blood and 
tissue at steady-state is taken care of by a blood-tissue partition coefficient.  
Some of the nanoparticles that enter the tissue are captured by the tissue PCs. The 
uptake rate is a function of the efficacy and saturation level of the PCs and decreases 
as the nanoparticles in the PCs become saturated. For now, we assume that all PCs 
have the same efficacy and saturation level for a certain type of nanoparticle, 
independent of their location. However, the numbers of PCs differ between organs, 
causing different phagocytosis capacity at saturation. To fit a minimum number of 
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parameters, we will test the hypothesis that the relative saturation capacities of PCs 
across organs are independent of the nanoparticles types and be kept constant, while 
the absolute saturation capacities will change between different types of nanoparticles. 
We also assume that the uptake rate by PCs may also be altered to account for specific 
nanoparticles properties. 
A removal rate of nanoparticles is introduced in the model to account for biliary 
excretion, urination, and possibly biodegradation for some nanoparticles.  
The PBPK model was implemented in Berkely-Madonna
TM
 (version 8.3.18). For 
intravenous injection datasets, the model was first optimised by fitting the unknown 
model parameters against the PAA-peg experimental data. For the pulmonary 
exposure datasets, the inhalation model was first optimized using both the inhalation 
experiment presented in Chapter 3, and the instilled CeO2 nanoparticles dataset (He et 
al. 2010) which provided complementary information on pulmonary region PCs 
saturation capacities due to its higher dosage. The other biodistribution datasets were 
used in a second stage to parameterize the model to each type of nanoparticles. 
During the parameterization process, the maximum parameters were kept identical. 
Only those parameters that have a physiological relationship with the characteristics 
of different types of nanoparticles were changed in order to reflect the unique 
differences across the analyzed nanoparticles. This was done to preserve the 
parsimony of the common model framework. In addition, this practice could help 
identify which parameters are closely linked to certain characteristics of the 
nanoparticles. The parameters that were fitted and varied among different 
nanoparticles are summarized in Table 4.2 in the Results section of this chapter. 
4.2.3 Model evaluation and sensitivity analysis 
 76 
 
For model evaluation we determine the deviation from the 1:1 line between the log10 
of measured and predicted values, calculating the squared geometric standard 
deviation on the log as well as the corresponding R
2
 (McKone 1993). 
Model sensitivity can be evaluated for each model parameter based on the area under 
the curve (AUC) of blood and liver for the entire duration of each study. The AUC of 
blood and lungs are used to evaluate the sensitivity of parameters for the pulmonary 
exposure studies. To test the sensitivity, each parameter’s value is increased by 10% 
and the AUC recalculated. The relative sensitivity is then calculated using the 
following equation 
ji
ji
pAUC
dpdAUC
ty sensitiviRelative
/
/
     4.1 
Where AUCi represents area under the curve (AUC) for compartment i, and pj 
represents the parameter j. 
4.3 Results 
4.3.1 Comparison of time courses for nanoparticles of intravenous injection 
The time courses for all the intravenous injected nanoparticles datasets are shown in 
Fig. 4.3 below. A first group of nanoparticles with medium or slow kinetic in the 
blood composed of PAA-peg, PAA, and PLGA-mPEG nanoparticles, exhibited a 
similar pattern of time courses for all measured organs. The levels of nanoparticles in 
the blood gradually decreased over time while the levels in the other organs 
compensated for this loss in the blood, suggesting the transfer of nanoparticles from 
the blood to the other organs. The richly perfused organs (including the lungs, liver, 
kidneys, heart, bone marrow, and brain), especially the liver and spleen, in these three 
datasets all reached a plateau rather quickly (less than about five hours). The time 
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course for the rest of the body showed different evolutions between the PAA-
peg/PAA and the PLGA-mPEG nanoparticles datasets. For the PAA-peg and PAA 
nanoparticles, the amounts of nanoparticles in the rest of the body continued 
increasing towards 120 hours after injection and were much higher than those in the 
richly perfused organs. But in the PLGA-mPEG dataset the removal from the blood 
was faster, and the rest of the body saturated in less than five hours after injection at a 
level comparable with the richly perfused organs, suggesting a faster distribution of 
PLGA-mPEG nanoparticles from the blood to other organs.  
A second group of intravenously applied nanoparticles, composed of for BVP-PLA 
and Ag nanoparticles showed a markedly different behaviour. The levels of 
nanoparticles in the blood for these two types of nanoparticles dropped over 90% in 
less than one hour after injection of the dose. Unlike the other intravenous injection 
datasets, the increase of nanoparticles amounts in other organs measured in the 
experiments for BVP-PLA and Ag nanoparticles was not large enough to compensate 
this huge decrease in the blood and resulted in much lower recovery rates of the total 
administrated dose. This indicates that there is a rapid removal kinetic for the 
nanoparticles that are not captured by the other organs, with eventually a competition 
between the rate constants for PCs capture and for removal from blood. In the Ag 
nanoparticles experiments, we can also see a steady decrease in the liver throughout a 
much longer timeframe (17 days versus five days at most for the other nanoparticles 
experiments) that suggest a slow release and elimination of nanoparticles captured by 
PCs or an elimination of the PCs themselves. 
A more detailed examination of the model predicted time courses that differentiate the 
nanoparticles captured by PCs and those that are not can be found in Appendix A4.1. 
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Fig. 4.3 Time courses for PAA-peg, PAA, PLGA-mPEG, BVP-PLA, and Ag 
nanoparticles of different sizes, intravenous injection. 
4.3.2 Comparison of time courses for nanoparticles of pulmonary exposure 
The time courses for the intratracheal instilled and inhaled CeO2 nanoparticles are 
shown in Fig. 4.4 below. The time courses share a number of similarities: lungs and 
feces contain the highest amounts of nanoparticles; amount in the lungs slowly 
decreases after exposure; amount in the cumulated excreted feces increases quickly 
within two days of exposure, then keeps on increasing but at a much slower pace; the 
amount of nanoparticles in extrapulmonary organs is very small compared to amounts 
in lungs and feces. There are also some differences in the time courses for these two 
experiments: the inhaled CeO2 nanoparticle experiment shows higher amounts in the 
feces than lungs but the instilled CeO2 nanoparticle experiment shows the contrary; 
the decrease in the lungs  is faster for the inhaled CeO2 nanoparticles as it decreased 
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by more than 50% during the seven days post exposure, while the decline over the 
same period of time is only 9% for instilled CeO2 nanoparticles; the amount of 
nanoparticles in the extrapulmonary organs is about 4% of the total recovered amount 
for all organs in the inhaled CeO2 experiment but is only about 0.1% in the instilled 
CeO2 experiment for which the applied doses is much higher. 
A more detailed examination of the model predicted time courses that differentiate the 
nanoparticles captured by PCs and those that are not can be found in Appendix A4.1. 
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Fig. 4.4 Time courses measured and predicted amounts of CeO2 nanoparticles 
exposed via intratracheal instillation and inhaled in lungs, cumulated feces and 
extrapulmonary organs. 
4.3.3 Parameterization of the model 
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For the different types of nanoparticles in this study, Table 4.2 summarizes all the 
fitted parameters. Parameters that are totally independent of the type of nanoparticles 
such as organ weights are not shown in Table 4.2.  
Removal rates: The two groups identified in the discussion of the time course showed 
markedly different removal rates: Those with slower kinetic have low removal rate 
kremoval (PAA-peg, PAA, and PLGA-mPEG) and those with rapid removal consistently 
have a high kremoval (BVP-PLA and Ag).  
Uptake capacity at saturation: It was possible to keep the relative saturation 
capacities of PCs across organs at the same relative value for all studied nanoparticles, 
confirming that this relative saturation across organs may be independent of the 
nanoparticles types. When comparing PAA-peg with larger size PLGA-mPEG 
nanoparticles (both have surface modification and low kremoval), the UCS increased by 
340% when size of the nanoparticles increased by 270%, suggesting that larger 
nanoparticles may have a larger uptake capacity for PCs at saturation. This would be 
plausible and consistent with the hypothesis that macrophage saturation may be 
related to the number rather than the mass of nanoparticles as discussed in Chapter 2, 
but this need to be further confirmed by looking at a larger number of experiments 
reaching saturation. When comparing PAA-peg and PAA nanoparticles (only 
difference is with or without surface modification), the UCS remained almost the 
same while kab0 was higher for PAA nanoparticles. Since BVP-PLA and Ag 
nanoparticles had a high removal rate in the blood, the amount of nanoparticles 
reached the organs were too low to reach any meaningful saturation level of PCs. 
Therefore the model is not limited by UCS for these nanoparticles.  
PCs uptake and desorption rates: It is the competition between kab0 and kremoval that is 
critical in the biodistribution of the nanoparticles that have high kremoval. In order to 
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model the decrease in organ amounts of BVP-PLA and Ag nanoparticles, the values 
of kde for these nanoparticles were many orders of magnitude higher than the other 
nanoparticles. Interestingly, the amounts of nanoparticles for BVP-PLA and Ag 
nanoparticles in the brain were too high to be explained solely by the residual blood. 
Therefore, the permeability coefficient for brain was fitted to a non-zero value, 
whereas it is set to zero for the other nanoparticles.  
Partition coefficient and transfer rates from tracheobronchial region to GI tract: 
Among parameters directly influencing the biodistribution of nanoparticles in the 
extrapulmonary organs, P showed great change between the inhaled and instilled 
CeO2 nanoparticles, which was 60 times higher for the instilled CeO2 nanoparticles 
than the inhaled CeO2 nanoparticles, possibly associated with the much smaller 
particle size in the instilled nanoparticles. The values of other parameters for the 
extrapulmonary organs had similar values for the two experiments. This could 
indicate that the dynamics of nanoparticles outside the extrapulmonary organs are 
mostly independent of the nanoparticles in these two experiments. It is noted that kgi 
was much higher for the instilled CeO2 experiment than the inhaled CeO2 experiment. 
This may be due to the exposure pathway. The tracheobronchial trees may response to 
the direct instilled solution more intensively and induce a faster transfer process to 
remove the foreign object. It was possible to keep the same partition coefficient for all 
organs for most experiments, a second separate partition coefficient value being 
needed to explain the observed biodistribution for liver and spleen  in the BVP-PLA, 
20 nm and 80 nm Ag experiments. 
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Table 4.2 Different nanoparticles and fitted parameters. 
Parameters Description 
PAA-peg 
(31 nm) 
PAA 
(31 nm) 
PLGA-
mPEG (114 
nm) 
BVP-
PLA (319 
nm) 
Ag (20 nm) Ag (80 nm) 
Ag (110 
nm) 
CeO2 
(instilled, 13 
nm) 
CeO2 
(inhaled, 146 
nm) 
UCS (unitless)  a Uptake capacity at saturation for PCs 1.00 0.96 4.39 11.7 0.71 3.99 4.02 0.23 0.23 
kab0 (per h) Maximum uptake rate by PCs 16.1 20.9 8.4 19.9 16.18 16.1 16.0 0.98 0.98 
kabs0 (per h) Maximum uptake rate by splenic PCs 0.112 0.191 0.800 4.91 4.16 5.00 16.1 1.33 0.540 
kde (per h) Desorption rate by PCs 4.9E-19 4.9E-19 4.9E-19 1.4E+00 5.2E-03 5.6E-03 5.2E-03 4.9E-19 4.9E-19 
P (unitless) b 
Partition coefficient between tissue and 
blood 
0.147 0.192 0.501 2.10 0.63 0.80 0.80 3.49 0.074 
kremoval (per h) Removal rate from the body 0.018 0.02 0.116 32.4 14.5 4.96 5.00 0.008 0.008 
χ rich (unitless) 
Permeability coefficient for richly 
perfused organs 
1.1E-03 4.0E-04 9.9E-03 3.4E-01 4.4E-01 2.8E-01 2.9E-01 1.5E+00 3.1E-01 
χrest (unitless) 
Permeability coefficient for rest of the 
body 
8.3E-05 2.7E-04 1.6E-03 3.0E-02 5.6E-08 7.2E-05 3.1E-04 9.9E-04 1.8E-02 
χbrain (unitless) Permeability coefficient for brain 0.0E+00 0.0E+00 0.0E+00 3.3E-01 2.5E-03 2.5E-04 2.5E-03 0.0E+00 0.0E+00 
  
Parameters specific for pulmonary exposure 
  
Mpulcap (μg/g) 
c 
Uptake capacity for PCs in pulmonary 
region 
              179 179 
kgi (per h) 
Transfer rate from tracheobronchial 
region to GI tract        
1.613 0.056 
kheadbr (per h) Transfer rate from head region to brain               0.004 0.01 
kbrhead (per h) Transfer rate from brain to head region        
0.04 0.1 
CLEgif (per h) Clearance from GI tract lumen               0.072 0.072 
a UCS is the limiting factor for PAA-peg, PAA, and PLGA-mPEG nanoparticles due to the high doses injected to the blood. For the other nanoparticles, the PCs in all organs are far from saturation 
and the model is not limited by this parameter. 
b For BVP-PLA, Ag (20 nm), and Ag (110 nm) nanoparticles, all organs except liver and spleen have a different value for P in order to fit the measured data. These values are 0.46 for BVP-PLA, 
0.048 for Ag (20 nm), and 0.064 for Ag (110 nm). 
c Mpulcap is not the limiting factor for CeO2 (inhaled) since the dose is much lower than CeO2 (instilled). 
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4.3.4 Evaluation of the model 
Figure 4.5 displays separately for each type of particle and experiment the predicted 
concentration in each organ against the corresponding measured. The values of R
2
 
range from 0.69 to 0.97 (Fig. 4.5) indicate that the model predicted the experimental 
data relatively well across the different organs. Besides of the Ag nanoparticles, the 
GSD
2
 for all nanoparticles fall within 10, indicating that the accuracies of predictions 
of individual data points are of maximum one order of magnitude. For the Ag 
nanoparticles, there are outliers in the blood data that induced a much larger GSD
2
 
(Fig. 4.5). According to the measured data (Lankveld et al. 2010), no nanoparticles 
were detected in the blood towards the end of the study. Since the limit of detection 
was not given in the original study, these data points cannot be represented on the log 
scale graph. In order to make these two data points available on the log10 scale, their 
values were set to 0.001 µg (smallest value found in blood elsewhere was 0.359 µg, 
no limit of detection was given in the original study). 
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Fig. 4.5 Log10 of predicted nanoparticles amount as a function of log10 of 
measured amount. 
4.3.5 Sensitivity of the model 
The relative sensitivities were calculated according to Eq. 4.1 for all types of 
nanoparticles in this study and are listed in Table 4.3. For the intravenously injected 
nanoparticles, the model is most sensitive to the parameter UCS for PAA-peg, PAA, 
and PLGA-mPEG nanoparticles. Although the relative sensitivities for UCS to blood 
for the other nanoparticles have high values, it should be noted that it is only because 
most of the amount in the blood are stored in PCs for those nanoparticles. kab0 only 
becomes a sensitive parameter to the model for BVP-PLA. For the nanoparticles with 
high kremoval (BVP-PLA and Ag), the model is sensitive to both kremoval, and kab0, that 
are of the same order of magnitude and reflect the competition between PCs uptake 
and direct removal from blood. kde also is a sensitive parameter for these nanoparticles 
with fast kinetic as it participates indirectly in the competition between kremoval and 
kab0. The amounts in liver are also sensitive to P for all three Ag nanoparticles, as it 
heavily influences the biodistribution in organs on the long term, the Ag experiments 
having the longest duration of measurements.  
For the instilled and inhaled CeO2 nanoparticles, the predicted amount of 
nanoparticles in the blood is sensitive to the partition coefficient P, especially for the 
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instilled CeO2 nanoparticles. In contrast, as can be expected, variations in P will not 
affect the predictions of the amount of nanoparticles in the lungs for either experiment, 
since this amount is determined by the quantity instilled instillation or the quantity 
deposited in the respiratory tract in case of inhalation. The instilled CeO2 
nanoparticles had a high enough dose administrated in the experiment to saturate the 
PCs in the pulmonary region, therefore making Mpulcap a sensitive parameter. In 
contrast, the amount inhaled for the other CeO2 nanoparticles was too small for the 
pulmonary region PCs to come close to saturation and the model is not sensitive to 
Mpulcap in this case. Looking at Table 4.3, it may seem that UCS is also a very 
sensitive parameter for both CeO2 nanoparticles. However, this is because the UCS 
affects the Mpulcap just like the uptake capacities of PCs in other organs as well for the 
instilled CeO2 nanoparticles and consequently impacts the overall biodistribution by 
decreasing the free nanoparticles in the pulmonary region that could enter the 
systemic circulation. Similarly to the Ag nanoparticles, the reason why the amount in 
blood is sensitive to UCS for the inhaled CeO2 nanoparticles is because most of the 
amounts in the blood are stored in PCs. 
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Table 4.3A Relative sensitivities for some parameters 
a
. 
Nanoparticles 
UCS   kab0   kabs0   kde   P 
Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs 
PAA-peg -0.19 0.67   0.00 0.00   -0.02 0.00   0.00 0.00   -0.12 0.17 
PAA -0.38 0.54 
 
-0.01 0.00 
 
-0.01 0.00 
 
0.00 0.00 
 
-0.32 0.12 
PLGA-mPEG 
b
 -0.73 0.44   -0.06 0.07   -0.01 0.06   -0.01 0.00   -0.34 0.10 
BVP-PLA 0.17 0.01 
 
0.06 0.67 
 
0.00 0.00 
 
-0.06 -0.52 
 
0.00 -0.01 
Ag(20) 0.81 0.00   0.08 0.82   0.00 0.00   -0.05 -0.47   0.02 0.81 
Ag(80) 0.89 -0.01 
 
0.04 0.63 
 
0.00 0.00 
 
-0.02 -0.35 
 
0.00 0.63 
Ag(110) 0.88 0.00   0.04 0.66   0.00 0.00   -0.03 -0.36   0.00 0.66 
CeO2 (instilled) -0.24 -0.11  
0.13 0.00 
 
-0.04 0.00 
 
0.00 0.00 
 
-0.58 0.00 
CeO2 (inhaled) 0.82 0.00   -0.01 0.00   0.00 0.00   0.00 0.00   -0.11 0.00 
a
 The relative sensitivities were calculated by the percentage change divided by the percentage change in the parameter (set at 10%) according to Eq. 4.1. 
Lungs were analyzed for the CeO2 nanoparticles instead of the liver. Relative sensitivities with absolute values larger than 0.1 are marked in bold. 
b
 Spleen and liver were grouped together in the results of the experiment. 
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Table 4.3B. Relative sensitivities for some parameters 
a
. 
Nanoparticles 
kremoval   χrich   χrest   χbrain 
Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs 
PAA-peg -0.05 -0.02   -0.01 0.02   -0.49 -0.13   N/A 
PAA -0.04 -0.03 
 
-0.03 0.04 
 
-0.31 -0.10 
 
N/A 
PLGA-mPEG 
b
 -0.11 -0.02   -0.08 0.11   -0.16 -0.08   N/A 
BVP-PLA -0.77 -0.87 
 
0.03 0.13 
 
-0.02 -0.04 
 
0.00 0.00 
Ag(20) -0.24 -0.88   0.01 0.08   0.00 0.00   0.00 0.00 
Ag(80) -0.12 -0.77 
 
0.01 0.12 
 
0.00 0.00 
 
0.00 0.00 
Ag(110) -0.14 -0.79   0.01 0.12   0.00 0.00   0.00 0.00 
CeO2 (instilled) 0.00 0.00  
-0.03 0.00 
 
-0.03 0.00 
 
N/A 
CeO2 (inhaled) 0.00 0.00   0.00 0.00   -0.03 0.00   N/A 
a
 The relative sensitivities were calculated by the percentage change divided by the percentage change in the parameter (set at 
10%) according to Eq. 4.1. Lungs were analyzed for the CeO2 nanoparticles instead of the liver. Relative sensitivities with 
absolute values larger than 0.1 are marked in bold. 
b
 Spleen and liver were grouped together in the results of the experiment. 
 
Table 4.3C. Relative sensitivities for some parameters 
a
. 
Nanoparticles 
Mpulcap   kgi   kheadbr   kbrhead   CLEgif 
Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs   Blood Liver/lungs 
CeO2 (instilled) -0.40 -0.11  
0.00 0.00 
 
0.00 0.00 
 
0.00 0.00 
 
0.00 0.00 
CeO2 (inhaled) 0.00 0.00   0.00 0.00   0.00 0.00   0.00 0.00   -0.05 0.00 
a
 The relative sensitivities were calculated by the percentage change divided by the percentage change in the parameter (set at 10%) according to Eq. 4.1. 
Lungs were analyzed for the CeO2 nanoparticles instead of the liver. Relative sensitivities with absolute values larger than 0.1 are marked in bold. 
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4.4 Discussion 
The PBPK model predictions of the nanoparticles biodistribution for these datasets 
agree relatively well with the measured data when including phagocytosis. The 
similarities and differences in the biodistribution across the analysed datasets can be 
explained by the PBPK model framework after considering the specific characteristics 
of the nanoparticles and the specifications of experiment such as exposure method and 
administrated dose. The PBPK model indicates that the saturation effect in the richly 
perfused organs is due to the PCs uptake of nanoparticles. The maximum uptake 
amount for the PCs determines the saturation level is observed when the 
administrative dose is high enough.  
For the nanoparticles with slow or medium kinetic, the amount of nanoparticles in the 
rest of the body stopped increasing after about five hours for the PLGA-mPEG 
experiment instead of following the course in the PAA-peg and PAA experiments. 
This can be explained by the relatively low uptake rate by PCs and higher 
permeability coefficients between tissue and capillary blood. The combination of 
these two factors enables a quicker removal from the blood to the other organs in 
which the nanoparticles were captured. Also, once captured by the PCs, the 
nanoparticles will be relatively immobilized, explaining the very low decrease of 
nanoparticles amounts in the organs (except for blood, which has a low PCs uptake 
capacity) after saturation across all experiments. The tissue sub-compartment in 
organs may only accumulate nanoparticles after the PCs sub-compartment are 
saturated and there are still considerable amounts of nanoparticles in the blood, as 
shown in the PAA-peg and PAA nanoparticles experiments (Fig. 2.3 and Fig. A4.2).  
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For the nanoparticle with fast removal, According to (Liu et al. 2008), the core of the 
BVP-PLA nanoparticles, BVP, has a very short half-life in blood, which is reflected 
in the sharp decrease in the blood after administration of BVP-PLA nanoparticles and 
the low recovery rate over all. For the Ag nanoparticle, it is suggested by Lankveld et 
al. (2010) that the administered silver nanoparticles could be transformed into silver 
ions inside the body, a transformation associated with a dramatic change in behaviour. 
This would possibly explain the fast decrease in the blood and the lower recovery 
rates. These specific characteristics of the BVP-PLA and Ag nanoparticles also lend 
support to having a high removal rate in the PBPK model. In addition, both of these 
studies conducted a short term (less than an hour) kinetic study of the blood 
concentration following injection and confirmed this fast remove phenomenon. The 
data from BVP-PLA and Ag nanoparticles support the model having a permeability 
coefficient for the brain, indicating the blood brain barrier could be breached, which 
seems contradictory to other researches (Sadauskas et al. 2007; Hardas et al. 2010). 
However, the BVP-PLA nanoparticles were releasing BVP that are not nanoparticles 
(Liu et al. 2008) and are known to enhance the permeability of blood-brain barrier 
(Liu et al. 2002). Some other studies also suggest that silver nanoparticles could cross 
the blood-brain barrier by transcytosis or increasing the permeability of brain 
microvessel endothelial cells (Trickler et al. 2010). 
The difference in behaviour between the instilled and inhaled CeO2 nanoparticles can 
be associated to the difference between the exposure pathways. When instilled, the 
nanoparticles have little chance of entering the GI tract directly and the transfer to 
feces will occur through the slow clearance from the pulmonary region by mucociliar 
movements. But inhalation exposure could have a direct transfer into the GI tract. In 
addition, nanoparticles deposited on the fur during inhalation experiments could also 
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serve as a secondary exposure source, as rats will unintentionally ingest the 
nanoparticles when licking their fur. These differences resulted in a higher fraction of 
the administrated dose in the GI tract for the inhaled CeO2 nanoparticle, leading to a 
higher amount of nanoparticles in the feces than the lungs. On the contrary, the 
instilled CeO2 nanoparticles are directly instilled in the lung, thus the higher 
concentration in lung than in feces. In addition, the administrated dose in the instilled 
CeO2 experiment was almost 100 times higher than the dose in the inhaled CeO2 
experiment. This resulted in the saturation of PCs in the pulmonary region for in the 
instilled experiment but not in the inhaled experiment. As a result, for the instilled 
CeO2 nanoparticle, there were abundant free nanoparticles in the pulmonary region to 
migrate into the systemic circulation, causing a steady rise of nanoparticles amount in 
the extrapulmonary organs. In contrast, for the inhaled CeO2 nanoparticles, the 
amount deposited in the pulmonary region was almost totally captured by the PCs in 
vicinity and limited their transfer through the alveolar wall into the blood stream. This 
explains why the inhaled CeO2 experiment did not show the steady increase of 
nanoparticles amount across all extrapulmonary organs. Without the direct transport 
of free nanoparticles from the air in the pulmonary region during exposure, we would 
have seen much lower amount in the extrapulmonary organs for the inhaled CeO2 
nanoparticles. 
By examining the differences in certain parameters in the model for different 
nanoparticles, we may explore the relationship between the characteristics of 
nanoparticles and the determinants of their biodistribution. Choi et al. (2014) also 
observed a positive correlation between size of the nanoparticles and uptake by PCs. 
This could indicate that the PCs are saturated by the number of nanoparticles rather 
than absolute mass, as deducted in Chapter 2 of this thesis. An alternative explanation 
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would be the larger nanoparticles may more easily attach to the PCs, as suggested by 
previous studies (Tabata and Ikada 1988; Champion et al. 2008). The results of 
parameterization of the model for the experiments in this study do not disprove this 
positive correlation, but cannot strongly confirm it either because most experiments 
did not administrated a dose high enough for the PCs to reach saturation. Compared to 
the other nanoparticles in this study, the BVP-PLA and Ag nanoparticles are removed 
from the body three to four orders of magnitude faster than the other nanoparticles in 
this study. The high removal rates are justified by the short half-life of BVP for BVP-
PLA nanoparticles and possibility of conversion to ionic form for silver nanoparticles 
(Liu et al. 2008; Lankveld et al. 2010).  
Interestingly, even with the same core and no surface modifications, the partition 
coefficient between tissue and blood for the instilled CeO2 nanoparticles is much 
larger than that for the inhaled CeO2 nanoparticles. Literatures suggest that the 
partition coefficient may be linked with the biocorona formation around nanoparticles 
(Nel et al. 2009; Lundqvist et al. 2008) with size and surface properties playing a 
main role (Lundqvist et al. 2008). The differences between the partition coefficients 
between these two types of CeO2 nanoparticles may therefore be caused by their 
different sizes, since there are little differences in other characteristics of these two 
nanoparticles. The PAA and PAA-peg nanoparticles also have different partition 
coefficients. In this case, the difference may be linked to the different surface 
properties since the size of these two nanoparticles are the same. The relationship 
between a specific characteristic of nanoparticles with the partition coefficient is less 
clear for PLGA-mPEG, BVP-PLA, and Ag nanoparticles, as they differ from each 
other in core, size, and surface modifications. 
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The model’s sensitivity to UCS for most nanoparticles in this study reflects the role of 
PCs, as a major reservoir for nanoparticles. The reason for the model for BVP-PLA is 
not sensitive to UCS but to kab0 can be explained by the short duration of the BVP-
PLA nanoparticles study, which lasted only for three hours while experiments for the 
other nanoparticles were at least 24 hours. It is possible that the PCs cannot be 
saturated within three hours in the BVP-PLA nanoparticles study and therefore 
making the UCS an insensitive parameter but the kab0 a sensitive one. 
4.5 Conclusions and outlook 
The PBPK model framework developed in Chapter 2 and 3 can be extended to other 
nanoparticles with little modifications and maintain its robustness in predictability. It 
is found that the main differences in biodistribution of the nine nanoparticles 
examined here can be explained either by the exposure procedure or certain 
characteristics of the different nanoparticles. By adjusting only the parameters linked 
with unique characteristics of the nanoparticles, the model offers insights on how 
these characteristics may affect the nanoparticles biodistribution. 
For further study, it is worth designing more detailed experiments to test the 
hypothesis of increase in nanoparticle size would increase the uptake capacity of PCs. 
Since a very fast removal of the Ag nanoparticles from the body was observed but 
little is known about their fate, it would also be of interest to pay more attention to the 
excretion within one hour of dosing since for the Ag nanoparticles and identify what 
form – nanoparticles or ions – there are in the excreta. 
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CHAPTER 5 
Conclusions 
This thesis developed a PBPK model that describes the biodistribution of PAA-peg 
nanoparticles through intravenous injection and CeO2 nanoparticles via inhalation. 
The model was able to represent well the time evolution observed in collected 
experimental data. Though multiple parameters needed to be fitted, the 
physiologically sound mechanisms used to build the model offer explanations of most 
phenomena observed in the biodistribution of nanoparticles. The parsimonious design 
allows the model to be extended to different types of nanoparticles by modifying a 
limited number of parameters, while maintaining its robustness in predictions. We 
first discuss hereby the lessons learned, potential, and limitations of this model, 
regarding its ability to answer the three scientific questions raised in Chapter 1 about 
phagocytosis, exposure by inhalation and the influence of particles characteristics. We 
then discuss the need and ideas for future research opportunities stemming from this 
thesis. We finally look at perspectives and outlook.  
5.1 Lessons learned, potential, and limitations 
Lessons regarding the biodistribution of nanoparticles inside the body can be learned 
from the PBPK model developed in this study. In the meanwhile, there are still 
several limitations exist that prevent the model to reach its full potential. These 
lessons, potential, and limitations revolve around three topics in this thesis, which are 
accounting for phagocytosis in the biodistribution of nanoparticles, relating inhaled 
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nanoparticles to extrapulmonary uptake, and connecting biodistribution with 
nanoparticles characteristics. 
5.1.1 Accounting phagocytosis in the biodistribution of nanoparticles 
A sub-compartment of PCs for specifically addressing phagocytosis of the 
nanoparticles, which is an experimentally proved nano-specific phenomena, is 
incorporated for each organ in the PBPK model developed in this thesis. By 
accounting for phagocytosis, the PBPK model is adequate to explain the organ 
saturation effect observed in measured data. Within 15 hours, most nanoparticles are 
captured by the PCs unless the given dose is much above the saturation level. 
Depending on the dose administrated, PCs could be the major reservoir of 
nanoparticles in the body. When the administrated dose is not high enough to saturate 
the PCs within organs or there is a high removal rate directly from the blood, the 
uptake rate of PCs exhibits a greater role in the biodistribution of nanoparticles, 
especially for the short-term duration after exposure.  
Although different types of PCs could have different uptake limits and rates for the 
same nanoparticles, this thesis uses a single uptake rate for all PCs in all organs 
(except for the spleen, which has a different structure that can delay the contact 
between nanoparticles and splenic PCs). This single uptake rate is a proxy of the 
average of uptake rates for different types of PCs weighted by their relative 
population in the organs. The results show this single uptake rate is sufficient to 
model the biodistribution of nanoparticles. The relative uptake capacities of the PCs 
across organs should be independent of the type of nanoparticles that enters the body. 
This is because the relative uptake capacities are a representation of the abundance of 
PCs in different organs and should be only dependent on the animal species of study. 
The parameterization of uptake capacities of PCs in the PBPK model agree well with 
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known physiology – spleen, liver, lungs (especially the pulmonary region) are rich in 
PCs and they indeed are the organs with highest values for the parameter of uptake 
capacities. Although these relative uptake capacities of the PCs may stay the same no 
matter what type of nanoparticles the animal is exposed to, the absolute amount of 
nanoparticles each PC can uptake could vary due to different sizes, surface 
modifications, and other factors.  
There are several limitations of this PBPK model and phagocytosis sub-model. 1) 
Many model parameters, such as the partition coefficient, permeability coefficient, 
uptake rate and capacity of PCs, are fitted based on the experimental data, instead of 
having experimentally validated values. This increases the uncertainty of the model. 2) 
During the optimization process, some parameters are not limited by the measured 
data and could have a wide range of possible values. This was the case for the uptake 
capacity of PCs in the blood, which later needed to be refitted when extending the 
original model based on the PAA-peg nanoparticles study to other biodistribution data, 
thus the interest to have the model robustness tested on several types of particles. 3) 
Although the sub-compartment of PCs could explain some of the biobehavior of 
nanoparticles, the dynamic of the interactions between PCs and nanoparticles in this 
model is still in a rather crude phase and has much room for improvement. 
Specifically, the current sub-module of PCs does not reflect the two-step phagocytosis 
process suggested by experiments (Luciani et al. 2009); it also does not differentiate 
the uptake rate and capacities of different types of PCs which could be a major barrier 
when there is a need to model specific areas of a target organ. 
5.1.2 Relating inhaled nanoparticles to extrapulmonary uptake 
As shown in Chapter 2, the biodistribution of fresh and aged CeO2 nanoparticles 
followed the same patterns, with the highest amounts recovered in feces and lungs. 
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The slow decrease of nanoparticle levels in the lungs is explained by mucociliar 
clearance to the GI tract and then to the feces. This indicates the crucial need for the 
PBPK model to include the transfer of nanoparticles from the respiratory system to GI 
tract. For the extrapulmonary organs, the nanoparticle level in the blood peaked at the 
end of exposure and decreased afterwards. A detailed mass balance analysis of the 
size distribution and the amount of nanoparticles recovered from the extrapulmonary 
region suggests that the extrapulmonary uptake of nanoparticles could be size 
dependent. In the intratracheal instillation of CeO2 nanoparticles He et al. (2010) also 
found the lungs and cumulated feces with the highest amount of nanoparticles. The 
instillation study showed an increase of nanoparticle amounts in the extrapulmonary 
organs over time which could be explained by the much higher dose administrated in 
the pulmonary region. When applied to intratracheal instillation of CeO2 nanoparticles, 
the model is able to explain well the similarity and differences between the two 
datasets, modifying only a few parameters.  
Several important lessons are also learned from conducting first hand a CeO2 
inhalation study. First, controlling the size of nanoparticles that the animals are 
exposed to is crucial for the quality of results, since large aggregates may have been 
stored in the facility and released in an unpredictable and uncontrollable manner. In 
this specific CeO2 specific experiment presented in Chapter 3, it was not possible to 
properly relate the size distribution recorded by the SMPS to the exposed contents to 
the rats as measured by the filter packs, until the cascade impactor was added 
upstream of the exposure chamber. In the early stage of the experiment, the filter 
packs were receiving nanoparticle aggregates larger than 500 nm in diameter and 
randomly reported high and variable exposure concentration, while the SMPS was 
more stable since it already filtered nanoparticles larger than 500 nm. Second, 
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multiple and most contributing organs should all be collected and analyzed, in order 
to ensure a sufficiently high recovery rate and to provide a holistic understanding of 
the relative change of nanoparticles amount in different organs. If feces had not been 
collected and analyzed in the CeO2 experiments, the majority of the inhaled dose 
would not have been accounted for. This would have generated large uncertainties 
regarding the fate of the nanoparticles, and prevented understanding of how they are 
removed from the body. 
Two major challenges still exist for modeling the extrapulmonary uptake. 1) Although 
the hypothesis that only nanoparticles below a certain size (< 70 nm) could penetrate 
the alveolar wall and enter the systemic circulation can explain the mass balance from 
the CeO2 nanoparticles inhalation study in Chapter 3, there is no direct evidence to 
confirm this hypothesis so far. If this hypothesis does not hold, then it would mean the 
model is missing some other mechanism for the extrapulmonary uptake from 
inhalation and would not perform well with nanoparticles with different size 
distributions. 2) The measured data from the CeO2 inhalation studies clearly show a 
steady increase in the liver and kidney over time, but the model cannot predict this 
effectively. It is possible that this increase in extrapulmonary organs has its source in 
the nanoparticles stored in the GI tract lumen as discussed in Chapter 3. However, 
certain mechanisms could be missing in the current model and causing the model to 
perform poorly for absorption from the GI tract. This will be an even greater 
challenge when applying the current model to nanoparticles with ingestion as the 
primary exposure route. 
5.1.3 Connecting biodistribution with nanoparticles characteristics 
Extending the PBPK model to various biodistribution datasets for nanoparticles 
allows the exploration of relationship between the key determinants of biodistribution 
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and the nanoparticles characteristics or the exposure conditions. The nanoparticles 
core, sizes, surface modifications, direct removal from the blood, and administrated 
dose levels are found to have impacts on the biodistribution. Most interestingly, the 
parameterization of the model may suggest there is a positive correlation between the 
sizes of nanoparticles and the uptake capacities of PCs. The kinetics of biodistribution 
will also be different and more dependent on the uptake rate by PCs when the 
administrated dose is not high enough to saturate the PCs within organs. The detailed 
sensitivity analysis of the model for different datasets is important to help us identify 
the most influential parameters governing the biodistribution. A closer examination of 
these parameters could then inform us about why they are important, and may lead to 
proposals of innovative hypotheses to be explored in the future.  
Some weaknesses in the model need also to be emphasized. 1) In its current state, the 
model is not able to extrapolate a quantitative relationship between values of certain 
parameters with nanoparticles characteristics quantitatively, e.g. the uptake capacities 
of PCs and the size of nanoparticles. This creates the need to optimize the model for 
all parameters every time when used to study the biodistribution of a different 
nanoparticle. 2) When optimizing for some datasets in Chapter 4, the model has to 
sacrifice some of its parsimony in order to fit the data (different partition coefficients 
for liver/spleen and other organs for BVP-PLA and Ag nanoparticles). This could 
indicate that there are other underlying factors or phenomena in the biodistribution of 
nanoparticles that are not captured by this model. 3) Finally, the present approach has 
considered each nanoparticle individually, whereas nanoparticle mixtures could lead 
to synergistic effects, e.g. linked to the PCs saturation effects. Studying some 
mixtures could be of special interest for drug delivery as suggested by Wenger et al. 
(2011) and the present PBPK model could be used to test and design further 
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experiments, for example saturating PCs in untargeted organs and cells with inactive 
nanoparticles prior to injecting chemotherapy nanoparticles which would then better 
reach the targeted organs. 
5.2 Future research opportunities 
The research of this thesis not only made progress to build an innovative PBPK model 
for nanoparticles and answered the scientific questions proposed at the beginning, but 
also generated some research ideas that could further advance our knowledge on the 
biodistribution of nanoparticles. The three most important challenges still to be solved 
are: modeling the detail dynamics of interaction between nanoparticles and PCs, 
identifying the influence of nanoparticles size on extrapulmonary uptake from 
inhalation exposure, and characterizing the relationship between nanoparticles 
properties and the phagocytosis process. 
5.2.1 Dynamics of interaction between nanoparticles and phagocytizing cells 
As shown in this thesis, the interactions between PCs and nanoparticles play a crucial 
role in the biodistribution of nanoparticles. It is therefore of high interest to study 
these interactions in a more extensive way. To better improve the parameterization of 
the sub-model of PCs, experiments exposing macrophages to both fresh and aged 
CeO2 nanoparticles in vitro will be conducted to study the kinetic of 
absorption/desorption and internalization of nanoparticles to PCs. This may allow us 
to better characterize this important biobehaviors of nanoparticles in the body. 
It is hypothesized that the capture of nanoparticles by macrophages is a two-step 
process (Luciani et al. 2009). The first step is passive adsorption of nanoparticles to 
the surface of macrophages and the second step is active internalization into the 
macrophages. Each step has an amount limit for adsorption/internalization and a rate 
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for these processes. Under a temperature of 4 ˚C, the macrophage may become 
inactive and the internalization will not take place. The in vitro study will first expose 
macrophages to a gradient of concentrations of CeO2 nanoparticles at 4 ˚C and 37 ˚C 
for four hours. The contents of nanoparticles in the macrophages will then be 
analyzed. The content should increase as the exposed concentration increases until 
saturation is reached. The differentiation of 4 ˚C and 37 ˚C will then provide the 
saturation level for surface adsorption alone and the combined saturation level for 
adsorption and internalization. Then, another group of macrophages will be exposed 
to CeO2 nanoparticles at concentration over the saturation levels, again at 4 ˚C and 37 
˚C degree. The exposure duration will last from 5 min to 16 hours. The results will 
then provide information regarding the adsorption rate alone with the 4 ˚C data and 
internalization rate after considering the 37 ˚C data. 
Once these parameters have been determined, a feasibility study we have carried out 
has shown that it will be possible to substitute the model equation representing the 
particulate mass balance in PCs by an equation adapted from Luciani et al. (2009). 
5.2.2 Influence of size on extrapulmonary uptake from inhalation 
The importance of nanoparticle size for inhalation exposure is two-fold: deposition 
fraction of the inhaled nanoparticles in different regions of the respiratory system, and 
the potential of penetrating the alveolar wall and entering the systemic circulation 
directly from the air during the inhalation exposure period. By filtering nanoparticles 
down to a gradient of maximum sizes, future research should be conducted to study 
the relationship between nanoparticles size and uptake in the extrapulmonary organs 
by inhalation. Another possible approach would consist of examining the nanoparticle 
sizes on each side of the alveolar wall to determine how well the alveolar wall able to 
block larger nanoparticles from passing through this wall. In addition, the sizes and 
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morphology of nanoparticles in the pulmonary region could be changed due to 
aggregation in the microenvironment of alveolar sacs. In order to better understand 
the relationship of size and extrapulmonary uptake of nanoparticles from inhalation, it 
would be worth documenting any differences in size and other characteristics between 
nanoparticles in the ambient air and those in the pulmonary region. 
5.2.3 Relationship between nanoparticles characteristics and phagocytosis 
The possible positive correlation between nanoparticles size and uptake capacities of 
PCs is a topic to be studied in more detail and quantitatively. In Chapter 4, there were 
not enough qualified biodistribution data to confirm this correlation with confidence 
when parameterizing the model. More experiments with high enough dose to saturate 
PCs in the organs are needed to better characterize this relationship. Given the 
importance of phagocytosis, quantitatively identifying this relationship would help us 
better parameterize the model and predict the biodistribution of different nanoparticles. 
It should also be noted that other characteristics such as surface modifications could 
influence phagocytosis of the nanoparticles and may need to be taken into account 
when examining the data. 
5.3 Outlook and perspectives 
Toxicity of nanoparticles has been a popular topic in the scientific community for 
more than a decade and has generated a wealth of data. In order to fully evaluate the 
potential human health risks imposed by various nanoparticles, both the toxicity and 
exposure should be well characterized. However, research on the biodistribution of 
nanoparticles is far less sufficient and systematic. When conducting literature review 
of the biodistribution studies on nanoparticles, I found many of the studies not 
considering the mass balance of the administered dose. Some biodistribution studies 
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only consisted of two time points, making it impossible to infer the full dynamics 
from their results. These issues make it difficult for other researchers to fully leverage 
the results from these previous studies. Therefore I would suggest future research 
consider having at least three time point measurements, and include enough organs 
analyses to account for at least 50% of the dose. On the brighter side, nanoparticle 
characterizations are better documented in more recent published results than they 
were in the past. However, the influences of different characteristics of nanoparticles, 
such as size, surface modifications, shape, core, etc, on biodistribution still lack the 
attention they need compared to recent studies on the toxicity of nanoparticles.   
In terms of PBPK modeling, the importance of phagocytosis is receiving more and 
more attention. Failure to address this critical phenomenon for nanoparticles would 
prevent modelers from developing a comprehensive PBPK model that can be applied 
to a number of different types of nanoparticles without heavily optimizing many of 
the models parameters for each biodistribution dataset. As a consequence, the model 
would inevitably lose robustness in predictability of other datasets when overfitted for 
one set of data. If a “more general” PBPK model for nanoparticles emerges in the 
future, I envision it to be a parsimonious one whose parameters will be a function of a 
limited number of nanoparticle properties, similar to those for modeling the 
environmental fate of chemicals. It will be built under an overarching framework to 
achieve a screening level precision of the biodistribution of nanoparticles once the 
dose, exposure route, and key characteristics of the nanoparticles are given. If the 
modeler wishes to go into more depth for a specific type of nanoparticle, then details 
and modifications could be added to the parsimonious model.  
As a researcher that has addressed not only PBPK modeling but also environmental 
fate modeling (see e.g. Appendix 5), I have a vision for a more comprehensive model, 
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linking toxicity tests and toxicodynamic approaches, PBPK models, and 
environmental fate models. This would extend beyond nanoparticles to human health 
impact assessment for chemicals in general. The environmental fate model would 
allow us to estimate the intake rate of a certain chemical. The PBPK model then takes 
up the task to predict the specific concentrations in the target organs based on the 
results of the environmental fate model. Once the concentrations in the organs are 
evaluated, it would be then possible to link these concentrations to in vitro toxicity 
tests to see if those concentrations are at alarming levels. A quantitative estimate of 
the health impact to individual persons of this chemical could be obtained by 
integrating the toxicity data, PBPK model, and environmental fate model with just the 
physicochemical properties and in vitro toxicity data of that chemical as input. Going 
further, incorporating quantitative structure-activity relationship (QSAR) models into 
this system would even allow us to predict the human health impacts of new 
chemicals that are artificially created on a global scale. All of the above is for one 
single chemical. It should be noted that the current trend for environmental fate model, 
toxicity tests, and QSAR are on the tract towards high-throughput methodology. 
Developing high-throughput PBPK models would complete the picture above and 
make possible the screening for human health risks of thousands of chemicals, new or 
old. 
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APPENDIX 2 
Physiologically based pharmacokinetic modeling of 
polyethylene glycol-coated polyacrylamide nanoparticles in 
rats 
A2.1 Mathematical representation of the model 
A2.1.1 Dynamics of the nanoparticles in tissues, as a function of capillary blood 
concentrations 
The dynamic of nanoparticles in the tissue sub-compartment in different organs can 
be summarized as follow. The sources of nanoparticles for tissues are capillary blood 
which is part of the systemic circulation. Parts of the nanoparticles will be exchanged 
back to capillary blood and return to the systemic circulation while other parts are 
captured by phagocytizing cells (PCs). For those captured by PCs, desorption is also 
possible to re-enter the tissue. In certain organs, excretion out of the organ is a 
clearance route. The equation describing these processes is:  

    
excretionby  clearance
exe
PCs  withninteractio
demtabttt
bloodcapillary   withtransfer net
tbtt
t
dt
dM
kMkCWPCCPA
dt
dM ,
,,, )()/( 
 A2.1 
where 
Mt [µg] – Amount of nanoparticles in the tissue of organ t. 
Wt [g] – Weight of organ t. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
Ct,b [µg per g] – Concentration of nanoparticles in the capillary blood of organ 
t. 
 115 
 
PAt [mL per hour] – Permeability coefficient-surface area cross-product. It is 
approximated as the product of permeability coefficient between capillary 
blood and tissue and regional blood flow, χα×Qt, in this model, assuming the 
surface area is proportional to the regional blood flow. 
P [unitless] – Partition coefficient of nanoparticles between tissue and blood.  
Mt,m [µg] – Amount of nanoparticles captured by PCs in organ t. 
kt,ab [per hour] – Current uptake rate of nanoparticles by PCs in organ t. 
kde [per hour] – Desorption rate of nanoparticles from PCs to tissue. 
Me,ex [µg] – Amount to excreta from source e. e only applies to tissue in liver 
and capillary blood in kidneys. 
A2.1.2 Dynamics of the nanoparticles in capillary blood, as a function of 
concentrations in arterial and venous blood 
The nanoparticle concentration in capillary blood is determined by the concentrations 
in the arterial blood and in the tissue. The interaction between capillary blood and 
tissue can be described as: 
)/()( ,,
,
PCCPACCQ
dt
dM
tbttbtartt
bt   
 A2.2 
where 
Mt,b [µg] – Amount of nanoparticles in the capillary blood of organ t. 
Qt [mL per hour] – Blood flow through organ t. 
Cart [µg per g] – Concentration of nanoparticles in arterial blood. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
Tissue uptake of nanoparticles from the capillary blood is modeled as a diffusion 
limited process, therefore the movement of the nanoparticles from capillary blood to 
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the cellular matrix of the tissue is proportional to the permeability coefficient-surface 
area cross-product (Krishnan 2007) which can be expressed as a proportion of the 
blood flow Qt, assuming the surface area is proportional to the regional blood flow: 
tt QPA         
 A2.3 
with χα the permeability coefficient between capillary blood and organ t. This 
parameter has specific values for the rest of the body (χrest) and brain (χb) and the 
same generic value for the richly perfused organs (χrich), which are spleen, liver, bone 
marrow, lungs, heart, kidneys, and brain. 
We can simplify the model by eliminating the specific sub-compartment of capillary 
blood and calculate concentration of the capillary blood as a function of the arterial 
blood, assuming btC , is in quasi steady state equilibrium between Cart and Ct. We then 
have: 
)/()( ,, PCCPACCQ tbttbtartt   
 A2.4 
Combining Eq. A2.3 and Eq. A2.4 we have the concentration in organ capillary blood 
Ct,b as: 
)1(
/
,







PCC
C tartbt   
 A2.5 
Eq. A2.5 applies for all organs in the systemic circulation except for the lungs because 
the lungs receive the collective venous blood. Therefore we have the concentration in 
lungs capillary blood Clu,b as a function of venous blood:  
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 A2.6 
where 
Cven [µg per g] – Concentration of nanoparticles in venous blood. 
χrich [mL per hour] – Permeability coefficient between capillary blood and 
richly perfused organs. 
A2.1.3 Dynamics of the nanoparticles in arterial and venous blood 
For the arterial blood we have: 
)()( ,,, demartabbloodartartartblutot
art kMkCWCCQ
dt
dM

 A2.7 
where 
Mart [µg] – Amount of nanoparticles in arterial blood. 
Qtot [mL per hour] – Total cardiac output. 
Wart [µg] – Weight of arterial blood. 
kblood,ab [per hour] – Uptake rate of PCs in blood, mathematical description can 
be found later in this section. 
Mart,m [µg] – Amount of nanoparticles captured by PCs in arterial blood.  
kde [per hour] – Desorption rate from PCs. 
And the concentration of nanoparticles in the arterial blood Cart is: 
art
art
art
W
M
C      
 A2.8 
The dynamic of nanoparticles in the venous blood is: 
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)()( ,,, demvenabbloodartvenventotbtt
ven kMkCWCQCQ
dt
dM

 A2.9 
where 
Mven [µg] – Amount of nanoparticles in venous blood. 
Cven [µg per g] – Concentration of nanoparticles in the venous blood. 
Wven [g] – Weight of venous blood. 
Mven,m [µg] – Amount of nanoparticles captured by PCs in venous blood.  
The initial value for Mven is the injected dose. And the concentration of nanoparticles 
in the venous blood Cven is: 
ven
ven
ven
W
M
C      
 A2.10 
Approximately, arterial blood takes up 20% of the total blood and venous blood takes 
up 80% of the total blood (Despopoulos and Silbernagl 2003). We also assume the 
PCs in arterial and venous blood are distributed in this 20/80 ratio. Therefore, Wart = 
0.2 × Wblood, Mart,m = 0.2 × Mblood,m, Wven = 0.8 × Wblood, Mven,m = 0.8 × Mblood,m, where 
Wblood is the weight of total blood and Mblood,m is the amount of nanoparticles captured 
by PCs in the total blood. 
A2.1.4 Dynamics of the nanoparticles in tissues, as a direct function of arterial and 
venous concentrations 
By introducing Eq. A2.5 to Eq. A2.1 we can directly express the dynamic of amount 
of nanoparticles in different organs (except for lungs) other than the blood as a 
function of the arterial blood, eliminating the sub-compartment of capillary blood and 
simplifying the model as follows: 
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 A2.11  
The amount of nanoparticles in the lungs is related to the venous blood instead of the 
arterial blood and can be described as: 
)()/(
)1(
,, demluablulululuven
rich
totrichlu kMkCWPCC
Q
dt
dM
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

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 A2.12 
where 
Mlu [µg] – Amount of nanoparticles in the tissue of lungs. 
Wlu [g] – Weight of lungs. 
Clu [µg per g] – Concentration of nanoparticles in lungs. 
Mlu,m [µg] – Amount of nanoparticles captured by PCs in lungs. 
klu,ab [per hour] – Current uptake rate of nanoparticles by PCs in lungs. 
In addition, the outflow from the spleen feeds directly into the liver, instead of joining 
the venous blood in circulation. 
A2.1.5 Capture of nanoparticles by phagocytizing cells 
The PCs capture nanoparticles from the tissue and in the meanwhile, desorption from 
the PCs will release part of the captured nanoparticles back to the tissue. The PCs 
capture the nanoparticles in a saturable manner. That is, as the amount captured 
approaches the capacity for the PCs in the various organs, the uptake rate kt,ab will 
decrease and eventually the capture of nanoparticles will be in a dynamic balance 
with the desorption. The equation describing these behaviors is: 
demtabttt
mt kMkCW
dt
dM
 ,,
,
  
 A2.13  
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The initial uptake rate is assumed to be equal for all organs, while saturation levels of 
PCs will be adjusted for each compartment independently, reflecting the potential 
variation in PCs density in various organs. Thus the uptake rate is related to the 
amount of nanoparticles already captured and the maximum uptake capacity in 
different organs:  
)1(
,
,
0,
tcapt
mt
ababt
WM
M
kk

    
 A2.14 
where 
kab0 [per hour] – Maximum uptake rate by PCs. 
Mt,cap [µg] – PCs uptake capacity for nanoparticles per organ t weight. 
A2.1.6 Excretion 
The excretion of nanoparticles is assumed to be a first order elimination from the 
tissue of liver and capillary blood of kidneys. This is summarized as below: 
ubkfl
exeex CLEMCLEM
dt
dM
dt
dM
 ,
,
 
 A2.15 
where 
Mex [µg] – Amount in excreta. 
CLEf [per hour] – Clearance rate to feces from liver tissue. 
CLEu [per hour] – Clearance rate to urine from capillary blood in kidneys. 
A2.1.7 Codes of the model 
Codes of the model in Berkeley-Madonna
TM
 (version 8.3.18) and acslX
TM
 (version 
3.0.2.1) are available by request (Dingsheng Li, email: dingsli@umich.edu). 
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A2.2 Linear regression of the model’s prediction against measured data 
Fig. A2.1 shows the statistical analysis of the model’s prediction versus measured 
data. The R
2
 is 0.97. The standard error on the residuals (McKone 1993) on the log10 
of predicted and measured values is 0.14, corresponding to a squared geometric 
standard deviation of 1.9 which means the model is able to predict masses of PAA-
peg nanoparticles within a factor of 1.9. The coefficient of a linear regression between 
the log10 of predicted and measured values is 0.99. 
For excreta, the feces have an approximate 8 h of delay from the removal from the 
system until actual sampling. Therefore the measured results’ corresponding time are 
modified when being compared to the predicted results, e.g. the original measured 
nanoparticles amount in feces at 24 h is being compared to the model’s prediction for 
feces at 16 h. The original experiment only measured 0.02 g of the bone marrow 
(Wenger et al. 2011) while the bone marrow weights about 3% of the rat’s body 
weight (Travlos 2006). This means that 99.7% of the bone marrow was included in 
the rest of the body in the original experiment. Therefore when comparing predicted 
results to experimental one, we first estimate the nanoparticle amount in the total bone 
marrow by multiplying the concentrations found in parts of the bone marrow in the 
experiment with the total amount of bone marrow (3% of body weight). Then we sum 
99.7% of the predicted nanoparticles mass in the bone marrow with the rest of the 
body to predict the total nanoparticles mass in the rest of the body. According to 
model results, bone marrow contributes to 8.7% of the nanoparticles found in the rest 
of the body. In addition, we sum the amount of nanoparticles found in the lymph 
nodes, which is less than 0.1% of the injected dose, with the rest of the body. 
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Fig. A12.1 Log10 of predicted PAA-peg nanoparticle mass in blood and different 
organs as a function of log10 of measured mass. 
A2.3 Sensitivity study of the rest of the body to permeability coefficient 
The richly perfused organs are only sensitive to their corresponding permeability 
coefficient in the short-term. However, the permeability coefficient between capillary 
blood and the rest of the body is a very sensitive parameter to the rest of the body in 
this model. The corresponding relative sensitivities (definition and calculation can be 
found in the main text) for the 10 hours AUC and 120 hours AUC for the rest of the 
body are 0.28 and 0.41 respectively, compared to values of 0.20 and 0.02 for 10 hours 
AUC and 120 hours AUC for the liver in respond to 1% change in the permeability 
coefficient between capillary blood and the liver. 
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Fig. A2 .2 Sensitivity analysis of the model for the rest of the body to permeability 
coefficient between capillary blood and tissue in rest of the body (χrest). Error 
bars showing the standard deviation of measured data. “PCs” is the abbreviation 
for phagocytizing cells. Reference values from Table 2.1 are in black and 
sensitivity study are shown in red and blue. 
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APPENDIX 3 
Physiologically based pharmacokinetic modeling of cerium 
oxide nanoparticles by inhalation exposure in rats 
A3.1 Calculation of deposition fractions in different regions of the respiratory 
system 
We combined two sets of information to calculate the deposition fractions of 
nanoparticles in the head region, tracheobronchial region, and the pulmonary region. 
First we gathered the detailed size distribution of nanoparticles in the study with the 
scanning mobility particle sizer (SMPS), which are shown in Fig. A3.1 below.  
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Fig. A3 .1 Size distribution of the mass based concentration of CeO2 
nanoparticles for four runs based on SMPS collected data. 
Second, we utilized the Multiple-Path Particle Dosimetry Model (MPPD v2.11) to 
obtain the deposition fractions in different regions of the respiratory system for the 
size range of nanoparticles in this study, assuming the density of CeO2 nanoparticles 
in this study was 6.96 g/cm
3
.  Then we matched the percentage of a certain size of 
nanoparticles in the study with the deposition fractions of the corresponding size in 
the MPPD model results. By repeating this process for the whole size distribution, we 
arrived with the cumulated deposition fractions of the inhaled nanoparticles for the 
different regions of the respiratory system. 
A3.2 Mathematical representation of the model 
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A3.2.1 Calculation of total inhaled nanoparticles 
The total amount of nanoparticles inhaled, expressed in µg, during the study is 
described by the following equation: 
InsFrTVBFExpedTConcintake    
 A3.1 
where 
intake [µg] – Total inhaled amount of nanoparticles during the study. 
Conc [µg/m
3
] – Concentration of nanoparticles in the air. 
ExpedT [hour] – Exposed duration. 
BF [per hour] – Breathing frequency. 
TV [m
3
] – Tidal volume. 
InsFr [unitless] – Inspiratory fraction 
The values for Conc and ExpedT follow the study settings. The values for BF, TV, and 
InsFr were taken from the default values for rats in the MPPD model. 
Inflows and outflows in different regions of the respiratory system and GI tract lumen 
After inhaled, the nanoparticles enter different regions of the respiratory system. They 
can they exchange with nearby organs. The GI tract lumen is relevant here also 
because nanoparticles can either be directly deposited in the GI tract lumen during 
inhalation, or swallowed down after mucociliar clearance from the pulmonary region. 
The inflows and outflows for the different regions of the respiratory system and GI 
tract lumen are described as below. 
Pulmonary region 
dt
dM
kfrMfr
ExpedT
intake
dt
dM mpul
pulbspulpul
pul ,
  
 A3.2 
where 
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Mpul [µg] – Amount of nanoparticles in the pulmonary region. 
frpul [unitless] –Fraction of nanoparticles deposited in the pulmonary region. 
frs [unitless] –Fraction of nanoparticles smaller than 70 nm. 
kpulb [per hour] – Transfer rate from pulmonary region blood. 
The last term describes the interaction with phagocytizing cells (PCs), which is 
described in details in the following sections. 
Tracheobronchial region 
gitrapulmtrapulmtra
tra kMkMfr
ExpedT
intake
dt
dM
  
 A3.3 
where 
Mtra [µg] – Amount of nanoparticles in the tracheobronchial region. 
frtra [unitless] –Fraction of nanoparticles deposited in the tracheobronchial 
region. 
Mpulm [µg] – Amount of nanoparticles in the pulmonary region PCs. 
kpulmtra [per hour] – Transfer rate of saturated PCs from pulmonary region to 
tracheobronchial region. 
kgi [per hour] – Transfer rate nanoparticles from tracheobronchial region to GI 
tract. 
Head region 
headheadbrheadbrheadbrheadhead
head CLEMkMkMfr
ExpedT
intake
dt
dM
  
 A3.4 
where 
Mhead [µg] – Amount of nanoparticles in the head region. 
frhead [unitless] –Fraction of nanoparticles deposited in the head region. 
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kheadbr [per hour] – Transfer rate of nanoparticles from head region to brain. 
Mbr [µg] – Amount of nanoparticles in the brain tissue. 
kbrhead [per hour] – Transfer rate of nanoparticles from brain to head region. 
CLEhead [per hour] – Clearance rate from head region. 
GI tract lumen 
giabgilumenfgigilumengitragi
gilumen
kMCLEMkMfr
ExpedT
intake
dt
dM

 A3.5 
where 
Mgilumen [µg] – Amount of nanoparticles in the GI tract lumen. 
frgi [unitless] –Fraction of nanoparticles directly deposited in the GI tract 
lumen. 
CLEfgi [per hour] – Clearance rate from the GI tract to feces. 
kgiab [per hour] – Absorption rate of nanoparticles from the GI tract to the liver. 
Note that the first two terms has a delay of two hours in time for the nanoparticles to 
come down from larynx to the GI tract lumen. 
A3.2.2 Dynamics of the nanoparticles in tissues, as a function of capillary blood 
concentrations 
The dynamic of nanoparticles in the tissue sub-compartment in different organs can 
be summarized as follow. The sources of nanoparticles for tissues are capillary blood 
which is part of the systemic circulation. Parts of the nanoparticles will be exchanged 
back to capillary blood and return to the systemic circulation while other parts are 
captured by PCs. For those captured by PCs, desorption is also possible to re-enter the 
tissue. In certain organs, excretion out of the organ is a clearance route. The equation 
describing these processes is:  
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
    
excretionby  clearance
exe
PCs  withninteractio
demtabttt
bloodcapillary   withtransfer net
tbtt
t
dt
dM
kMkCWPCCPA
dt
dM ,
,,, )()/( 
 A3.6 
where 
Mt [µg] – Amount of nanoparticles in the tissue of organ t. 
Wt [g] – Weight of organ t. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
Ct,b [µg per g] – Concentration of nanoparticles in the capillary blood of organ 
t. 
PAt [mL per hour] – Permeability coefficient-surface area cross-product. It is 
approximated as the product of permeability coefficient between capillary 
blood and tissue and regional blood flow, χα×Qt, in this model, assuming the 
surface area is proportional to the regional blood flow. 
P [unitless] – Partition coefficient of nanoparticles between tissue and blood.  
Mt,m [µg] – Amount of nanoparticles captured by PCs in organ t. 
kt,ab [per hour] – Current uptake rate of nanoparticles by PCs in organ t. 
kde [per hour] – Desorption rate of nanoparticles from PCs to tissue. 
Me,ex [µg] – Amount to excreta from source e. e only applies to tissue in liver 
and capillary blood in kidneys. The elimination of nanoparticles directly from 
the GI tract is described separately 
A3.2.3 Dynamics of the nanoparticles in capillary blood, as a function of 
concentrations in arterial and venous blood 
The nanoparticle concentration in capillary blood is determined by the concentrations 
in the arterial blood and in the tissue. The interaction between capillary blood and 
tissue can be described as: 
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)/()( ,,
,
PCCPACCQ
dt
dM
tbttbtartt
bt   
 A3.7 
where 
Mt,b [µg] – Amount of nanoparticles in the capillary blood of organ t. 
Qt [mL per hour] – Blood flow through organ t. 
Cart [µg per g] – Concentration of nanoparticles in arterial blood. 
Ct [µg per g] – Concentration of nanoparticles in the tissue of organ t. 
Tissue uptake of nanoparticles from the capillary blood is modeled as a diffusion 
limited process, therefore the movement of the nanoparticles from capillary blood to 
the cellular matrix of the tissue is proportional to the permeability coefficient-surface 
area cross-product (Krishnan 2007) which can be expressed as a proportion of the 
blood flow Qt, assuming the surface area is proportional to the regional blood flow: 
tt QPA         
 A3.8 
with χα the permeability coefficient between capillary blood and organ t. This 
parameter has a specific value for the brain (χb) and the same generic value for the 
richly perfused organs (χrich), which are lungs, spleen, liver, kidneys, heart, and the GI 
tract. 
We can simplify the model by eliminating the specific sub-compartment of capillary 
blood and calculate concentration of the capillary blood as a function of the arterial 
blood, assuming btC , is in quasi steady state equilibrium between Cart and Ct. We then 
have: 
)/()( ,, PCCPACCQ tbttbtartt   
 A3.9 
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Combining Eq. A3.8 and Eq. A3.9 we have the concentration in organ capillary blood 
Ct,b as: 
)1(
/
,







PCC
C tartbt   
 A3.10 
Eq. A3.10 applies for all organs in the systemic circulation except for the lungs 
because the lungs receive the collective venous blood. Therefore we have the 
concentration in lungs capillary blood Clu,b as a function of venous blood:  
)1(
/
,
rich
lurichven
blu
PCC
C




    
 A3.11 
where 
Cven [µg per g] – Concentration of nanoparticles in venous blood. 
χrich [mL per hour] – Permeability coefficient between capillary blood and 
richly perfused organs. 
Dynamics of the nanoparticles in arterial and venous blood 
In addition to the systemic circulation, the arterial blood is also receiving inputs of 
nanoparticles penetrating the alveolar wall from the pulmonary region. Therefore we 
have the arterial blood as: 
)(
)(
,,
,
demartabbloodartart
artblutotlubalvspulairbloods
art
kMkCW
CCQkfrMfrfr
ExpedT
intake
dt
dM


 A3.12 
where 
Mart [µg] – Amount of nanoparticles in arterial blood. 
frairblood [unitless] – Direct transferred fraction of nanoparticles from the 
pulmonary region to the blood during exposure. 
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Qtot [mL per hour] – Total cardiac output. 
Wart [µg] – Weight of arterial blood. 
kblood,ab [per hour] – Uptake rate of PCs in blood, mathematical description can 
be found later in this section. 
Mart,m [µg] – Amount of nanoparticles captured by PCs in arterial blood.  
kde [per hour] – Desorption rate from PCs. 
And the concentration of nanoparticles in the arterial blood Cart is: 
art
art
art
W
M
C      
 A3.13 
The dynamic of nanoparticles in the venous blood is: 
)()( ,,, demvenabbloodartvenventotbtt
ven kMkCWCQCQ
dt
dM

 A3.14 
where 
Mven [µg] – Amount of nanoparticles in venous blood. 
Cven [µg per g] – Concentration of nanoparticles in the venous blood. 
Wven [g] – Weight of venous blood. 
Mven,m [µg] – Amount of nanoparticles captured by PCs in venous blood.  
The initial value for Mven is the injected dose. And the concentration of nanoparticles 
in the venous blood Cven is: 
ven
ven
ven
W
M
C      
 A3.15 
Approximately, arterial blood takes up 20% of the total blood and venous blood takes 
up 80% of the total blood (Despopoulos and Silbernagl 2003). We also assume the 
PCs in arterial and venous blood are distributed in this 20/80 ratio. Therefore, Wart = 
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0.2 × Wblood, Mart,m = 0.2 × Mblood,m, Wven = 0.8 × Wblood, Mven,m = 0.8 × Mblood,m, where 
Wblood is the weight of total blood and Mblood,m is the amount of nanoparticles captured 
by PCs in the total blood. 
A3.2.4 Dynamics of the nanoparticles in tissues, as a direct function of arterial and 
venous concentrations 
By introducing Eq. A3.10 to Eq. A3.6 we can directly express the dynamic of amount 
of nanoparticles in different organs (except for lungs) other than the blood as a 
function of the arterial blood, eliminating the sub-compartment of capillary blood and 
simplifying the model as follows: 
dt
dM
kMkCWPCC
Q
dt
dM exe
demtabttttart
tt ,
,, )()/(
)1(








 A3.16  
The amount of nanoparticles in the lungs is related to the venous blood instead of the 
arterial blood and can be described as: 
)()/(
)1(
,, demluablulululuven
rich
totrichlu kMkCWPCC
Q
dt
dM






 A3.17 
where 
Mlu [µg] – Amount of nanoparticles in the tissue of lungs. 
Wlu [g] – Weight of lungs. 
Clu [µg per g] – Concentration of nanoparticles in lungs. 
Mlu,m [µg] – Amount of nanoparticles captured by PCs in lungs. 
klu,ab [per hour] – Current uptake rate of nanoparticles by PCs in lungs. 
In addition, the outflows from the spleen and GI tract feed directly into the liver, 
instead of joining the venous blood in circulation. 
A3.2.5 Capture of nanoparticles by phagocytizing cells 
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The PCs capture nanoparticles from the tissue and in the meanwhile, desorption from 
the PCs will release part of the captured nanoparticles back to the tissue. The PCs 
capture the nanoparticles in a saturable manner. That is, as the amount captured 
approaches the capacity for the PCs in the various organs, the uptake rate kt,ab will 
decrease and eventually the capture of nanoparticles will be in a dynamic balance 
with the desorption. The equation describing these behaviors is: 
demtabttt
mt kMkCW
dt
dM
 ,,
,
  
 A3.18  
The initial uptake rate is assumed to be equal for all organs, while saturation levels of 
PCs will be adjusted for each compartment independently, reflecting the potential 
variation in PCs density in various organs. Thus the uptake rate is related to the 
amount of nanoparticles already captured and the maximum uptake capacity in 
different organs:  
)1(
,
,
0,
tcapt
mt
ababt
WM
M
kk

    
 A3.19 
where 
kab0 [per hour] – Maximum uptake rate by PCs. 
Mt,cap [µg] – PCs uptake capacity for nanoparticles per organ t weight. 
A3.2.6 Elimination 
Parts of the nanoparticles are assumed to be excreted by a first order elimination from 
the head region, GI tract lumen, tissue of liver, and capillary blood of kidneys. This is 
summarized as below: 
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,
 A3.20 
where 
Mex [µg] – Amount in excreta. 
CLEf [per hour] – Clearance rate to feces from liver tissue. 
CLEu [per hour] – Clearance rate to urine from capillary blood in kidneys. 
A3.2.7 Codes of the model 
Codes of the model in Berkeley-Madonna
TM
 (version 8.3.18) are available by request 
to the corresponding author (Dingsheng Li, email: dingsli@umich.edu). 
A3.3 Time evolution for concentration in feces from a preliminary study 
Data showed a rapid decrease in concentrations until the fourth day then stayed stead 
at lower levels. 
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Fig. A43.2 Concentrations found in feces in the preliminary study. Error bars 
representing one standard deviation on the means. 
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A3.4 Individual organ concentrations of CeO2 nanoparticles for all runs 
The following tables show the individual organ concentrations of CeO2 nanoparticles for all runs. Rat 9-892 in run fresh 1, 13-892 in run 
fresh 2 was deemed as outliers due to exceptionally high concentrations in the heart and feces respectively. These concentrations violated 
the mass balance by themselves and therefore the data from these two rats were discarded from further analysis of the data. 
Run 
fresh 1 
 
      
    Exposure  Necropsy  Lung Liver Kidney Heart Brain Spleen Olfactory Feces Urine Serum 
Rat ID 
duration 
(hrs) post exposure 
(µg/kg
) 
(µg/kg
) 
(µg/kg
) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (ng/mL) (ng/mL) 
1-892 4 15 min 261 0.6 0.17 0.10 0.17 0.38 0.8 - - 3.5 
2-892 4 15 min 465 0.4 0.29 0.14 0.16 1.76 0.7 - - 2.1 
3-892 4 15 min 226 0.4 0.21 0.14 0.16 0.60 0.6 - - 3.7 
4-892 4 24 hrs 229 1.7 1.28 0.16 0.13 0.28 0.9 91 1.9 3.1 
5-892 4 24 hrs 193 1.2 0.59 0.15 0.69 0.20 0.8 88 7.4 2.7 
6-892 4 24 hrs 255 1.5 1.09 0.81 15.83 0.14 0.8 96 8.1 - 
7-892 4 7 days 185 9.9 1.98 0.29 0.69 4.19 0.9 - - 1.9 
8-892 4 7 days 3 3.4 1.37 0.37 0.85 0.33 0.5 - - 1.8 
9-892 4 7 days 4 0.1 0.17 1214.80 6.33 BID 87.2 - - 2.3 
*BID: below detection limit 
          - no sample 
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Run 
fresh 2 
  Exposure  Necropsy  Lung Liver Kidney Heart Brain Spleen Olfactory Feces Urine Serum 
Rat ID 
duration 
(hrs) post exposure (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (ng/mL) (ng/mL) 
10-892 6 15 min 1645 0.9 0.92 0.76 1.23 0.15 7.7 - - 2.3 
11-892 6 15 min 1431 1.2 0.98 0.58 1.19 0.15 25.2 - - 2.7 
12-892 6 15 min 1704 0.8 0.94 0.49 0.92 BID 6.2 - - 2.0 
13-892 6 24 hrs 1540 2.3 1.57 0.53 0.97 0.23 3.1 9654 - 2.1 
14-892 6 24 hrs 4 0.5 0.84 0.47 0.93 0.57 10.0 465 - 2.4 
15-892 6 24 hrs 1866 2.6 1.99 0.65 0.96 0.35 4.6 1074 - 2.2 
16-892 6 7 days 2017 8.4 5.74 0.86 1.29 BID 5.9 - - 2.3 
17-892 6 7 days 13 0.5 1.20 0.46 1.55 6.24 3.5 - - 1.9 
*BID: below detection limit 
          - no sample 
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Run aged 
1 
 
        
   Exposure  Necropsy  Lung Liver Kidney Heart Brain Spleen Olfactory Feces Urine Serum 
Rat ID 
duration 
(hrs) post exposure (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (ng/mL) (ng/mL) 
1-893 4 15 min 1136 0.55 0.25 0.11 BID -- BID - - 1.4 
2-893 4 15 min 1754 0.19 0.31 0.16 BID -- BID - - 1.4 
3-893 4 15 min 1031 0.18 0.15 0.47 0.34 -- BID - - 1.6 
4-893 4 24 hrs 507 1.32 0.48 0.81 BID -- BID 235 3.1 1.5 
5-893 4 24 hrs 20 0.25 0.57 BID BID -- BID 686 0.9 2.0 
6-893 4 24 hrs 958 2.22 0.70 0.17 BID -- BID 1096 1.0 1.8 
7-893 4 7 days 647 5.98 1.93 0.22 BID -- BID - - 0.6 
8-893 4 7 days 1145 3.76 1.98 0.32 BID -- BID - - 1.3 
9-893 4 7 days 533 9.34 1.26 0.20 BID -- BID - - 0.9 
*BID: below detection limit 
          - no sample 
           -- under analysis 
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Run aged 
2 
 
          
  Exposure  Necropsy  Lung Liver Kidney Heart Brain Spleen Olfactory Feces Urine Serum 
Rat ID 
duration 
(hrs) post exposure (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (µg/kg) (ng/mL) (ng/mL) 
10-893 4 15 min 1289 0.43 1.38 1.50 2.12 1.28 BID - - 1.5 
11-893 4 15 min 1484 0.22 1.14 1.25 1.18 1.15 BID - - 1.0 
12-893 4 15 min 85 BID 1.07 1.32 1.61 1.15 BID - - 1.0 
13-893 4 24 hrs 1706 1.07 2.06 1.22 1.24 1.14 0.9 785 1.1 0.7 
14-893 4 24 hrs 1322 2.16 2.00 1.50 2.68 2.05 BID 630 4.3 0.5 
15-893 4 24 hrs 1236 1.68 1.72 1.26 1.55 1.46 BID 554 0.5 0.5 
16-893 4 7 days 571 2.98 2.53 1.43 1.08 2.17 BID - - 1.0 
17-893 4 7 days 1043 4.24 2.80 1.52 1.50 1.87 BID - - 0.5 
18-893 4 7 days 1174 3.50 3.56 1.45 1.63 1.71 BID - - 1.2 
*BID: below detection limit 
          - no sample 
          -- reanalysis 
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A3.5 Individual organ time courses simulated by the PBPK model 
The following figures show the model’s simulations on individual organs for each run, 
compared to the measured data. The simulations on organs are further differentiated 
into PCs captured and the total in the organ. Amount captured by PCs in organ t and 
the total amount in organ t have the symbols of Mtm and Mtt, respectively. The 
measured data are circles on the figure. X-axis is time in hours, with 0 hour the start 
of the exposure. Y-axis is the amount of nanoparticles, with the unit of µg. The 
number 1, 2, 3, and 4 at the end of each symbol indicates which run this simulation 
and data are for. 1: fresh 1; 2: fresh 2; 3: aged 1; 4: aged 2. Organs with in sufficient 
measurement data are only shown the model simulation results. The feces are not 
shown too since they are represented in Fig. 3.5 in Chapter 3 and they don’t have PCs 
sub-compartment. The order of figures in each run’s results is: blood, spleen, liver, 
brain, heart, kidneys, and lungs. 
From these results, we can see the model predicts PCs capturing almost all of the 
nanoparticles in the organs. There are some free nanoparticles in organs during 
exposure period and shortly after, but diminish over time. 
A3.5.1 Run fresh 1 
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Fig. A53.3 Individual organ time course for run fresh 1. 
A3.5.2 Run fresh 2 
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Fig. A63.4 Individual organ time course for run fresh 2. 
A3.5.3 Run aged 1 
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Fig. A73.5 Individual organ time course for run aged 1. 
A3.5.4 Run aged 2 
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Fig. A83.6 Individual organ time course for run aged 2. 
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APPENDIX 4 
Adaptation of the physiologically based pharmacokinetic 
model to other nanoparticles 
A4.1 Individual organ time courses simulated by the PBPK model 
The following figures show the model’s simulations on individual organs for each run, 
compared to the measured data. The simulations on organs are further differentiated 
into PCs captured and the total in the organ. Amount captured by PCs in organ t and 
the total amount in organ t have the symbols of Mtm and Mtt, respectively. The 
measured data (mean) are circles on the figure. X-axis is time in hours, with 0 hour 
the start of the exposure. Y-axis is the amount of nanoparticles, with the unit of µg. 
A4.1.1 PAA-peg 
Please refer to Fig. 2.3 in Chapter 2. 
A4.1.2 PAA 
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Fig. A94.1 Individual time courses for PAA nanoparticles. For the rest of the body, 
only one time point data available at 120 hours with a value of 8204 µg. 
A4.1.3 PLGA-mPEG 
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Fig. A104.2 Individual time courses for PLGA-mPEG nanoparticles. 
A4.1.4 BVP-PLA 
 
  
157 
 
 
 
 
 
  
158 
 
 
 
 
Fig. A114.3 Individual time courses for BVP-PLA nanoparticles. 
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A4.1.5 Ag, 20 nm 
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Fig. A124.4 Individual time courses for Ag (20 nm) nanoparticles. 
A4.1.6 Ag, 80 nm 
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Fig. A134.5 Individual time courses for Ag (80 nm) nanoparticles. 
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A4.1.7 Ag, 110 nm 
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Fig. A14 .6 Individual time courses for Ag (110 nm) nanoparticles. 
A4.1.8 CeO2, instilled 
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Fig. A154.7 Individual time courses for CeO2 (instilled) nanoparticles. 
A4.1.9 CeO2, inhaled 
Please refer to Appendix A3.5.1 for details. 
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APPENDIX 5 
Life cycle health impacts of polycyclic aromatic hydrocarbon 
for source-specific mixtures 
A5.1 Introduction 
Polycyclic aromatic hydrocarbons (PAHs) in the environment are emitted as by-
products from incomplete combustion of fossil fuels or wood (Li et al. 2006). Several 
PAHs are classified as carcinogenic or probably/possibly carcinogenic to humans by 
the International Agency for Research on Cancer (IARC 2010). Depending on the 
Life Cycle Impact Assessment (LCIA) method used, PAHs may be considered to be 
the dominant contributors to human health impacts for several products and services 
(Kohler and Künniger 2003; Andersen and Shier 2009; Amienyo et al. 2013). For 
instance, using the CML 2001 method (Guinée 2001), Amienyo et al. (2013) 
compared the impacts on human toxicity of different soft drink packaging finding that 
PAHs contributed 97% of the impact from aluminum cans. However, several factors 
generate large uncertainties in assessing the human health impact of PAHs in LCIA 
that may bias product comparison.  
On the fate and exposure side, estimates of half-lives for the PAHs vary among 
frequently referred sources (Howard et al. 1991; Mackay et al. 2006; U.S. EPA 2009), 
which result in very different residence times for PAHs in the environment. In 
addition, estimated PAH concentrations in environmental and food media from 
different models are inconsistent with measured concentrations (Lang et al. 2007; 
Prevedouros et al. 2004). These discrepancies lead to inconsistent predictions of 
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intake for the population. An additional difficulty is the partition behaviors of PAHs 
between gas or dissolved phase and particle bound phase could be significantly 
affected by black carbon and should be considered in modeling the fate of PAHs 
(Hauck et al. 2007; Armitage et al. 2008; Prevedouros et al. 2008). 
On the effect side, current LCIA models such as USEtox (Ralph K Rosenbaum et al. 
2008), IMPACT 2002 (Pennington et al. 2005), and USES-LCA (Huijbregts et al. 
2000) use animal experiment data to estimate the human toxicity of PAHs whereas 
human epidemiological data is preferred if available (Rosenbaum et al. 2011). The 
World Health Organization (WHO 2000) and other studies (Gibbs 1997; Armstrong et 
al. 2004; Armstrong and Gibbs 2009) have given estimated unit risks or relative risks 
for PAH mixtures based on epidemiological data. However, these estimates are solely 
attributed to benzo[a]pyrene while other PAHs’ contributions to the impact of the 
PAH mixture are also relevant to quantify in LCIAs (Pennington et al. 2006) and 
could have in addition an interaction with the effective dose-response of 
benzo[a]pyrene. Thus, it is necessary to develop effect factors for all relevant PAHs 
based on these available epidemiological data accounting for possible interactions 
between different PAHs in estimating dose-responses. 
The goal of this study is to assess the life cycle human health impact of PAH mixtures 
by refining estimates of fate, exposure, and effects of the 16 PAHs listed as Priority 
Pollutants by the U.S. Environmental Protection Agency (U.S. EPA 2013). It 
specifically aims to a) address the influence of black carbon adsorption and photolysis 
on the multimedia multi-pathway intake fractions of individual PAHs; b) to 
recalculate the effect factors and compare the human health impact per kg emitted of 
16 PAHs for different models; c) to derive impact per kg emitted – so-called 
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characterization factors – for source-specific PAHs mixtures; and d) to illustrate this 
study’s use and importance in assessing human health impact in LCIA. 
To this end, we first incorporate black carbon adsorption and photolysis of PAHs in 
the USEtox multimedia model (Ralph K Rosenbaum et al. 2008). We then show the 
influences of these new and updated model specifications on the intake fractions, the 
effect factors, and the characterization factors for health impacts on humans by PAHs. 
The characterization factors for PAHs are applied to specific PAH mixtures from the 
aluminum industry, domestic combustion, and the general world emission. We 
ultimately illustrate the importance of the proposed refined treatment of PAHs in a 
case study, comparing results of the newly developed factors to those of earlier LCIA 
methods. 
A5.2 Methods 
A5.2.1 General framework 
A general framework using a multimedia model evaluating toxicity of different 
chemicals was developed and peer-reviewed by an independent expert panel in a 
UNEP-SETAC workshop (Jolliet et al. 2006). This framework was described by 
(Rosenbaum et al. 2007) and adopted in this study. Impact per kg emitted, the so-
called characterization factor (CF, in cases/kgemitted), is a product of the fate factor (FF, 
in day), exposure factor (XF, in 1/day), and effect factor (EF, in cases/kgintake). The 
total health impact score (S, in cases) due to a given emission of PAHs (M, in kgemitted) 
is then derived by multiplying the characterization factor with the corresponding 
emission for a given technology: 
MEFiFMEFXFFFMCFS  )()(  
 A5.1 
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The result of XF and FF can be expressed as intake fraction (iF, kgintake/kgemitted) 
which is defined as the fraction of the mass released to the environment that is taken 
in by the population integrated over time (Bennett et al. 2002).  
The UNEP-SETAC USEtox model (Ralph K Rosenbaum et al. 2008) is used as a 
starting point for the improvement for the PAHs characterization factors for human 
health. IMPACT 2002 (Pennington et al. 2005) and USES-LCA (Huijbregts et al. 
2000), which have explicit calculation of fate in vegetation and utilize alternative 
landscape parameters, are used to compare results between different models. 
A5.2.2 Fate and exposure 
Evaluating the fate of chemicals in the environment requires considering the 
chemicals’ physico-chemical properties and degradation half-lives. Currently, the 
chemical properties of PAHs in USEtox are based on Estimation Programs Interface 
Suite™ v4.00 (U.S. EPA 2009) (EPI Suite™ v4.00) although more up-to-date data 
exists for these chemical properties (Ma et al., 2010). USEtox also does not include 
the influences of black carbon adsorption and photolysis that are shown to be 
important in the fate of PAHs in other studies (Hauck et al. 2007; Prevedouros et al. 
2008; Chen et al. 2001; Hauck et al. 2008). 
An updated comprehensive review of physico-chemical properties for 15 PAHs (all 
16 PAHs except for dibenz[a,h]anthracene) was done by Ma et al. (2010) and 
provides the molecular weight (MW), octanol-water partition coefficient (Kow), 
octanol-air partition coefficient (Koa), Henry’s Law constant at 25 ˚C  (KH25), vapor 
pressure at 25 ˚C (Pvap25), solubility at 25 ˚C (Sol25), and sub-cooled liquid vapor 
pressure (Subcooled VP) values used in our study. Soil Absorption Coefficient (Koc) 
is not included by Ma et al. (2010) therefore we estimate from Kow according to the 
method proposed by Doucette (2000), which is used by EPI Suite™ v4.00 (U.S. EPA 
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2009). The physico-chemical properties for dibenz[a,h]anthracene  are directly taken 
from EPI Suite™ v4.00 (U.S. EPA 2009). The values of these parameters are 
provided in Table S1 in the electronic supplementary material (ESM). For discussion 
purposes, the 16 PAHs can be differentiated into two groups based on their number of 
rings and their affinity to lipids. Benzo[g,h,i]perylene, indeno[1,2,3-cd]-pyrene, 
dibenz[a,h]anthracene, benzo[a]pyrene, benzo[b]fluoranthene, benzo[k]fluoranthene, 
benz[a]anthracene, chrysene, pyrene, and fluoranthene have 4 rings or more and have 
a higher affinity to lipids (Kow>90 000) while the others have 2 or 3 rings and are less 
lipophilic and more volatile. 
Black carbon can be emitted as a byproduct of incomplete combustion, which is one 
of the major sources of PAHs. In addition, black carbon is known to strongly absorb 
other pollutants (Ni et al. 2014). The presence of black carbon may increase the 
fractions of PAHs bound to particles affecting the fate and bioavailability of PAHs. 
Several black carbon inclusive multimedia models have been proposed (Hauck et al. 
2007; Armitage et al. 2008; Prevedouros et al. 2008; Lohmann and Lammel 2004). In 
this study, the model and parameters from Koelmans et al. (2006) and Prevedouros et 
al. (2008) supplemented with the data of Total Suspended Particulate (TSP) from 
other literature sources (Lohmann and Lammel 2004; Gustafsson et al. 2001) are 
implemented in USEtox to examine the effects of black carbon on the fate of the 16 
PAHs (see section 10 in the ESM for details of the implementation). 
Degradations of PAHs in air, water, sediment, soil, and plants are considered in this 
study. As for air, photo-oxidation with radical species and photolysis are the major 
mechanisms responsible for the breakdowns of PAHs (Chen et al. 2001; Atkinson 
1987). Photo-oxidation rates are taken from EPI Suite™ v4.00 (U.S. EPA 2009), 
which reflects a 24 hour average value. Photolysis rates are corrected from rates 
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obtained in laboratory conditions by Chen et al. (2001), applying a factor of four to 
reflect photolysis rates in the natural environment. This correction accounts for a 
factor two between the day/night cycle under ambient conditions, and is multiplied by 
another factor 2 to account for the difference in the light intensity of the incubator 
model used by Chen et al. (2001) and the annual average light intensity at 25 degrees 
north latitude (National Aeronautics and Space Administration 2012). For surface 
water, biodegradation and photolysis are the dominant removal mechanisms (Lane 
and Katz 1977). Biodegradation rates are taken from Howard et al. (1991). For 
photolysis in water, degradation rates depend on the water depth. Deeper water bodies 
have less sunlight penetration and result in lower photolysis degradation rates of 
PAHs (Schwarzenbach et al. 2003). Since most reported photolysis degradation rates 
were obtained experimentally in vials (Lane and Katz 1977; Muel and Saguem 1985; 
Fukuda et al. 1988), it is necessary to adjust these values for water depths. We follow 
Schwarzenbach et al. (2003) by considering the ratio between light absorption rates at 
a given water depth to that at near-surface. This ratio, known as the screening factor, 
is a function of maximum adsorption wavelength, attenuation coefficient and water 
depth (Schwarzenbach et al. 2003). The photolysis rates in water obtained in 
laboratory conditions are further corrected in the same manner for photolysis rates in 
air by a factor of four. Based on the findings of previous studies (Behymer and Hites 
1985; Larson and Weber 1994), we assume that PAHs will not be subject to photo-
oxidation in air or photolysis in both air and water when bound to particles. Compiled 
data for half-lives for PAHs in different media used in this study are listed in Table S2 
in the ESM. 
A5.2.3 Effect factors 
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To evaluate the health impacts of individual PAHs, we multiply the effect factor of 
benzo[a]pyrene by the PAH specific Toxicity Equivalence Factor (TEFi) that 
expresses the toxicity of an individual PAH i in kg benzo[a]pyrene equivalent: 
PaBii EFTEFEF ][     
 A5.2 
As described by Nisbet and LaGoy (1992), U.S. EPA (1993), and U.S. EPA (2010), 
TEFs are derived from available toxicology data to assess the health impacts of 
chemicals with similar structures, using benzo[a]pyrene as a reference substance (see 
Table S3 in the ESM). For carcinogenic effects, we use the TEFs from the (U.S. EPA 
1993) due to their prevalent use in worldwide regulatory guidance (Jennings 2012) 
and we then consider alternative TEFs in a sensitivity study.  
Currently, the USEtox toxicity database includes carcinogenic effect factors only for 
benzo[a]pyrene and naphthalene, and non-carcinogenic factors for pyrene, 
fluoranthene, anthracene, fluorene, and acenaphthene. All these human health effect 
factors were extrapolated from chronic animal experiments. To decrease the 
uncertainty from animal-human extrapolation, we can take advantage of 
epidemiological data that are available for impacts of benzo[a]pyrene and PAHs. The 
carcinogenic factor for benzo[a]pyrene is therefore recalculated based on residential 
related lifetime lung cancer risks from Gibbs (1997). We use the unit risks data from 
Gibbs (1997) because these data consider the differences between occupational and 
residential settings, as well as the background lung cancer rates that are critical in 
calculating effect factors, but are lacking in other studies using relative risks 
(Armstrong et al. 2004; Armstrong and Gibbs 2009). We calculate the effect factor of 
a PAH mixture (EFmixture) expressed in cases per kg inhaled by multiplying the unit 
risk by the corresponding breathing rate and exposure duration (Gibbs, 1997). Both 
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the unit risk and initial effect factor are calculated assuming that all effects were 
attributed to benzo[a]pyrene as did Gibbs (1997). In reality, workers had also been 
exposed to other PAHs in addition to benzo[a]pyrene. To avoid double counting when 
also assessing the impacts of other PAHs, we first need to separate the contribution of 
benzo[a]pyrene alone from the contribution of the other PAHs by accounting for the 
industry-specific emission profile. Since the emission profile is available for coke 
ovens (Petry et al. 1996; Strunk et al. 2002; Yang et al. 2007), we use as a starting 
point the unit risk (UR) of being exposed to PAHs emitted from coke oven 
recalculated by Gibbs (1997) as 
mixture
PaBtoattributedUR ][ = 7.8 ng/m
3
 per 100 000 persons in 
the general population exposed over lifetime (IR × Tlifetime). This value is itself based 
on one of the largest and most detailed PAH-related epidemiology study by 
Costantino et al. (1995). Considering separately the contribution of each PAH, the 
effect of the mixture entirely attributed to benzo[a]pyrene can be disaggregated into: 
PaBiiii
mixture
PaBtoattributedPaB EFTEFfEFfEFf ][][][  
 A5.3 
Thus the effect factor for benzo[a]pyrene alone ( PaBEF ][ ) is a function of the TEF and 
the fraction (fi) of each PAH i in the mixture emitted for the considered coke oven 
technology: 
 



ii
PaB
lifetime
mixture
PaBtoattributed
ii
PaBmixture
PaBtoattributedPaB
TEFf
f
TIRUR
TEFf
f
EFEF
][
][
][
][][   
A5.4 
The detailed calculations can be found in section 11 of the (ESM). 
For non-carcinogenic effects of PAHs we use the default USEtox effect factors that 
are available for pyrene, fluoranthene, anthracene, fluorene, acenaphthene, and 
naphthalene (Ralph K Rosenbaum et al. 2008) . 
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A5.2.4 Sensitivity analysis on the characterization factors 
To explore the sensitivity of results to changes in the updated parameters, the 
characterization factors from this updated USEtox model are respectively compared to 
those of the adapted model without black carbon adsorption or without photolysis. 
Alternative values of TEFs are also explored to examine the impacts of different TEFs 
on the characterization factors of PAHs. 
A5.2.5 Source-specific emission profiles 
Given the emission profile of a certain source, the total impact per kg emitted or 
characterization factor (CF) of a PAH mixture from source or technology j can be 
calculated as: 
 
i
j
ii
j
mixture PAH fCFCF     
 A5.5 
where iCF is the characterization factor of the individual PAH i and
j
if is the mass 
fraction of emitted PAH i of the total PAH mixture from source j. 
The total health impact (SPAH mixture) of the mixture that may involve various sources j 
for the whole product/region of interest is given by multiplying the PAH mixture CF 
of each specific source by the total PAH mass emitted by this source ( jmtotal  ) and 
summing them up across all sources: 
 
j
jj mCFS totalmixture PAHmixturePAH   
 A5.6 
We then can derive CFs for different sources that represent important contribution, to 
PAHs emissions (Shen et al., 2013) and for which we have detailed emission profile, 
i.e for aluminum production and domestic combustion. For aluminum, anode plants 
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and Søderberg plants are responsible for most of the PAHs emissions during 
aluminum production (European Aluminium Association 2008). Their specific 
emission profiles are introduced in equation (5) to derive CFs. For domestic 
combustion, straw, wood, and sawdust briquettes, and kerosene are considered (Oanh 
et al. 2002). The worldwide PAH mixture emission profile in 2007 (Shen et al. 2013) 
is employed to provide a general CF when the source emission profile cannot be 
determined. For aluminum production, the ratio of rural/urban air emission is assumed 
to be 48:52, which is equal to the world rural/urban population ratio in 2011 (The 
World Bank 2013). For domestic combustion it is assumed all PAHs are entirely 
emitted to rural air. For the worldwide mixture, the sources of PAH mixtures were 
adapted from Shen et al. (2013) – we then assume PAHs emitted from biofuel burning, 
open straw burning, and wild fire are 100% emitted to rural air, while PAHs emitted 
from domestic coal burning, industrial sources, traffic oil, and consumer products are 
emitted to rural and urban air also based on rural/urban population ratio in year 2011 
(The World Bank 2013). The emission profiles of aluminum production, domestic 
combustion, and worldwide can be found in Table S4-b in the ESM. 
2.6 Life cycle case study 
The method in this study is compared with three other LCIA methods, namely CML 
2001 (Guinée 2001), ReCiPe (Goedkoop et al. 2008), and the USEtox-based IMPACT 
World + (Bulle et al. 2012) to examine the changes in human health impacts for the 
production of one kg primary aluminum. Inventory data are taken from Ecoinvent 2.2 
(Frischknecht et al. 2005). 
A5.3 Results 
A5.3.1 Intake fractions 
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Intake fractions (iFs) via inhalation and ingestion from emission to rural air calculated 
using the USEtox default scenario and three updated scenarios with black carbon 
adsorption, new degradation data including photolysis, and these two modifications 
altogether are shown in Fig. A5.1.  
 
Fig. A165.1 Intake fractions (iFs, kgintake/kgemitted) from emission to rural air of 
the 16 PAHs ordered in decreasing Kow/Koa (from left to right) calculated by 
USEtox under different scenarios. 
Accounting for photolysis alone reduces ingestion iFs by 36% - 78% for all PAHs 
except for acenaphthene, acenaphthylene, and naphthalene, which only have 
reductions of 2% - 15% (Fig. A5.1). Since photolysis generally gives a half-life much 
lower than biodegradation (Table S2 in ESM), the residence time in water for PAHs 
decreases up to seven-fold after adding photolysis. This explains the decreases in the 
iFs. On the contrary, accounting for black carbon adsorption alone results in 1.5- to 
5.3-fold higher ingestion iFs for benzo[g,h,i]perylene, indeno[1,2,3-cd]-pyrene, 
dibenz[a,h]anthracene, benzo[a]pyrene, benzo[b]fluoranthene, and 
benzo[k]fluoranthene (Fig. 1). The inclusion of black carbon adsorption lowers the 
gaseous/dissolved fractions of PAHs and reduces the photo-oxidation rates in air and 
photolysis rates in both air and water. For water, the increased adsorption to black 
carbon also increases PAHs dry deposition from air and net sedimentation in water. In 
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addition, the bioavailability of PAHs in water decreases after adsorbing to black 
carbon and lowers the iFs of relevant pathways (drinking water, fish consumption, 
etc.). However, the major contributor to the ingestion iFs is exposed produce (grain, 
vegetables, etc.), which is directly related to the PAHs in air, so the reduction of iFs in 
water related pathways does not affect the overall iFs significantly. 
Overall, when accounting for photolysis and black carbon (USEtox with all 
modifications in Fig. 1), the iFs via ingestion are not substantially changed for the 
PAHs with three rings or less, but iFs are increased by up to 350% for the most 
lipophilic PAHs. Considering both modifications, iFs of the 16 PAHs via inhalation 
vary from 5.6×10
-8 
kgintake/kgemitted for acenaphthylene to 1.9×10
-6
 kgintake/kgemitted for 
indeno[1,2,3-cd]-pyrene. Except for fluorene, acenaphthene, acenaphthylene, and 
naphthalene, iFs via ingestion are higher by one to two orders of magnitude than via 
inhalation, and span more than three orders of magnitude. Results from different 
USEtox scenarios show similar trends among the 16 PAHs (Fig. A5.1).  
The variations of iFs among the different model scenarios can be explained by the 
influences from photolysis inclusion and black carbon adsorption as a function of the 
fractions in gaseous/dissolved phases and of the half-lives for each PAH in air and 
water. The inclusion of photolysis has a direct decreasing effect on the half-lives of 
PAHs but this effect is interactive with the fraction gaseous/dissolved phase that is 
also affected by the black carbon adsorption. For PAHs with low Koa and Kow, the 
inclusion of black carbon adsorption decreases their gaseous phase fraction by only 
less than 1% and decreases their fractions in dissolved phase by 7% - 34%, and thus 
has little influence on their iFs. On the contrary, accounting for black carbon 
adsorption strongly affects the fate of PAHs with high Koa and Kow: Fractions in 
gaseous phase decrease by as much as 98% and fractions in dissolved phase decrease 
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by 48% - 79%. This in turn inhibits their degradation processes, extending their 
persistency in the environment, and thus increases their iFs. For example, taking the 
black carbon adsorption effect into account reduces the fraction of 
benzo[g,h,i]perylene in the gaseous phase in air from 87% to 1.8% and its fraction in 
dissolved phase from 27% to 5.6%, resulting in a 4.4 fold increase in its iF. 
The iFs from emission to urban air are also calculated and range from 1.1×10
-5
 to 
2.5×10
-5
 kgintake/kgemitted (Table A5.1). These are one to three orders of magnitude 
higher than the inhalation iFs for emission to rural air. The significant increases of 
inhalation iFs for urban areas make inhalation an exposure pathway comparable to 
ingestion for PAHs with high Kow and the dominant pathway for PAHs with low Kow.  
The comparison between this study and the IMPACT 2002 and USES-LCA models 
show very similar trends and a consistent relative ranking in iFs between the three 
models. For the inhalation iFs of PAHs, the three models are in relatively good 
agreement with each other. For ingestion, results from this study are generally higher 
by one order of magnitude than those from USES-LCA, while IMPACT 2002 
provides systematically higher values due to differences in the vegetation modeling. 
Details can be found in Fig. S1 of the ESM. 
A5.3.2 Carcinogenic effect factors  
The updated cancer effect factor (EF) for benzo[a]pyrene of 73 cases/kgintake, based on 
epidemiological data, is 61 times higher than the default USEtox cancer EF of 1.2 
cases/kgintake, which is based on animal toxicity data. By applying the TEFs, the 
proposed cancer EFs for the 16 PAHs ranged from 7.3×10
-2
 to 73 cases/kgintake (Table 
A5.1). Although the TEF of dibenz[a,h]anthracene was assigned as 1 by U.S. EPA 
(1993) and widely employed among worldwide regulatory guidance (Jennings 2012), 
Nisbet and LaGoy (1992) proposed a higher value of 5. Moreover, U.S. EPA 
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recommended a value of 10 of TEF for dibenz[a,h]anthracene and a set of varying 
TEFs for other PAHs in a recent report (U.S. EPA 2010) (this report is still in external 
review status and we therefore do not use it as our base scenario). Also, U.S. EPA 
(2010) reported a higher TEF for benzo[b]flourene (value of 0.8) and a lower TEF for 
benzo[k]flourene (value of 0.03). A sensitivity study is performed to investigate EF 
responses to the change of the TEFs. Increasing the TEF for dibenz[a,h]anthracene 
indirectly leads to a decrease of the relative importance of benzo[a]pyrene when 
accounting for PAH emission profiles from coke ovens that underlie the 
epidemiological data. This results in a decrease in the EF of benzo[a]pyrene from 73 
to 54 cases/kgintake (-26%) with TEF values given by Nisbet and LaGoy (1992) and to 
27 cases/kgintake (-63%) with TEF values given by U.S. EPA (2010). The sensitivity to 
dibenz[a,h]anthracene TEF is of special interest: Changing only 
dibenz[a,h]anthracene TEF from 1 to 5 or 10 only results in an increase of the impact 
per kg dibenz[a,h]anthracene intake by  268% and 505% due to the parallel decrease 
in the reference EF for benzo[a]pyrene. When dibenz[a,h]anthracene TEF is changed 
to 10 and the other PAHs TEFs are also changed to U.S. EPA (2010), the impact per 
kg dibenz[a,h]anthracene intake only increases by  274% compared to U.S. EPA 
(1993). 
A5.3.3 Health impacts per kg emitted of individual PAHs 
Combining iFs and EFs enables us to analyze the cancer cases per kg emitted for the 
individual PAHs, or the so-called characterization factors (Fig. A5.2). Default 
characterization factors are only shown for PAHs for which cancer effect data are 
readily available in the USEtox database. The influence of black carbon adsorption 
and photolysis on these characterization factors corresponds to the patterns of iFs via 
ingestion from emission to rural air, confirming that ingestion is the major exposure 
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route for rural emissions. For benzo[a]pyrene, the increases in iFs and EFs lead to a 
final characterization factor 66 times higher than the default 4.1×10
-5
 cancer cases/kg 
benzo[a]pyrene emitted. For naphthalene, the modifications in both fate and EF result 
in a characterization factors increased by 17% compared to its default value. 
 
Fig. A175.2 Characterization factors (CFs, cancer cases/kgemitted) for emissions to 
rural air of the 16 PAHs ordered in decreasing Kow/Koa (from left to right) 
calculated by USEtox under different scenarios. In its default version USEtox 
has carcinogenic characterization factors only for benzo[a]pyrene and 
naphthalene. 
Table A15.1 Intake fractions, effect factors and characterization factors 
calculated by USEtox with all modifications. 
PAHs 
Intake fractions 
a
                                                 
(kgintake/kgemitted) 
Effect factors
b, c
                                                        
(cases/kgintake) 
Characterization 
factors 
d
 
(cases/kgemitted) 
Inhalation Ingesti
on 
Cancer 
Non-
cancer 
Rural Urban 
Rural Urban 
B[ghi]Pe  1.9E-06 2.5E-05 2.3E-04 7.3E-01 n/a 1.7E-04 1.8E-04 
I[cd]P 1.9E-06 2.5E-05 2.3E-04 7.3E+00 n/a 1.7E-03 1.8E-03 
dB[ah]An 4.9E-07 2.1E-05 6.3E-05 7.3E+01 n/a 4.6E-03 5.4E-03 
B[a]P 5.3E-07 2.2E-05 3.7E-05 7.3E+01 n/a 2.7E-03 3.9E-03 
B[b]F 9.0E-07 2.3E-05 8.1E-05 7.3E+00 n/a 6.0E-04 6.9E-04 
B[k]F 6.3E-07 2.2E-05 6.2E-05 7.3E+00 n/a 4.5E-04 5.6E-04 
B[a]An 2.0E-07 1.8E-05 1.8E-05 7.3E+00 n/a 1.3E-04 2.3E-04 
Cry 2.8E-07 1.9E-05 2.8E-05 7.3E-01 n/a 2.1E-05 3.1E-05 
P 2.6E-07 1.9E-05 1.8E-05 7.3E-02 6.0E-03 1.3E-06 2.4E-06 
F 6.3E-07 2.2E-05 4.2E-05 7.3E-02 3.6E-03 3.1E-06 4.3E-06 
An 3.2E-07 2.0E-05 4.9E-06 7.3E-01 4.5E-04 3.8E-06 1.8E-05 
Ph 6.7E-07 2.2E-05 1.0E-05 7.3E-02 n/a 7.8E-07 2.3E-06 
Fl 8.4E-07 2.3E-05 3.2E-06 7.3E-02 3.6E-03 2.9E-07 1.9E-06 
Ace 2.9E-07 2.0E-05 5.5E-07 7.3E-02 2.6E-03 6.1E-08 1.5E-06 
Acy  5.6E-08 1.1E-05 1.3E-07 7.3E-02 n/a 1.3E-08 8.0E-07 
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Nap 7.2E-07 2.3E-05 1.1E-07 7.3E-02 7.2E-02 6.1E-08 1.7E-06 
a
 The intake fractions via ingestion from emission to urban air is within 30% deviation 
from the intake fractions via ingestion from emission to rural air, therefore only the 
intake fraction via inhalation from emission to urban air are shown. 
b
 The effect factors for inhalation and ingestion is considered the same when more 
specific experimental values are not available according to Rosenbaum et al. (2008). 
c
 For naphthalene, the non-carcinogenic effect factor for ingestion is 1.3E-2 
cases/kgintake based on experiments. 
d
 Only carcinogenic effect is accounted. 
 
 
 
 
 
A5.3.4 Health impact: Application to mixture and specific emission profiles  
Figure 3 shows that benzo[a]pyrene and dibenz[a,h]anthracene have a major 
contribution to the total characterization factors (58% – 91%) for the aluminum 
production, straw combustion, wood combustion, sawdust briquettes combustion, and 
unspecified sources derived from worldwide PAH emissions. The large contribution 
of benzo[k]fluoranthene for kerosene combustion is due to the high percentage of 
benzo[k]fluoranthene in the PAH emission from kerosene combustion (10.8%) and its 
relatively high TEF (0.1). Results for CFs are not very sensitive to the variation in 
TEFs from 1 to 10 for dibenz[a,h]anthracene nor from the variation from 0.1 to 0.8 for 
benzo[b]fluoranthene (details shown in Table A5.2). A more detailed analysis of 205 
countries and regions PAH mixtures can be found in Fig. S2 in the ESM and Table S9.  
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Fig. A185.3 Characterization factors (CFs, cancer cases/kgemitted) calculated by 
USEtox for the emission of 16 PAH mixtures from aluminum production, 
domestic combustion, and worldwide emission (unspecified source). 
Comparing various sources only based on their impacts per kgemitted as described by 
the CFs may however be misleading, since overall quantities of PAHs emitted to meet 
a given function (production of a functional unit of one ton aluminum or of one MJ 
domestic heat) could depend on the considered sources. Figure 4 shows the impacts of 
a) aluminum production and b) domestic combustion on this functional basis. 
Although the CF for the PAH mixture of the anode plant is 101% higher than that of 
the Søderberg plant, the mass of the PAH mixture emitted per ton of aluminum 
produced is 69% lower and the resulting impact of PAHs per ton of aluminum 
produced by anode plant is only 64% of the Søderberg plant. For domestic 
combustion, straw combustion has much higher impact per MJ heat produced, even if 
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its CF is of the same order of magnitude as other fuels. This is because of a low heat 
value and a much higher overall mass of PAHs emitted (detailed calculations in Table 
S5 in the ESM). 
Table A25.2 Sensitivity of CFs to TEF value for PAHs mixtures from USEtox. 
Products/regions Sources CFs 
a
 
CFs for 
sensitivity 
study 1 
b
 
CFs for 
sensitivity 
study 2 
c
 
  
(cases/kgemitted) (cases/kgemitted) (cases/kgemitted) 
Aluminum 
production 
Søderberg 
plant 
1.04E-04 1.25E-04 1.12E-04 
Anode plant 2.51E-04 7.97E-04 8.01E-04 
Domestic 
combustion 
Straw 9.80E-05 8.76E-05 8.30E-05 
Wood 4.33E-05 6.23E-05 7.05E-05 
Sawdust 
briquettes 
1.67E-05 2.46E-05 2.43E-05 
Kerosene 9.64E-05 7.09E-05 5.26E-05 
Worldwide Various 5.73E-05 8.93E-05 8.98E-05 
a
 (U.S. EPA 1993). 
b
 (Nisbet and Lagoy 1992). 
c
 (U.S. EPA 2010) 
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Fig. A195.4 Impacts per reference unit calculated by USEtox for the emission of 16 
PAH mixture from a) aluminum production (cancer cases per kg production); 
and b) domestic combustion (cancer cases per MJ production). 
The high percentages of dibenz[a,h]anthracene and benzo[a]pyrene in the PAH 
mixture emitted from aluminum anode plant production resulted in much higher CFs 
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compared to the Söderberg plant, domestic combustion, and the PAH mixture 
emission from an unspecified worldwide source. Although having much lower effect 
factors due to lower TEFs, benzo[b]fluoranthene and benzo[k]fluoranthene still 
constitute a large part of the PAH mixture CFs from straw burning and kerosene 
burning. This shows the importance of identifying the emission profile of a PAH 
mixture to estimating its health impacts. When the specific emission profile cannot be 
obtained, the worldwide unspecified source of the PAH mixture can be used as a 
generic estimate of health impact for PAH mixture with a CF of 5.7×10
-5
 cancer 
cases/kgemitted. Considering a global emission of 5.1×10
8
 kg PAH/year (Shen et al. 
2013), we obtain a total burden of disease of PAH emitted to air of the order of 
magnitude of 30 000 cancer cases per year worldwide.  
A5.3.5 Non-carcinogens 
This study does not extend its scope to the exploration of non-carcinogenic effects in 
details. Based on the current non-carcinogenic EFs available in the USEtox database, 
the magnitude of non-carcinogenic EFs are comparable to the carcinogenic EFs for 
naphthalene (see Table A5.1). To examine the potential contribution of non-
carcinogenic effects to the overall impact of PAH emissions, we introduce a severity 
factor which translates cases of diseases into Disability-Adjusted Life Year (DALY) 
for the EF according to Huijbregts et al. (2005). The carcinogenic effect of PAHs is 
induced respiratory cancer, therefore a severity factor of 16.5 DALY/case is applied 
(Huijbregts et al. 2005). As a sensitivity study, the generic severity factor of 2.7 
DALY/case is applied to the non-carcinogenic effect of PAHs (Huijbregts et al. 2005). 
After applying the severity factors, the non-carcinogenic health impacts from PAHs 
with non-carcinogenic data are one to four orders of magnitude lower than their 
carcinogenic health impacts. Details can be found in Table S6 in the ESM. 
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A5.3.6 Case study 
The results of the life cycle case study for one kg primary aluminum are presented in 
Figure 5. The overall human health impacts composite toxicity effects and health 
effects by primary/secondary particulate matters induced by the emission of various 
chemicals in the life cycle. More specifically, contributors of the toxicity effects are 
grouped into four categories, namely PAHs, other organics, and inorganics. While 
CML 2001 assigns 89% of the total human health impact to PAHs, this fraction was 
less than 1% for the other methods in this case study. Compared to the original 
USEtox results employed by IMPACT World +, the modifications made in this study 
increase the relative contribution of PAHs to the total impact from 0.002% (IMPACT 
World + with USEtox default) to 0.7% (IMPACT World + with USEtox modified). 
USEtox gives a much higher value of impact per kg emitted for arsenic and therefore 
the contribution of human health impacts by inorganics in IMPACT World + with 
USEtox default versus modified are 93% and 92%, respectively. In contrast, the 
ReCiPe suggests 36% of the total human health impacts are caused by toxicity 
induced by inorganics, while the rest are health effects by primary/secondary 
particulate matters. 
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Fig. A205.5 Contributions from different categories to the total human health 
impacts of the life cycle case study for 1 kg primary aluminum estimated by 
CML 2001, ReCiPe, IMPACT World + with USEtox default, and IMPACT 
World + with USEtox modified. 
A5.4 Discussion 
A5.4.1 Factors influencing the intake fraction of PAHs 
The differentiated effects of black carbon adsorption on the fate of PAH as a function 
of their physico-chemical properties are in agreement with previous studies (Hauck et 
al. 2007; Prevedouros et al. 2008; 2008). The intake fraction of benzo[a]pyrene via 
ingestion calculated in this study (3.7×10
-5
 kgintake/kgemitted) is in the lower end of the 
intake fraction ranges calculated based on monitored concentration in foods in the 
United States, aproximately 1.4×10
-5 
to 8.0×10
-4 
kgintake/kgemitted (Kazerouni et al. 
2001), and Europe, aproximately 7.0×10
-5
 to 1.8×10
-3
 kgintake/kgemitted (Pennington et 
al. 2006). 
In addition to black carbon, other particles related to PAH emissions (e.g. aluminum 
oxide in aluminum production) could also adsorb PAHs and further decrease their 
fractions in gaseous/dissolved phases and thus influence their intake fractions. There 
are limitations in estimating the photolysis half-lives in real world from values 
0.00% 0.01% 0.10% 1.00% 10.00% 100.00%
CML 2001
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IMPACT World +
with USEtox default
IMPACT World +
with USEtox modified
Health effects by
particulate matters
Toxicity by inorganics
Toxicity by other
organics
Toxicity by PAHs
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obtained in experiments either in labs or outdoors. Detailed knowledge of the 
experimental values, light intensity, and longitude of locations of the experiments 
should be taken into consideration to adjust the estimates of real world photolysis 
half-lives if available. It should also be noted that in this study neither the role of 
dermal absorption or indoor exposure are considered. 
The degradation of PAHs in vegetation could also play a critical role in human’s 
exposure since the intake fraction via ingestion is dominated by exposed produce. 
Currently the USEtox model is extrapolating the vegetation degradation rate from the 
soil degradation rate. Several studies (Wild et al. 2005; Chen et al. 2010; 2011) tested 
the degradation of fluoranthene, anthracene, phenanthrene, and fluorene on plant 
surfaces and within plants and linked them with photodegradation. Substituting these 
measured values with the extrapolated vegetation degradation rates in the current 
USEtox model, the intake fractions via ingestion of fluoranthene, anthracene, 
phenanthrene, and fluorene decreased two to nine fold (Fig. S3 in ESM). It can, 
however, not be assumed that photolysis is the major factor in vegetation degradation 
for all PAHs. The four PAHs with measured degradation rates in vegetation are all 
with low Kow. The PAHs with much higher Kow may have a larger fraction 
transferred into the cellular structure, blocking the photolysis to a greater extent which 
is supported by the experimental values from Wild et al. (2005). Biodegradation 
within the plant may therefore be a dominant removal pathway for PAHs with high 
Kow. 
A5.4.2 Effect factors for PAH mixtures. 
Although benzo[a]pyrene is one of the most important PAH in terms of assessing the 
health impacts of PAH mixtures, benchmarking PAH mixtures’ health impacts based 
on the concentrations of benzo[a]pyrene alone could lead to incomplete estimates 
  
193 
 
 
(Gibbs 1997; Armstrong et al. 2004; Armstrong and Gibbs 2009; Costantino et al. 
1995). It is therefore essential to account for the full PAHs emission profile when 
interpreting results of epidemiological studies and translating them into health risk 
estimates for individual PAHs. 
PAHs can react with oxidants (OH, NO3, O3) in the atmosphere and form nitrated 
PAHs (NPAHs), which are also recognized as carcinogens (Albinet et al. 2007; 
Huang et al. 2014). From the perspective of TEFs, some of the NPAHs may even be 
more toxic than their PAH precursors (RIDEM, 2008). This transformation of PAHs 
to NPAHs is not considered in the present study, similarly to the way other toxics are 
treated in most LCIA methods. To ensure that the human health impacts of PAH 
mixtures are not underestimated, further research is needed to characterize the fraction 
of each PAH degraded into its degradation compounds, as well as the fate, exposure 
and effect of these compounds. 
A5.4.3 Importance of emission profile 
As shown in this study, the intake fractions and effect factors of different PAH 
species vary by orders of magnitudes and therefore result in great variations in the 
health impacts of individual PAHs. It is important to acknowledge these differences 
when conducting LCIA practices. For example, although the anode plant emits much 
less PAHs in quantities than Søderberg plant for producing one ton of aluminum, the 
larger percentages of benzo[a]pyrene and dibenz[a,h]anthracene in the mixture make 
the overall impact of PAHs mixture higher and may counter the advantage of a lower 
emission to some extent. Mitigation strategies for reducing PAHs emissions should 
therefore focus on the dominant PAHs in priority.  
We recommend for LCIA application that practitioners prioritize collection of 
information on the emission profile for the technology responsible for the PAHs main 
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emissions in order to apply individual PAH characterization factors. In cases where 
this is not possible, the practitioner may use in priority the generic world estimate for 
PAH mixtures of 5.7×10
-5
 cancer cases/kgemitted. The country specific CFs provided in 
Table S9 are primarily useful to assess the impacts of overall PAHs emissions for a 
given region (rather than source specific emissions) or to test the sensitivity of the 
generic world characterization factor to regional variations. 
Finally, if the assessment method assigns the impact of benzo[a]pyrene to all PAHs - 
as does the CML 2001 method (Guinée 2001) - the health impact of PAHs could be 
highly overestimated and bias the overall impacts of product life cycle with PAH 
emissions. 
A5.5 Conclusions 
This study demonstrates the importance of including black carbon adsorption and 
photolysis in predicting the fate of PAHs, which have been neglected in LCIA 
practices. Employing these modifications leads to predictions closer to measured 
values of intake fractions for benzo[a]pyrene, showing its potential for other PAHs. 
This study also provides a method based on the Toxicity Equivalence Factors (TEFs) 
to incorporate the emission profile to the epidemiology data and shows the 
contributions of PAHs other than benzo[a]pyrene, especially dibenz[a,h]anthracene, 
benzo[b]fluoranthene, and benzo[k]fluoranthene, depending on the emission profile, 
are not negligible. Although the TEF values vary among different reports (U.S. EPA 
1993; Nisbet and Lagoy 1992; U.S. EPA 2010), the resulting effect factors are much 
less variable once health effect is attributed to the whole mixture and not just to 
benzo[a]pyrene. This also means that it is essential both for LCIA and 
epidemiological studies to report emissions and concentrations not only for 
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benzo[a]pyrene but also for the other PAHs and at least for dibenz[a,h]anthracene, 
benzo[b]fluoranthene, and benzo[k]fluoranthene. 
The new factors, especially the effect factors, proposed in this study lead to 
substantial changes for the health impacts of PAHs in LCIA results for aluminum and 
other products emitting PAHs during their production when compared to the default 
USEtox. Our health impacts estimate for PAH mixture falls intermediary between the 
CML 2001 and ReCiPe. This study offers a method that can assess the health impacts 
of all 16 individual PAHs. Combined with the knowledge of source-specific emission 
profiles of the product of interest, the health impacts of PAH mixtures can be 
evaluated more comprehensively and avoid biased results that are based solely on 
benzo[a]pyrene or total PAH emission quantities. Given the importance of emission 
profiles of PAH mixtures, we thus recommend future LCIA studies to include 
emissions of individual PAHs, and specifically of dibenz[a,h]anthracene, 
benzo[b]fluoranthene, and benzo[k]fluoranthene in addition to benzo[a]pyrene. 
 
Electronic supplementary material 
The electronic supplementary material contains the physico-chemical properties, 
degradation rates, TEFs, emission profiles of the 16 PAHs used in this study, results 
of the calculated degradation half-lives in air and water, comparison of iFs calculated 
in this study and from IMPACT 2002 and USES-LCA, sensitivity of the choice of 
TEFs, detailed implementation of black carbon adsorption model, and the calculation 
of unit risk for benzo[a]pyrene. In a separated excel file with the detailed calculation 
for the half-lives in air and water can be found.  
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